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Boxed warnings (BWs) are the highest-level prescription drug warning issued by the U.S. 
Food and Drug Administration (FDA). These warnings are reserved for the most serious adverse 
drug reactions, such as those causing death, hospitalization, serious disability, or congenital 
anomaly. The FDA uses boxed warnings to communicate important drug safety information to 
healthcare professionals for consideration in their prescribing decisions. 
The objective of this dissertation is to increase knowledge about whether boxed warnings 
work as intended, and why boxed warnings vary in their impact on prescribing. I study five boxed 
warnings spanning multiple drugs, classes, and treatment areas: 1) suicidality risks of 
antidepressants among children and adolescents, 2) mortality risks of atypical antipsychotics 
among elderly with dementia, 3) cardiovascular risks of COX-2 inhibitors among patients with 
cardiovascular disease or risk factors, 4) congestive heart failure risks of glitazones among patients 
with heart failure, 5) decreased efficacy of Plavix among poor CYP2C19 metabolizers. 
In Study 1, I assess the relative impacts of boxed warnings versus low-level FDA warnings. 
I find that prescribers generally do not change prescribing after initial low-level FDA risk 
communications, but that boxed warnings have dampening effect on prescribing, although 
statistical significance is limited. This suggests prescribers comprehend that boxed warnings 
 iv 
indicate more serious risks and higher evidence levels than low-level warnings, and are calibrating 
their prescribing changes accordingly.  
In Studies 2 and 3, I assess prescriber and patient heterogeneity in post-boxed warning 
prescribing changes to evaluate potential sources of variation in boxed warning impact. On the 
prescriber side, I hypothesize that certain prescriber characteristics will be correlated with net costs 
of learning, and will thus predict variation in post-boxed warning prescribing changes. I find little 
evidence that prescriber characteristics are related to boxed warning response. On the patient side, 
I examine whether patients subgroups who are at risk of receiving lower quality care are less likely 
to have a decrease in prescribing following the boxed warning. I find little evidence that patient 
characteristics predict variation in post-boxed warning prescribing, suggesting that there are not 
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CHAPTER 1: INTRODUCTION 
 
Adverse drug reactions kill 100,000 people each year, impose serious morbidity on another 
2 million more, and cost the United States $136 billion annually (FDA 2018). To reduce adverse 
drug reactions, the Food and Drug Administration (FDA) continues to monitor drug safety issues 
after a product is approved, and has multiple tools for communicating drug safety issues to 
healthcare professionals and patients. The FDA’s main risk communication tool for healthcare 
professionals is prescription drug labeling, also referred to as the “package insert,” which provides 
FDA-approved drug safety and efficacy information for a given product (FDA 2012a; FDA 2016; 
FDA 2012b). All drug labels include information about possible drug side effects, but few side 
effects are sufficiently serious to meet the criteria for a “boxed warning” (BW)1.  
Boxed warnings are the highest level of prescription drug warning issued by the Food and 
Drug Administration and are reserved for the most serious adverse drug reactions. Boxed warnings 
differ from other FDA risk communications in important ways. First, BWs require a higher 
threshold of evidence than other risk communications. Second, the FDA reserves BWs for the 
most serious safety concerns, such as those causing death, hospitalization, a serious and/or long-
term disability, or congenital anomaly or birth defect (FDA 2011). Third, BWs are the most 
prominent risk communication in the prescription drug labeling. Specifically, the FDA requires 
that BWs be placed at the top of the first page of the prescription drug labeling, written in bolded 
text, and surrounded by a black box (hence their name “boxed warnings” or “black box warnings”) 
                                                        
1 Boxed warnings are informally known as “black box warnings,” but I will use the FDA’s terminology of “boxed 
warning” throughout. 
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(FDA 2007; FDA 2011; FDA 2012b). For illustrative purposes, Appendix 1 shows the prominent 
placement of the boxed warning on the Avandia prescription drug labeling. 
The FDA can require a drug manufacturer to add a boxed warning to a drug label at any 
point in a drug’s lifecycle. When pre-approval studies reveal serious drug risks the FDA can 
require a boxed warning as a condition of approval, in which case the drug label will contain a 
boxed warning from the moment it launches. These boxed warnings are often referred to as “pre-
market boxed warnings.” In contrast, if risks meriting a boxed warning are not realized until after 
drug’s approval and launch, the FDA can require the addition of a boxed warning after the drug 
has been on the market for some time. These boxed warnings are known as “post-market boxed 
warnings.” Some drugs receive multiple boxed warnings over the course of their lifecycle, and 
thus it is possible for a drug to have both pre-market and post-market boxed warnings.  
Among FDA-approved prescription drugs, about one third have boxed warnings (Cheng 
2014a; Cheng 2014b). Among these drugs with boxed warnings, 14% have both pre- and post-
market BWs, 58% have only pre-market BWs, and 28% have only post-market BWs (Cheng 
2014a). This study focuses on the latter category: drugs that have only a post-market BW. In total, 
9% of approved drugs launch without a boxed warning and then receive a post-market BW. 
The proportion of drugs that have boxed warnings is increasing over time (Cheng 2014a; 
Cheng 2014b). Researchers propose several potential explanations for increases in BW prevalence. 
First, the FDA increased its focus on drug safety and communication of drug risks due to recent 
initiatives (Cheng 2014b; FDA 2017). Second, increases in FDA review speed, particularly for 
drugs that qualify for accelerated approvals (e.g. orphan drugs, breakthrough therapies, etc.), may 
make drugs more susceptible to FDA safety actions (Heemstra 2010; Frank 2014). Third, biologic 
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drugs, which are becoming more common, tend to have higher risks of boxed warnings (Cheng 
2014b; Giezen 2008).  
While the prevalence of drugs with boxed warnings is increasing, it is not clear whether 
boxed warnings work as intended to transmit drug risk information to prescribers. Previous studies 
have found variation in both the volume and patterns of prescribing following boxed warnings and 
lower-level risk communications (Dusetzina 2012; Wagner 2006; McClellan 2019). Some studies 
find large drops in prescribing following boxed warnings (Dorsey 2010; Ventimiglia 2010; Cohen 
2010; Stewart 2009; Habib 2008). Others find little or no change in prescribing (Chen 2011; 
Kornfield 2013; Mittal 2014) or find prescribing decreases after lower-level risk communications 
but not after the boxed warning (Libby 2009; Du 2012). 
Research is needed to determine whether boxed warnings provide an additional impact 
over lower-level risk communications that precede the boxed warning, and why there is so much 
variation in the impact of boxed warnings on prescribing. Variation in post-boxed warning 
prescribing is not problematic in and of itself. The goal of boxed warnings is to transmit 
information to prescribers so they can accurately weigh drug risks and benefits when making their 
prescribing decisions. Since patients vary in their individual risks and benefits, some variation in 
post-boxed warning prescribing is expected. However, variation may be cause for concern if it 
indicates underlying differences in prescriber awareness of boxed warnings, or unequal receipt of 
drug safety information by patients. 
Indeed, there is some evidence that prescribers vary in their awareness and knowledge of 
specific boxed warnings drugs (Karpel 2009; Smollin 2016). One study found that prescribers were 
unaware of a drug’s boxed warning for 64% of the drugs surveyed, and that 87% of prescribers 
could not identify which serious drug risks were mentioned in the boxed warning (Smollin 2016). 
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Prescribers who are not aware of the new drug safety information in a drug’s boxed warning are 
likely to underestimate the drug’s risks when weighing the relative risks and benefits of the drug 
to make their prescribing decision. All else equal, this means that prescribers who are not aware 
of the boxed warning will be more likely to prescribe the boxed warning drug, and thus, that their 
patients will be at higher risk for the drug’s adverse events.  
In addition to prescriber variation in awareness of boxed warnings, there are other potential 
reasons that patients may have unequal receipt of drug safety information. There is extensive 
literature showing that patient characteristics are an important predictor of health care utilization 
and health disparities (Babitsch 2012; Ben 2017; Insaf 2010; AHRQ 2019; IOM 2003; Nelson 
2002). Patient race, ethnicity, sex, age, and insurance status are known to impact quality of care 
(Ben 2017; AHRQ 2019; IOM 2003; Nelson 2002; Teunissen 2016). Patients receiving poorer 
quality care may be more likely to see prescribers who are unaware of the updated safety 
information in the boxed warning, or who are not implementing those safety findings into their 
prescribing decisions. To the extent that this occurs, certain patient groups may be more at risk for 
prescribing decisions that are not concordant with new safety information, which would be 
concerning from an equity and health disparities perspective.  
Many studies that assess the impact of FDA risk communications focus on a single risk 
communication for a single drug or drug class. This makes it difficult to make generalizations 
about the impact of risk communications on prescribing. To address this gap in the literature, I 
study lower-level risk communications and boxed warnings spanning multiple drugs, classes, and 
treatment areas. Specifically, this dissertation studies risk communications for the following 
serious safety issues: 1) suicidality risks of antidepressants, 2) mortality risks of atypical 
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antipsychotics, 3) gastrointestinal and cardiovascular risks of COX-2 inhibitors, 4) cardiovascular 
risks of glitazones, 5) efficacy concerns of Plavix. 
In this study, I aim to shed light on whether boxed warnings have any additional impact 
over lower-level risk communications, and to examine the role of prescriber and patient 
characteristics in predicting heterogeneity in the impact of boxed warnings on prescription rates. 
To address these goals, I pursue three specific aims:  
Aim 1: To evaluate the relative impacts of initial low-level FDA safety 
communications versus boxed warnings on prescribing. The main hypothesis for this aim is 
that both lower-level FDA risk communications and BWs will be associated with decreased 
probability of prescribing, but that the lower-level FDA risk communication will be less important 
than BWs in both magnitude and statistical significance. This study is presented in Chapter 2.  
Aim 2: To determine whether prescriber characteristics moderate post-boxed 
warning drug prescribing. The main hypothesis for this aim is that prescriber characteristics that 
predict lower net cost of information gathering will predict a larger decrease in prescribing 
following the addition of the boxed warning. For example, I hypothesize that prescribers in urban 
areas and group practices will have a lower net cost of information gathering and thus will decrease 
prescribing by more than rural prescribers and prescribers in solo practices. This study is presented 
in Chapter 3.  
Aim 3: To determine whether patient characteristics moderate post-boxed warning 
drug prescribing. The main hypothesis for this aim is that patients who are more likely to receive 
lower quality care will be less likely to receive care that is concordant with new safety information, 
and thus will be less likely to have a decrease in prescribing probability after the boxed warning is 
added. I utilize existing literature on health disparities to generate hypotheses regarding which 
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patients will be at risk for receiving lower quality care. For example, I hypothesize that Hispanic 
ethnicity patients, non-White patients, and patients who do not have private health insurance will 
be more likely to receive low quality care, and less likely to have a reduction in prescribing 
following the boxed warning. This study is presented in Chapter 4. 
This dissertation contributes to knowledge of boxed warnings and drug risk 
communications in general. The goal of FDA risk communications is to convey drug safety 
information so prescribers can accurately weigh drug risks and benefits when making prescribing 
decisions. By comparing the relative impacts of low-level FDA risk communications versus boxed 
warnings on prescribing, I can assess whether prescribers’ prescribing changes are calibrated to 
the level of the risk concerns, or if prescribers respond similarly to all levels of FDA 
communications. Additionally, by studying multiple prescriber characteristics, I aim to increase 
knowledge about what factors influence prescriber learning and the role of prescriber 
characteristics in moderating post-boxed warning prescribing. Finally, I aim to determine whether 
there are patient disparities in the dissemination of drug safety information by examining whether 
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CHAPTER 2: STUDY 1:  
EVALUATING THE IMPACT OF FDA DRUG SAFETY COMMUNICATIONS  
ON PRESCRIBING 
 
2.1.  INTRODUCTION 
Adverse drug reactions kill 100,000 people each year, impose serious morbidity on another 
2 million more, and cost the United States $136 billion annually (FDA 2018). To reduce adverse 
drug reactions, the FDA continues to monitor drug safety issues after a product is approved, and 
has multiple tools for communicating drug safety issues to healthcare professionals. In this study, 
I focus on six serious safety issues that were discovered after the drugs were on the market. These 
safety issues were subject to lower-level FDA risk communications before ultimately receiving 
the FDA’s highest warning – the boxed warning (BW). This presents the opportunity to assess the 
relative prescribing impact of lower-level FDA risk communications compared to boxed warnings. 
The FDA employs multiple postmarketing surveillance strategies to detect potential drug 
safety concerns. The FDA analyzes trends in adverse drug event reports from manufacturers, 
health professionals, and patients (FDA 2020; FDA 2016a; FDA 2019; Kessler 1993). 
Additionally, the FDA reviews findings from studies conducted by academic researchers, drug 
manufacturers, and the FDA itself (FDA 2019; FDA 2020; FDA 2016a; Scott Morton 2012).  
After the FDA finds a new safety concern, it uses two main channels of risk communication 
to warn prescribers and patients: prescription drug labeling and drug safety communications. 
Prescription drug labeling, often referred to as the “package insert,” is the FDA-mandated drug 
safety and efficacy information for a given product (FDA 2012a; FDA 2016c; FDA 2012b). There 
are multiple sections of the prescription drug labeling where safety information is communicated. 
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These include the following sections: Boxed Warning, Warnings and Precautions, Adverse 
Reactions, Contraindications, Drug Interactions, Clinical Pharmacology, and Clinical Studies 
sections (FDA 2011; FDA 2012a). FDA drug safety communications appear on the FDA website 
and include the following types of communications: Early Communication about an Ongoing 
Safety Review, Public Health Advisory, Letters to Health Care Professionals, Information for 
Health Care professionals, and Drug Safety Communications (FDA 2012a; FDA 2012b).  
To decide which risk communication tools to utilize, the FDA considers adverse event 
severity, reversibility, incidence, and the strength of evidence of the drug’s causal role in producing 
the adverse event (FDA 2012a). When safety findings are in preliminary stages, and the causal 
role of the drug is yet unknown, the FDA will often utilize lower-level risk communications, 
including drug safety communications, and non-boxed warning changes to prescription drug 
labeling (FDA 2012b; FDA 2016b; FDA 2016c). As additional findings are made, the FDA will 
utilize higher-level risk communications, including the boxed warning, as needed.  
Boxed warnings (BWs) represent the highest-level warning the FDA can put on 
prescription drug labeling.  They differ from other risk communications in important ways. First, 
BWs require a higher threshold of evidence than other risk communications. Second, the FDA 
reserves BWs for the most serious safety concerns, such as those causing death, hospitalization, 
serious and/or long-term disability, or congenital anomaly or birth defects (FDA 2011). Third, 
BWs are the most prominent risk communication in the prescription drug labeling. Specifically, 
the FDA mandates that BWs appear at the top of the first page of the prescription drug labeling, 
written in bolded text, and surrounded by a black box (hence their name “boxed warnings” or 
“black box warnings”) (FDA 2007; FDA 2011; FDA 2012b). For illustrative purposes, Appendix 
1 shows the prominent placement of the boxed warning on the Avandia prescription drug labeling. 
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About one third of prescription drugs have boxed warnings (Cheng 2014a; Cheng 2014b) 
and this rate is increasing over time. Researchers propose several potential explanations for 
increases in BW prevalence. First, the FDA increased its focus on drug safety and communication 
of drug risks due to recent initiatives (Cheng 2014b; FDA 2017). Second, increases in FDA review 
speed, particularly for drugs that that qualify for accelerated approvals (e.g. orphan drugs, 
breakthrough therapies, etc.), may make drugs more susceptible to FDA safety actions (Heemstra 
2010; Frank 2014). Third, biologic drugs, which are becoming more common, tend to have higher 
risks of boxed warnings (Cheng 2014b; Giezen 2008). However, research has not provided 
conclusive evidence on whether boxed warnings work as intended, or whether they provide any 
additional impact over lower-level risk communications that precede the boxed warning 
(McClellan 2019).  
Previous studies have found variation in both the volume and patterns of prescription 
medications following boxed warnings and lower-level risk communications (Dusetzina 2012; 
Wagner 2006; McClellan 2019). Some studies find large drops in prescribing following boxed 
warnings (Dorsey 2010; Ventimiglia 2010; Cohen 2010; Stewart 2009; Habib 2008). Others find 
little or no change in prescribing (Chen 2011; Kornfield 2013; Mittal 2014), or find prescribing 
decreases after lower-level risk communications but not after the boxed warning (Libby 2009; Du 
2012). In some cases, researchers have found that changes in total prescribing after the BW 
disappear after controlling for differences in visit counts (Chen 2011). This shows that it is 
important to control for changes in treatment seeking or propensity to diagnose, when measuring 
changes in prescribing probability. Studies that rely on aggregate annual data struggle to isolate 
the impact of risk communications when multiple risk communications occur in a given year, or 
when a risk communication occurs mid-year (Chen 2011; Pham 2013; Mittal 2014), highlighting 
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the need for monthly data to allow more precise separation between time periods. Most studies 
that assess the impact of risk communications focus on a single risk communication for a single 
drug or drug class, which make generalizing about the impact of risk communications on 
prescribing difficult. 
My study fills gaps in prior knowledge by comparing the impact of boxed warnings versus 
lower-level FDA risk communications on prescribing for six serious safety issues spanning 
multiple drugs, classes, and treatment areas. Specifically, I study the following serious safety 
issues: 1) suicidality risks of antidepressants, 2) mortality risks of atypical antipsychotics, 3) 
gastrointestinal and cardiovascular risks of COX-2 inhibitors, 4) cardiovascular risks of glitazones, 
5) variation in drug efficacy of Plavix. Each of these six serious safety issues in this study were 
initially unknown to the FDA and prescribers, then were subject to low-level FDA risk 
communications, and ultimately boxed warnings. I utilize monthly visit-level data to examine 
prescribing changes after initial FDA low-level risk communications and after the boxed warnings. 
I measure changes in prescribing probability among patients with conditions treated by these 
drugs, rather than aggregate prescribing counts to control for changes in total visits or diagnosis 
rates. I hypothesize that both lower-level FDA risk communications and BWs will be associated 
with decreased probability of prescribing, but that the lower-level FDA risk communications will 
be less important than BWs in both magnitude and statistical significance. 
This study contributes to knowledge on boxed warnings and on the role of drug risk 
communications in general. The goal of FDA risk communications is to convey information so 
prescribers can accurately weigh drug risks and benefits when making prescribing decisions. By 
comparing the relative impacts of low-level FDA risk communications versus boxed warnings on 
prescribing, I can assess whether prescribers’ prescribing changes are calibrated to the level of risk 
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concerns, or if prescribers respond similarly to all levels of FDA communications. If low-level risk 
communications show the same impact on prescribing as boxed warnings, the FDA may want to 
consider changes to their risk communications to better differentiate the distinct levels of risk and 
strength of evidence. This analysis also has methodical implications for future studies of boxed 
warnings. If initial FDA risk communications cause prescribing to decrease before the BW then 
studies that look only at pre-BW versus post-BW prescribing would miss an anticipatory drop in 
prescribing. Examining pre-BW prescribing changes will help us determine whether empirical 
models of boxed warnings need to adjust pre-periods to incorporate the impact of earlier drug risk 
communications. This study will also contribute to knowledge on reasons for variation in post-
BW prescribing. Overall, FDA boxed warnings and other risk communications provide a useful 
case study of the role of negative information on quantity demanded, and how to model negative 
information shocks. 
2.2.  CONCEPTUAL FRAMEWORK 
I utilize the principal-agent framework as a basis for understanding drug prescribing 
decisions. Specifically, I assume that prescribers act as patients’ agents in making prescribing 
decisions on behalf of their patients (principals) (McGuire 2000; Dranove 2000; Scherer 2000; 
Scott Morton 2012). To make prescribing decisions, prescribers rely on their knowledge of drug 
risks and benefits to choose the treatment with the highest expected health for their patients 
(McGuire 2000; Scherer 2000). Prescribers knowledge of drug risks and benefits is not static, and 
is updated as they learn new information. Prescribers have multiple sources of information 
regarding drug risks and benefits, including the FDA, drug companies, academic journals, media, 
medical conferences, and other physicians (Avorn 1982; Smollin 2016). 
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In this study, I focus on the FDA as a source for risk information. Specifically, I focus on 
two FDA risk communication events: 1) the date of the initial low-level FDA risk communication 
for a given safety concern, 2) the date of the boxed warning for that safety concern. I propose that 
as the level of FDA risk communication increases, there will be a commensurate increase in 
prescribers’ level of concerns regarding drug risks. I illustrate this hypothesis in my conceptual 
model (Figure 2.1) by defining discretized periods of FDA risk communications (no risk 
communications, low-level risk communications, and high-level risk communications) that 
correspond with proportional increases to prescribers’ drug risk concerns (minimal, moderate, and 
high concern). I hypothesize that during the period where there are no FDA risk communications, 
prescribers’ concern regarding drug risks will be minimal. After the initial FDA communication, 
prescribers’ concerns will increase slightly to a moderate level of concern regarding drug risks. 
Finally, after the boxed warning is announced, prescribers’ concerns will increase more drastically 
to a high-level of concern regarding drug risks.  
One of the reasons that I believe FDA risk communication levels will predict prescribers’ 
risk concern level is that I find FDA risk communications closely approximate the level of 
available knowledge regarding these safety concerns. This is because the FDA is designed to be 
sensitive to potential safety concerns, and therefore generally releases risk communications as soon 
as new concerns are identified (Murphy 2006; FDA 2012a; FDA 2012b). Indeed, for the safety 
issues in this study, I find that there are only minor hints regarding the safety issues prior to the 
first FDA risk communication. These early hints consist only of preliminary case studies or small 
sample size studies, and studies are relatively split between those finding evidence of concerns and 
those finding no evidence. Since these preliminary studies do not definitely conclude that there is 
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a problem, I propose that they are unlikely to result in widespread concerns about the drug risks, 
and thus will have little to no impact on prescribing probability.   
When the FDA’s initial risk communication is released, I posit that prescribers’ concerns 
regarding drug risks will increase for several reasons. First, some prescribers learn about the safety 
issues directly from the risk communication. Second, given the FDA’s proclivity for releasing risk 
communications as soon as safety concerns are identified, I find that for all of the safety issues in 
this study, the initial FDA risk communications occur before, or within one month of, any major 
releases of safety information (e.g. seminal journal articles or press releases by manufacturers) 
(see Figure 2.2). The FDA released the first Plavix risk communication within one month of the 
first large studies that found variation in Plavix efficacy (Simon 2009; Mega 2009). For glitazones, 
the first FDA risk communication occurred on the same day as the online publication of the seminal 
article suggesting that one of the two drugs in the glitazone class (Avandia) was associated with 
cardiovascular risks (Nissen 2007). Similarly, the first COX-2 inhibitor FDA risk communication 
was released on the same day that Merck announced their voluntary withdrawal of Vioxx from the 
market due to potential cardiovascular concerns (FDA 2004). For antidepressants and atypical 
antipsychotics, the initial FDA risk communications preceded any seminal articles regarding the 
study safety concerns.  
Compared to the period where there were no risk communications, I expect that the initial 
FDA risk communications will increase prescribers’ drug risk concerns. However, low-level risk 
communications are relatively common (McClellan 2019), and can be used for mild safety 
concerns and those which lack conclusive evidence about the drug’s causal role (FDA 2011). Thus, 
I expect that low-level risk communications will not attract the attention of all prescribers, and 
even among prescribers who are aware of initial risk communications, only some will conclude 
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that the risks are serious enough to change their prescribing behavior. Based on this, I hypothesize 
that prescribing will decrease after the initial FDA risk communication, but only among some 
prescribers, and only by a small amount. 
Compared to the initial low-level FDA risk communications, I expect that boxed warnings 
will have a larger impact on prescribing because boxed warnings are less common than low-level 
communications, indicate more serious safety concerns, and convey a higher strength of evidence 
of the drug’s causal role (FDA 2011). These characteristics of boxed warnings make them more 
likely to merit higher levels of attention from prescribers and patients, as well as greater coverage 
in journals, medical conferences, and the media. As a result, I propose that boxed warning safety 
concerns will reach a greater number of prescribers than those reached by low-level risk 
communications. Additionally, I hypothesize that the higher severity and strength of evidence 
conveyed by boxed warnings will mean that among prescribers who are aware of the boxed 
warning, a significant share will conclude that the risks are serious enough to merit changes in 
their prescribing decisions. 
Overall, I hypothesize that each FDA risk communications will increase the number of 
prescribers that are aware of drug risks and the overall perception of a drug’s risk level. To the 
extent that perceived risks increase enough to alter the balance of drug risks and benefits, risk 
communications will result in a decrease in prescribing. Among FDA risk communications, I 
expect that boxed warnings will have a larger marginal effect than initial low-level risk 
communications on the number of prescribers who are aware of drug risks, prescribers’ level of 




2.3.  DATA 
 
2.3.1.  Data Sources 
Visit data 
This study relies on visit-level physician survey data from the National Ambulatory 
Medical Care Surveys (NAMCS) and National Hospital Ambulatory Medical Care Surveys 
(NHAMCS). These data are collected using a multi-stage sampling design from a national sample 
of physicians in three health care settings: office-based outpatient visits, hospital outpatient visits, 
and emergency department visits. I utilize the publicly available data files for 2002 through 2011, 
the most recent data year that includes all three settings. NAMCS data include office-based 
outpatient visits from a national sample of office-based non-federal physicians. For each physician, 
a random sample of their visits in one week of each year is surveyed. NHAMCS data include 
hospital outpatient and emergency department visits from a national sample of non-federal, non-
institutional general and short-stay hospitals with at least six patient beds. For each hospital, a 
random sample of visits is surveyed from a randomly assigned four-week reporting period. 
NAMCS and NHAMCS data include patient diagnoses, reasons for visit, medications, 
demographics, visit setting, U.S. Census region, and physician/hospital characteristics. Data 
include complex survey data sampling weights to allow generation of nationally representative 
estimates. 
Drug information 
I rely on the Food and Drug Administration (FDA)’s website, and the National Institute of 
Health (NIH)’s Daily Med website for data on FDA safety communications and FDA drug labeling 
for the study drugs. I utilize historic and current drug labels to identify FDA approved indications, 
boxed warning date, and boxed warning content.  
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2.3.2.  Sample 
Selection of study boxed warnings 
To identify boxed warnings for this study, I collected boxed warning data for a large 
number of drugs, and then reviewed this list for the following considerations: 1) the boxed warning 
was added in the post-market period rather than at drug approval2, 2) the boxed warning was added 
between 2004 and 2010, to allow sufficient observation of prescribing trends during the pre- and 
post-boxed warning periods in the 2002-2011 NAMCS/NHAMCS data, 3) the boxed warning 
would affect a reasonable amount of patients, 4) the conditions treated by the drugs are identifiable 
using diagnosis codes.  
This study examines the initial FDA risk communications and boxed warnings for the 
following drug safety issues: 1) Antidepressants: Suicidality risks for younger patients, 2) Atypical 
antipsychotics: Mortality risks for elderly with dementia, 3) COX-2 Inhibitors: Cardiovascular and 
gastrointestinal risks, 4) Glitazones: Congestive heart failure risks, 5) Plavix: Diminished 
effectiveness for CYP2C19 poor metabolizers. The characteristics of these boxed warnings are 
described in more detail in Table 2.1, and the complete text of the boxed warnings for each safety 
issue is included in Appendix 2. These five boxed warnings span multiple drugs, classes, and 
treatment areas, and vary across other domains as well, including issuance date (October 2004 to 
March 2010), risk category (adverse event risk vs. efficacy risks), and scope (single drug vs. 
multiple drug classes) (see Table 2.1). 
 
 
                                                        
2 This study is limited to drugs that only have post-market BWs so it is possible to observe prescribing before the drug 
received a boxed warning. In total, 9% of approved drugs launch without a boxed warning and then receive a post-
market BW. (Cheng 2014a).  
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Identification of visits for analytic samples 
I identify separate analytic samples for each of the five boxed warnings (see Figure 2.3). 
To be included in an analytic sample, a visit must meet the following inclusion criteria: 1) the visit 
must be for a patient for whom the boxed warning is relevant (i.e. patients described in the boxed 
warning as having higher risk for the relevant adverse drug reactions), 2) the visit must occur in 
the relevant time period, defined as up to two years prior to the initial FDA risk communication 
through two years following the boxed warning, subject to the overall dataset time period (2002-
2011)3, 3) the visit must be for a patient with a condition eligible for treatment by the relevant 
study drug(s). Eligible conditions are defined as the labeled indications. However, for atypical 
antipsychotics, the boxed warning pertains to an off-label indication (dementia). Thus, assessing 
prescribing changes among these patients requires the eligible condition to be dementia, rather 
than the on-label indications for atypical antipsychotics.  
Based on the above inclusion criteria, the general definition of the analytic samples for 
each of the study drug groups is as follows: 1) Antidepressants: Children/adolescents (under 18 
years) with depression and/or anxiety, 2) Atypical antipsychotics: Elderly patients (65 years or 
older) with dementia, 3) COX-2 Inhibitors: Elderly patients (65 years or older) and/or patients with 
cardiovascular risk factors, with arthritis, ankylosing spondylitis, primary dysmenorrhea, and/or 
acute pain, 4) Glitazones: Heart failure patients with Type 2 diabetes, 5), Plavix: Patients with 
acute coronary syndrome, myocardial infarction, stroke, and/or peripheral arterial disease (PAD)4. 
Detailed criteria for identifying these visits, including ICD-9 codes, are defined in Table 2.2. 
                                                        
3 For all analytic samples, data are limited to visits that occurred in the years in which the 2002-2011 surveys took 
place. The 2002 NAMCS and NHAMCS data files includes a small number of visits that occurred at the end of 2001. 
I exclude these visits, which account for less than 1% of visits in the 2002 survey (see Figure 2.3). 
4 Note that the patients for whom the Plavix BW is relevant are CYP2C19 poor metabolizers. However, the 
NAMCS/NHAMCS data do not allow identification of poor metabolizers. Accordingly, the Plavix analytic sample 
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2.3.3.  Measures 
Dependent variables 
The dependent variable, Rx, is a binary variable indicating whether the boxed warning drug 
was prescribed in the eligible visit. The dependent variable is “1” if the visit indicates a prescription 
for the branded or generic versions of any of the following drugs: 1) Antidepressants: all classes 
of antidepressants. 2) Atypical antipsychotics: Abilify (aripiprazole), Clozaril (clozapine), Geodon 
(ziprasidone), Invega (paliperidone), Risperdal (risperidone), Seroquel (quetiapine), Zyprexa 
(olanzapine), 3) COX-2 inhibitors: Bextra (valdecoxib), Celebrex (celecoxib), and Vioxx 
(rofecoxib), 4) Glitazones: Avandia (rosiglitazone), and Actos (pioglitazone), 5) Plavix: Plavix 
(clopidogrel). 
Key independent variables 
Boxed warning is a binary variable indicating whether the visit occurred after the boxed 
warning was added. NAMCS/NHAMCS data specify the month and year in which each visit 
occurred, so boxed warning date is defined on the month-year level. For visits occurring in the 
month when the boxed warning is added it is not possible to ascertain whether the visit preceded 
the boxed warning. Thus, visits in the month the boxed warning was issued excluded from the 
analyses to avoid incorrect specification of event timing (Wagner 2002).  
FDA alert is a binary variable indicating whether the visit occurred after the first FDA risk 
communication pertaining to the safety concerns that later receive a boxed warning. As with the 
boxed warning variable, FDA alert is defined on the month-year level, and visits in the month of 
the initial FDA risk communication are excluded from the analyses (Wagner 2002).  
                                                        
includes all visits by patients with conditions that fall under Plavix’s FDA approved indications, rather than only those 
eligible for Plavix that are also poor metabolizers. 
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Control variables 
Control variables include patient race (White (referent), Black, or other), patient sex 
(female is referent), patient age (continuous variable), patient primary payer (private insurance, 
public insurance (referent), or other), physician specialty (primary care or specialist (referent)), 
and a monthly time trend. Referent values for categorical variables are assigned based on the most 
common value among visits in the evaluation dataset. 
2.4.  METHODS 
 
2.4.1.  Descriptive statistics 
For each analytic sample, I calculate mean prescribing rates for the overall data period, and 
for three sub-periods where I expect drug information levels to differ: 1) prior to FDA release of 
any information regarding the concerns in the BW, 2) after initial FDA alert regarding BW 
concerns for one or more of the drugs in the BW group, but before the addition of the BW, 3) after 
the BW is added. Differences in prescribing rates across the three time periods is assessed using 
chi-squared test, adjusted for complex survey design. Statistical significance is assessed at the 95% 
confidence level.  
2.4.2.  Empirical models 
Stratified models  
I estimate separate logit models for each boxed warning drug group, j, with and without 
controlling for FDA alert:  
Eqn. 1:   Pr#𝑅𝑥&'( = 1+ =
,-./01.
23,-./01.
  with	𝑋&'(𝛽& = 𝛽;& + 𝛽2&𝐵𝑊&'( + 𝛽?&𝐶&'(  
Eqn. 2:   Pr#𝑅𝑥&'( = 1+ =
,-./01.
23,-./01.
  with	𝑋&'(𝛽& = 𝛽;& + 𝛽2&𝐵𝑊&'( + 𝛽?&𝐴𝑙𝑒𝑟𝑡&'( + 𝛽F&𝐶&'(   
where j denotes boxed warning drug group, t denotes month, and i denotes individual visit.  
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The outcome variable, Rx, is a binary variable indicating a prescription for a boxed warning 
drug at the given visit. BW is a binary variable for whether the visit occurred after the BW was 
issued, Alert is a binary variable for whether the visit occurred after the first FDA risk 
communication, and C is a vector of control variables, which vary by model, but include patient 
race, patient age, patient sex, patient primary payer, prescriber specialty, and a monthly time trend.  
For each equation above, I estimate two versions of the models that vary on which control variables 
are included: A) a simple version of the model that controls only for a monthly time trend, B) a 
more robust model that also includes the additional individual-level patient and prescriber 
characteristics described above.  
Complex survey design features of the data are incorporated to adjust for multi-stage 
sample design of NAMCS and NHAMCS data.5 Analyses of eligible visits within each drug-group 
are done according to complex survey design requirements for subgroup analysis (Lee 2006).6  
I report odds ratios, average differential effects, and 95% confidence intervals. Average 
differential effects in the predicted probabilities are calculated using methods of recycled 
predictions. 95% confidence intervals for average differential effects are calculated using 
bootstrapped stratified clusters with 100 replications. 
Pooled models 
In addition to separate logit models for each BW drug group, I estimate several pooled 
models. Pooled models allow estimation of a common BW effect, and the larger sample size 
                                                        
5 Complex survey design features include adjustments for physician nonresponse, a post-stratification adjustment so 
that the sample distribution of visits by specialty is comparable to national of physicians by specialty group, and 
weight smoothing for outlier visit weights.  
6 Survey data analysis requires multiple primary sampling units (clusters) within each strata (Lee 2006). When a 
stratum contains only one cluster, the bootstrap sampling method does not work. On average less than 5% of 
observations/visits in each BW drug group are in a singleton strata. See Appendix 3 for the algorithm applied to these 
observations. 
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created by pooling the analytic samples may increase precision. However, an LR test comparing 
the pooled models to the individual BW drug group stratified logit models concludes that the 
pooled model is not an appropriate alternative to the individual models so I do not report these 
results. 
2.5.  RESULTS 
 
2.5.1.  Descriptive statistics 
There are six final analytic samples, one for each BW drug group, and one for the pooled 
BW analytic sample. Descriptive statistics show decreases in prescribing rates after the BW is 
added for all of the study BW drug groups (see Table 2.3, Figures 2.4 and 2.5). This post-BW 
decrease in prescribing is statistically significant for COX-2 inhibitors (p<0.001), glitazones 
(p=0.047), and the pooled BW analytic sample (p<0.001). Post-BW decreases in prescribing for 
antidepressants, atypical antipsychotics, and Plavix are not statistically significant.  
Among the BW drug groups, COX-2 inhibitors and glitazones have the largest decreases 
in prescribing between the pre-BW and post-BW periods. COX-2 inhibitor prescribing decreased 
by 65% between the pre-BW and post-BW periods, from 13% pre-BW (95% CI=11% to 15%) to 
5% post-BW (95% CI: 3% to 6%). Glitazones prescribing decreased by 61% between the pre-BW 
and post-BW periods: 14% pre-BW (95% CI: 6% to 21%) to 5% post-BW (95% CI: 1% to 10%).  
The antidepressants analytic sample includes 3,088 visits by children and adolescents with 
depression and/or anxiety (Table 2.3). Prior to the initial FDA alert, the prescribing rate of 
antidepressants was 52% (95% CI: 43% to 60%). Antidepressant prescribing remained at 52% 
after the initial FDA alert. After the BW was added, the prescribing rate decreased to 45% (95% 
CI: 38% to 52%); this change was not statistically significant.  
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The atypical antipsychotics analytic sample includes 1,500 visits for elderly patients with 
dementia (Table 2.3). Prior to the initial FDA alert, atypical antipsychotics were prescribed in 14% 
of visits by elderly with dementia (95% CI: 6% to 23%). There were no statistically significant 
changes to the prescribing rate after the FDA alert or the BW. Prescribing increased to 18% (95% 
CI: 11% to 24%) after the FDA alert and then decreased back to 14% (95% CI: 9% to 19%) after 
the BW was added.  
 The COX-2 inhibitor analytic sample includes 15,917 visits by patients who have 
gastrointestinal and/or cardiovascular risk factors, and are eligible for a COX-2 inhibitor 
prescription (Table 2.3). Prior to the initial FDA alert, the prescribing rate of COX-2 inhibitors 
was 14% (95% CI: 12% to 16%). After the FDA alert, prescribing decreased to 10% (95% CI: 7% 
to 13%), and then decreased further to 5% (95% CI: 3% to 6%) after the BW.  
The glitazone analytic sample includes 777 visits for Type 2 diabetes patients with heart 
failure (Table 2.3). Prior to the initial FDA alert, glitazones were prescribed in 11% of eligible 
visits (95% CI: 4% to 19%). After the FDA alert, there was a non-statistically significant increase 
in prescribing. When the glitazone BW was added prescribing decreased to 5% (95% CI: 1% to 
10%). The prescribing rates before and after the BW are statistically significantly different at the 
95% confidence level (p=0.047).  
The Plavix analytic sample contains 7,002 visits that are eligible for a Plavix prescription 
(Table 2.3). There were no statistically significant changes to the prescribing rate after the FDA 
alert or the BW. The initial Plavix prescribing rate was 18% (95% CI: 14% to 21%). After the 
FDA alert prescribing increased slightly to 21% (95% CI: 17% to 25%), and then returned to 18% 
after the BW (95% CI: 13% to 23%).  
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2.5.2.  Regression results 
I estimate four separate logit models for each of the five drug groups. The four models vary 
based on two attributes: 1) which events are included as key independent variables (BW only vs. 
BW and initial FDA risk communication), 2): which control variables are included in the model. 
Models 1A and 1B include a single key event: boxed warning. Model 1A is a simple model 
controlling only for monthly time trend, whereas Model 1B is a more robust model that includes 
additional controls for patient and prescriber characteristics. Model 2A and 2B include two key 
events: the initial FDA risk communication, and the boxed warning. Model 2A only controls for 
monthly time trend, while Model 2B has additional controls.  
Effect of initial FDA communications on prescribing    
Logit model results show that the initial FDA alert does not have a statistically significant 
impact on prescribing of any of the BW drugs (see Tables 2.4 and 2.5). Comparison of the models 
with and without the FDA alert variable show that adding the FDA alert variable has little impact 
on the size of the BW coefficient, and the direction of the effect is mixed. Adding the FDA alert 
variable to the models has no impact on the statistical significance of the BW coefficients for any 
of the BW drug groups. 
Effect of boxed warning on prescribing    
Logit model results show that the estimated effect of the BW on prescribing is negative for 
all BW drug groups, but statistical significance of the effect varies across drug groups and models 
(Table 2.4 and Table 2.5). The estimated BW effect is statistically significant across all COX-2 
inhibitor models and in some of the glitazones models. Models for antidepressants, atypical 
antipsychotics, and Plavix fail to reject the null hypothesis that the boxed warning has no effect on 
prescribing probability.  
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For COX-2 inhibitors, I estimate that the odds of prescribing a COX-2 inhibitor after the 
boxed warning is 0.5 times the odds of prescribing a COX-2 inhibitor before the boxed warning 
(see Table 2.4). This indicates that the odds of prescribing a COX-2 inhibitor after the BW is about 
half of the pre-BW odds of prescribing. This effect is statistically significant at the 95% confidence 
level. The magnitude and significance of this estimated effect is the same across all four models; 
in other words, the estimated BW effect is not affected by whether the model includes the initial 
FDA risk communication or additional individual-level control variables. I also estimate the 
average differential effect of the boxed warning on COX-2 inhibitor prescribing. I find that the 
COX-2 boxed warning is associated with a 5 percentage point decrease in prescribing probability, 
compared to the pre-boxed warning period, and that this effect is statistically significant at the 95% 
confidence level (Table 2.5).  
For glitazones, I find a statistically significant impact on the odds ratio of prescribing for 
the Models 1A and 2A, the simple models without individual-level control variables. These models 
estimate that the odds of prescribing a glitazone after the boxed warning is added are 0.07 to 0.09 
times the odds of prescribing a glitazone before the boxed warning. However, when I add 
additional control variables to the model I fail to reject the null hypothesis that the odds ratios are 
different than 1 (see Models 1B and 2B in Table 2.4). I also estimate the average differential effects 
of the boxed warning for all four glitazone models. I estimate that the boxed warning is associated 
with a 22 percentage points decrease in prescribing probability, compared to pre-BW period, for 
the simplest model (Model 1A: boxed warning only, minimal control variables). Adding additional 
control variables (Model 1B) reduces this estimated differential effect to a 17 percentage point 
decrease in prescribing probability following the boxed warning. Both of these differential effects 
are statistically significant at the 95% confidence level (see Models 1A and 1B in Table 2.5). 
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However, models that include the initial FDA risk communications (Models 2A and 2B) do not 
find a statistically significant differential effect of boxed warning on prescribing probability (see 
Model 2A and 2B in Table 2.5).  
2.6.  DISCUSSION 
 
2.6.1.  Effect of initial FDA risk communications on prescribing 
It is particularly interesting that COX-2 inhibitor models did not find a statistically 
significant change following the initial FDA risk communication because among all the study 
drugs, this is the only instance where the initial FDA alert occurred at the same time as a product 
withdrawal. Specifically, the initial COX-2 inhibitor risk communication occurred on the same 
day that one of the members of this drug class (Vioxx) was voluntarily withdrawn from the market. 
The withdrawal of Vioxx indicates a greater degree of safety concerns than is normally relayed by 
a safety communication, or even by a BW. Additionally, the withdrawal of Vioxx means that the 
product was no longer around to prescribe even if prescribers wanted to prescribe it. Prescribers 
still had the ability to prescribe other COX-2 inhibitors following the initial risk communication, 
but it is likely that not all prior-Vioxx users would switch to other COX-2 inhibitors. Some of them 
may discontinue use of COX-2 inhibitors altogether. Additionally, since Vioxx was a blockbuster 
drug, its withdrawal attracted significant media coverage. I expect media coverage to increase 
transmission of safety information to prescribers, so more media attention should result in earlier 
prescriber awareness of safety concerns. Accordingly, I would expect that COX-2 inhibitors had 
higher perceived safety concerns at the time of the initial risk communication than other drugs did 
at the time of their initial FDA risk communications. Given that the Vioxx withdrawal and media 
attention occurred at the same time as the FDA alert, I would expect the estimated effect of the 
FDA alert to be biased upwards because the model is attributing all decreased prescribing in that 
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month to the FDA alert, when in reality some portion of the change is due to the Vioxx withdrawal 
and media attention. Given this, the lack of statistical significance of the initial FDA risk 
communication for COX-2 inhibitors is particularly surprising, and may suggest that even major 
drug safety changes have a limited ability to impact prescribing. 
Overall, there is little evidence to support my hypothesis that initial FDA risk 
communications decrease prescribing. There are several possible reasons for this. First, low-level 
risk communications are relatively common. The high prevalence of these communications may 
lead to alert fatigue on the part of prescribers, which would cause prescribers to be desensitized to 
these communications (Ancker 2017). Second, low-level FDA risk communications often indicate 
that research is still ongoing (FDA 2012a; FDA 2012b). Prescribers may hold off on changing 
prescribing until more certain evidence is released by the FDA. Third, information dissemination 
is not immediate; it is likely to take some time for prescribers to learn about new risk evidence.   
2.6.2.  Effect of BW on prescribing 
In general, boxed warnings appear to decrease prescribing for patients targeted by the 
boxed warning. The fact that the trend is negative for all study BW groups supports the dampening 
effect of BWs on prescribing. Even when new safety issues are serious, the drug can still have 
important benefits for patients: the drug should still be prescribed when benefits exceed the risks 
for a given patient. Thus, decreased prescribing does not necessarily indicate an ideal response to 
risk communications. It is possible that decreased prescribing can result in undertreatment of 
legitimate medical issues. Ideally, risk communications allow prescribers to identify and 
discontinue prescribing for patients for whom the risks outweigh the benefits (high-risk patients) 
while continuing to prescribe the drug for patients for whom the benefits outweigh the risks (low-
risk patients). If risk communications are successful, a drug can safely remain on the market 
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because those at highest risk from taking the drug will discontinue the drug and/or receive 
additional monitoring to reduce the chance of the adverse event. More research is needed to 
determine whether risk communications improve prescribing decisions. 
My ability to find a prescribing effect from the Plavix BW may have been limited by the 
fact that it is not possible to limit the analyses to the patients described by the BW as being at 
highest risk for the safety concerns. Specifically, the BW is directed at patients who are poor 
metabolizers based on their CYP2C19 genotype. However, study data do not include genomic 
testing data, which would be required to identify these patients. It is possible that the BW has a 
large effect on the poor metabolizer patients, but that since the data are not limited to those patients, 
the effect among those patients is concealed by a lack of change among patients that are not poor 
metabolizers.  
One thing that I would expect to increase the Plavix BW effect is that the Plavix BW does 
not apply to the other drugs in Plavix’ drug class. Plavix is an anti-platelet drug in the 
thienopyridine drug class, which includes two other drugs (ticlopidine and prasugrel), neither of 
which have the same BW as Plavix. Thus, compared to the other BW analytic samples, prescribers 
in the Plavix analytic sample will have a greater ability to prescribe similar drugs that are not 
subject to the BW safety concerns. However, it is worth noting that ticlopidine and prasugrel also 
have BWs, just not the same BW as Plavix. Nonetheless, the presence of similar drugs that are not 
subject to the same safety concerns is a key difference between Plavix and the other study drugs. 
Other BWs in this study apply to either an entire class of drugs (COX-2 inhibitors, glitazones, 
atypical antipsychotics) or to multiple classes of drugs (antidepressants of all classes). Determining 
the role of alternative treatment options in BW response is an important area of future study. 
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2.6.3.  Limitations 
While this study has many strengths, there are some limitations. First, while I control for 
the initial FDA alert and BW, there could be events outside the scope of this study that impact 
prescribing (e.g. other FDA safety communications, media articles, new drug indications). For 
example, atypical antipsychotics were also subject to safety concerns other than those in the study 
BW; in the study period there were two FDA alerts and a Professional Society Consensus statement 
warning about metabolic risks of atypical antipsychotics. It is possible that inclusion of these co-
occurring safety events would impact the study findings.  
Second, omitted variable bias could be caused by variables not included in my analysis. 
For instance, I was not able to control for changes in pharmaceutical advertising and promotion, 
which is known to impact prescribing (Rosenthal 2003; Iizuka 2005; Dave 2014; Datta 2017). 
However, post-BW changes in promotion are likely to be related to the BW because the FDA 
prohibits certain promotional activities after a drug receives a BW (Lee Ventola 2011; FDA 2015). 
Third, there may be measurement error in identifying the timing of key FDA events. I 
operationalized the BW date as the date that the BW was announced by the FDA. However, in 
some cases there are a few months delay between the announcement of the BW and manufacturers 
adding the BW wording to their drug labels. Additionally, many prescribers may rely on drug 
compendia to stay up-to-date on drug information, and these sources are also susceptible to lags 
in adding the BW (Smollin 2016; Cheng 2011). These lags in implementation of the boxed warning 
could cause the boxed warning effect estimates to be biased towards the null. 
Fourth, I focused on initial FDA alerts in this study because they are the first sign from the 
FDA regarding the safety issues that ultimately become boxed warnings. However, it is possible 
that FDA alerts in general are important but that the initial FDA alert has little impact. One reason 
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this may be the case is that initial FDA alerts often mention only one drug, while subsequent FDA 
alerts often expand to additional drugs in the group. The sample size in this study was not large 
enough to allow differentiation between multiple FDA alerts, but this would be a good area of 
study in future research.  
Lastly, the study data have a few limitations worth noting. NAMCS and NHAMCS data 
have small sample sizes for some subgroups of visits, particularly for glitazones and atypical 
antipsychotics. Data are de-identified and do not allow following patients or prescribers over time.  
Thus, it not possible to see whether prescribing rates changed at the prescriber level. However, the 
NAMCS and NHAMCS data offer important strengths over prescription claims data. For instance, 
visit-level data allows easy identification of the diagnoses associated with the visit where a drug 
was prescribed. Additionally, visit data allows precise measurement of written prescriptions 
instead of relying on filled prescriptions.  
2.7.  CONCLUSION 
 
I find little evidence that initial FDA safety alerts decrease prescribing. This may indicate 
that prescribers accurately perceive that safety alerts are reserved for cases where the causal role 
of the drug is still uncertain. Alternatively, since initial safety alerts often pertain to a single drug, 
prescribers may not get alarmed until safety alerts or BWs extend safety concerns to the other 
drugs in a class. If this is the case, it is possible that initial safety alerts will have no effect on 
prescribing, but subsequent warnings will. Either way, more research should be done in this area 
to assess whether the effect of FDA alerts varies across drugs, and if so whether variation is 
associated with differences in the strength of evidence of initial safety findings or in other drug-
level factors. 
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I find that prescribing decreases after a boxed warning is added. This suggests that the 
highest level FDA warning is succeeding in conveying risk information to prescribers. However, 
the impact of the boxed warning varies widely. Some drug groups have only small or statistically 
non-significant changes in prescribing after the boxed warnings, while others have huge drops in 
prescribing. Further study is needed to assess the cause of variation in boxed warning response. In 
my next dissertation aims, I will assess whether prescriber or patient characteristics predict 
variation in boxed warning response.   
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FIGURES AND TABLES 
 
Figure 2.1. Conceptual Model: FDA Risk Communication Level as Predictor of Prescribers’ Level 
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Table 2.2. Identification of Study 1 Analytic Samples 
 
BW Drug Group Visit Inclusion Criteria for Analytic Samples 
Antidepressants Visit is for a patient with one or more of the following conditions:  
Depression: ICD-91: 296.2x, 296.3x, 300.4x, 309.00, 309.10, 311.xx; RFV2 code: 1110.0  
Anxiety: ICD-9: 293.84, 300.0x, 300.2x, 300.3, 309.24, 309.28, 309.81; RFV codes: 1100.0, 
1105.0, 1130.5 
and the patient has the following risk factors described in the BW: Age under 18 years 
and the visit occurs within the following time period: January 2002 - October 2006 
Atypical 
antipsychotics 
Visit is for a patient with the following condition:  
Dementia3: ICD-9: 290.0x, 290.1x, 290.2x, 290.3x, 290.4x, 294.1x, 294.2x, 294.8x, 331.0x, 
331.1x, 331.82 
and the patient has the following risk factors described in the BW: Age is 65 years or older 
and the visit occurs within the following time period: January 2002 – April 2007  
COX-2  
Inhibitors 
Visit is for a patient with one or more of the following conditions:  
Arthritis:   ICD-9: 715.xx, 714.0-714.2, 714.3x; RFV code: 2900.0 
Ankylosing Spondylitis:   ICD-9: 720.0x 
Primary Dysmenorrhea:   ICD-9: 625.3x; RFV code: 1745.2 
Acute Pain:   ICD-9: 338.1x, 338.3x, 346.xx, 719.4x, 723.1x, 724.1x, 724.2x, 724.5, 729.5x, 
780.96, 784.0x; RFV codes: 1055.0, 1055.4, 1060.0, 1060.1, 1210.0, 1900.1, 1905.1, 1910.1, 
1915.1, 1920.1, 1925.1, 1930.1, 1935.1, 1940.1, 1945.1, 1950.1, 1955.1, 1960.1, 1965.1, 
1970.1, 1980.1, 2365.0, 2675.5 
and the patient has one or more of the following risk factors described in the BW:  
Gastrointestinal risk factors: Age is 65 years or older 
Cardiovascular disease or risk factors:  myocardial infarction (410.xx, 412.xx), stroke (430.xx, 
431.xx-436.xx, 438.xx, V12.54), heart failure (398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 404.93, 428.xx), peripheral arterial disease (PAD) (249.70, 249.71, 
250.70, 250.71, 250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 
440.31, 440.32, 440.4, 440.8, 440.9, 443.1, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 
445.02), unstable angina (411.1, 413.0, 413.9), other ischemic heart disease (411.xx, 414.xx), 
hypertension (401.xx-405.xx), and/or CABG surgery (V45.81) 
and the visit occurs within the following time period: September 2002 – April 2007 
Glitazones Visit is for a patient with the following condition:  
Type 2 Diabetes: ICD-9: 250.x0, 250.x2 and age of 35 years or older4 
and the patient has one or more of the following risk factors described in the BW: 
Heart failure: ICD-9: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 
404.93, 428.xx; and/or congestive heart failure (CHF) identified by survey response5 
and the visit occurs within the following time period: May 2005 – August 2009 
Plavix  
(clopidogrel)6 
Visit for a patient with at least one of the following conditions: 
Acute coronary syndrome:   ICD-9: 410.xx, 412.xx, 411.1, 413.0, 413.9 
Myocardial infarction:   ICD-9: 410.xx, 412.xx 
Stroke:   ICD-9: 430.xx, 431.xx-436.xx, 438.xx, V12.54 
Peripheral arterial disease (PAD)7:   ICD-9: 249.70, 249.71, 250.70, 250.71, 250.72, 250.73, 
440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 440.31, 440.32, 440.4x, 440.8x, 
440.9x, 443.1x, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02 
and the visit occurs within the following time period: January 2007 – December 2011 
Notes: 
1: ICD-9 refers to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes. 
ICD-9 codes were identified in 2003-2011 code listings from the Center for Disease Control and Prevention (CDC). Changes in 
ICD-9 codes over time were assessed and accounted for where relevant (CDC; CDC 2013).  
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2: RFV code refers to Reason for Visit code; These codes are defined in the NAMCS/NHAMCS data file documentation. RFV 
codes are not listed for conditions that lack corresponding RFV codes (e.g. due to lack of specificity of codes). 
3 Dementia is not an FDA-approved indication for atypical antipsychotics but is included in the list of relevant conditions 
because dementia patients are the focus on the atypical antipsychotic boxed warning. 
4 Several studies note shortcomings of ICD-9 codes for identifying Type 2 diabetes among younger patients (Alexander 2008; 
Rhodes 2007). Following Alexander and others, I identify Type 2 diabetes patients using a combination of ICD-9 code and age 
criteria to address the fact that Type 1 patients are sometimes coded as Type 2 patients (Alexander 2008; Xie 2013; Karve 
2008). Excluding younger patients accounts for the fact the onset of Type 2 diabetes generally occurs in adulthood (CDC 2019). 
5 NAMCS/NHAMCS surveys include a question regarding whether the patient has congestive heart failure (CHF). 
6 The Plavix BW identifies patients that are CYP2C19 poor metabolizers as having higher risk of adverse events. However, the 
NAMCS/NHAMCS data do not allow identification of these patients. Accordingly, the Plavix analytic sample includes all visits 
by patients with conditions that fall under Plavix’s FDA approved indications, rather than only those eligible for Plavix that are 
also poor metabolizers. 
7 Peripheral arterial disease (PAD) ICD-9 codes are identified in a study of PAD incidence and prevalence (Kalbaugh 2017). 
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2002-2011 data files  
(n=335,824) 
Exclude visits that occurred in 2001 (n=285) 
NHAMCS OPD  
2002-2011 data files 
(n=335,824) 
NHAMCS ED  
2002-2011 data files 
(n=354,219) 
Total visits in NAMCS and NHAMCS 2002-2012 
data files (n=980,313) 
• Outpatient visits (n=626,094) 
• Emergency department visits  (n=354,219) 
 
Total visits assessed for eligibility for analytic 
samples (n=980,028) 
• Outpatient visits (n=625,922) 
• Emergency department visits  (n=354,106) 
 
 
Antidepressant analytic sample  
(n=3,088) 
 
Atypical Antipsychotic analytic sample  
(n=1,500) 
 
COX-2 Inhibitor analytic sample  
(n=15,917) 
 
Glitazone analytic sample  
(n=777) 
 
Plavix analytic sample  
(n=7,002) 
 




Table 2.3. Descriptive Statistics for Analytic Samples 
























Months 17 15 24 33 24 58
N (visits) 901 879 1,240 1,828 1,240 3,088
Rx rate 0.52 0.52 0.45 0.291 0.51 0.45 0.162 0.48
Standard error (0.045) (0.037) (0.035) (0.028) (0.035) (0.022)
















Months 15 23 24 39 24 64
N (visits) 350 553 558 923 558 1,500
Rx rate 0.14 0.18 0.14 0.676 0.16 0.14 0.521 0.15
Standard error (0.045) (0.035) (0.024) (0.027) (0.024) (0.019)
















Months 24 6 24 31 24 56
N (visits) 6,914 1,698 6,801 8,853 6,801 15,917
Rx rate 0.14 0.096 0.046 <0.001* 0.13 0.046 <0.001* 0.092
Standard error (0.01) (0.016) (0.0065) (0.0086) (0.0065) (0.0056)
















Months 24 2 24 27 24 52
N (visits) 329 35 381 384 381 777
Rx rate 0.11 0.32 0.054 0.036* 0.14 0.054 0.047* 0.096
Standard error (0.039) (0.18) (0.022) (0.039) (0.022) (0.023)
















Months 24 13 21 38 21 60
N (visits) 2,884 1,490 2,371 4,510 2,371 7,002
Rx rate 0.18 0.21 0.18 0.618 0.19 0.18 0.728 0.19
Standard error (0.018) (0.02) (0.025) (0.013) (0.025) (0.012)
95% CI [0.14,0.21] [0.17,0.25] [0.13,0.23] [0.16,0.22] [0.13,0.23] [0.16,0.21]
Pooled sample
N (visits) 11,160 4,581 11,080 16,195 11,080 27,705
Rx rate 0.16 0.19 0.095 <0.001* 0.17 0.095 <0.001* 0.14
Standard error (0.0091) (0.013) (0.0071) (0.0074) (0.0071) (0.0052)
95% CI [0.15,0.18] [0.16,0.21] [0.081,0.11] [0.16,0.18] [0.081,0.11] [0.13,0.15]
Means and standard errors are adjusted for complex survey data weights and design features. Linearized standard errors reported 
in parentheses. Differences between prescription rates in different time periods are tested using a Chi-squared test with complex 
survey design methods. * p<0.05
Three periods Two periods
 43 





































































































































































































































































Figure 2.5. Prescribing Rates Before and After Boxed Warnings 
 
  
   





































































































































































































Table 2.4. Odds Ratio of Prescribing Following Boxed Warning, FDA Alert 
 
  
[Model 1A] [Model 1B] [Model 2A] [Model 2B]
BW only BW only + controls BW + FDA alert BW + FDA alert + controls
BW 0.763 0.959 0.739 0.864
[0.384,1.516] [0.509,1.807] [0.345,1.580] [0.420,1.776]
FDA Alert 1.019 0.869
[0.509,2.040] [0.441,1.715]
N 3,068 3,017 3,020 2,969
F-statistic 0.982 10.000*** 0.856 10.185***
BW 0.476 0.480 0.393 0.411
[0.138,1.639] [0.150,1.534] [0.098,1.573] [0.108,1.559]
FDA Alert 0.710 0.749
[0.229,2.205] [0.252,2.226]
N 1,481 1,465 1,461 1,445
F-statistic 0.693 3.239*** 0.585 5.740***
BW 0.513* 0.508* 0.544* 0.534*
[0.292,0.905] [0.285,0.907] [0.303,0.975] [0.293,0.974]
FDA Alert 0.782 0.771
[0.439,1.395] [0.431,1.378]
N 15,654 15,488 15,413 15,248
F-statistic 26.694*** 8.634*** 18.011*** 7.794***
BW 0.088* 0.128 0.074* 0.124
[0.009,0.863] [0.016,1.049] [0.008,0.681] [0.014,1.061]
FDA Alert 2.469 2.307
[0.307,19.841] [0.298,17.876]
N 765 754 745 734
F-statistic 2.477 3.555*** 1.984 3.227***
BW 0.856 0.811 0.974 0.931
[0.445,1.647] [0.425,1.548] [0.460,2.061] [0.446,1.943]
FDA Alert 1.407 1.420
[0.736,2.690] [0.742,2.719]
N 6,881 6,771 6,745 6,637
F-statistic 0.110 1.596 0.602 1.530
Control variables
FDA alert No No Yes Yes
Monthly time trend Yes Yes Yes Yes
Patient variables No Yes No Yes
Physician specialty No Yes No Yes
Adjusted for complex 
survey design features
Yes Yes Yes Yes
Notes: 








Table 2.5. Average Differential Effects of Boxed Warning and FDA Alert 
 
  
[Model 1A] [Model 1B] [Model 2A] [Model 2B]
BW only BW only + controls BW + FDA alert BW + FDA alert + controls
BW -0.0675   -0.00929   -0.0755   -0.0323   
[-0.207, 0.0723] [-0.120, 0.101] [-0.230, 0.0796] [-0.159, 0.0940]
FDA Alert 0.00465   -0.0308   
[-0.157, 0.167] [-0.169, 0.107]
N 3,068   3,017   3,020   2,969   
F-statistic 0.982   10.0*** 0.856   10.2***
BW -0.0923   -0.0879   -0.116   -0.106   
[-0.230, 0.0451] [-0.210, 0.0339] [-0.271, 0.0384] [-0.248, 0.0352]
FDA Alert -0.0476   -0.0382   
[-0.178, 0.0823] [-0.160, 0.0838]
N 1,481   1,465   1,461   1,445   
F-statistic 0.693   3.24** 0.585   5.74***
BW -0.0504** -0.0506** -0.0461* -0.0468*
[-0.0855, -0.0153] [-0.0860, -0.0152] [-0.0824, -0.00968] [-0.0837, -0.00991]
FDA Alert -0.0197   -0.0207   
[-0.0643, 0.0249] [-0.0636, 0.0223]
N 15,654   15,488   15,413   15,248   
F-statistic 26.7*** 8.63*** 18.0*** 7.79***
BW -0.221* -0.165* -0.248   -0.171   
[-0.419, -0.0238] [-0.325, -0.00594] [-0.501, 0.00545] [-0.388, 0.0463]
FDA Alert 0.0819   0.0679   
[-0.167, 0.331] [-0.154, 0.290]
N 765   754   745   734   
F-statistic 2.48* 3.55*** 1.98* 3.23**
BW -0.0232   -0.0309   -0.00394   -0.0107   
[-0.113, 0.0670] [-0.120, 0.0586] [-0.113, 0.105] [-0.117, 0.0962]
FDA Alert 0.0508   0.0520   
[-0.113, 0.105] [-0.117, 0.0962]
N 6,881   6,771   6,745   6,637   
F-statistic 0.110   1.60   0.602   1.53   
Control variables
FDA Alert No No Yes Yes
Monthly time trend Yes Yes Yes Yes
Patient variables No Yes No Yes
Physician specialty No Yes No Yes
Adjusted for complex 
survey design features
Yes Yes Yes Yes
Notes: 








Figure 2.6. Estimated Odds Ratio of Prescribing after Boxed Warning 
 
   
 
Notes:  
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CHAPTER 3: STUDY 2:  
THE ROLE OF PHYSICIAN CHARACTERISTICS IN POST-BOXED WARNING 
PRESCRIBING 
 
3.1.  INTRODUCTION 
“Boxed warnings” (BW) are the highest level of warning issued by the Food and Drug 
Administration (FDA). These warnings are reserved for drugs with the most serious adverse drug 
reactions, such as those that cause permanent disability or death (FDA 2011). The FDA uses boxed 
warnings to communicate these serious drug risks to prescribers for consideration in their 
prescribing decisions. Given the safety risks of these drugs, prescribers should be aware of the 
boxed warning and incorporate the new risk information into their treatment decisions. However, 
prescribers vary in their awareness and knowledge of boxed warnings regarding specific drugs 
(Karpel 2009; Smollin 2016). One study found that prescribers were unaware of a drug’s boxed 
warning for 64% of the drugs surveyed, and that 87% of prescribers could not identify which 
serious drug risks were mentioned in the boxed warning (Smollin 2016).  
Generally, studies find variation in post-boxed warning prescribing volume and patterns 
(Dusetzina 2012; Wagner 2006); Some drugs have large drops in prescribing after receiving a 
boxed warning, (Dorsey 2010; Ventimiglia 2010; Cohen 2010; Stewart 2009; Habib 2008), while 
other drugs have little or no change in prescribing (Chen 2011; Kornfield 2013; Mittal 2014). 
However, few studies have examined whether boxed warning response varies between different 
types of prescribers.  Two studies suggested that boxed warnings’ impact on prescribing may vary 
between specialists and primary care prescribers, but findings were mixed (Kornfield 2013; Karpel 
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2009). Additionally, it is not known whether other prescriber characteristics are correlated with 
post-boxed warning prescribing. Variation in prescribers’ responses to boxed warnings may 
provide insight into differences in prescribers’ awareness of boxed warnings and/or areas for 
intervention.   
Since boxed warning drugs have the potential to cause serious adverse reactions, it is 
important to study whether prescriber-related characteristics are associated with lower 
responsiveness to boxed warnings. All else equal, if a prescriber has smaller decreases in post-
boxed warning prescribing than other prescribers, their patients will be more likely to receive the 
boxed warning drug, and thus at higher risk for the drug’s adverse events. Additionally, 
heterogeneity in post-boxed warning prescribing may provide insight into variation in prescribers’ 
awareness of boxed warnings. This information could help the FDA know which providers to 
target in drug safety communications or dissemination of other important drug information, and 
shed insight on causes of variation in boxed warning impact within and between drugs.  
In this study, I evaluate whether prescriber characteristics moderate post-boxed warning 
changes in prescribing. I hypothesize that characteristics that impact ease of information gathering 
will be correlated with higher prescriber awareness of boxed warnings, and thus with larger post-
boxed warning prescribing changes. Specifically, I hypothesize that prescriber characteristics that 
reduce the costs of acquiring new risk information (e.g. larger practice size, urban setting), or 
increase benefits of information gathering (e.g. prescribers that specialize in disease(s) treated by 
the given drug) will be correlated with larger changes in post-boxed warning prescribing.  
By studying multiple prescriber characteristics, I aim to increase knowledge about what 
factors influence prescriber learning and the role of prescriber characteristics in moderating post-
boxed warning prescribing. Given the previously documented variation in boxed warning impact 
 56 
across drugs, I study five boxed warnings, which span multiple drugs, drug classes, therapeutic 
treatment areas, and adverse event types. Studying a diverse set of boxed warnings will increase 
knowledge regarding the extent of variation in boxed warning impact between drugs.  
3.2.  MOTIVATION AND OVERVIEW 
3.2.1.  Overview of boxed warnings 
 “Boxed warnings” (BW) are the highest possible warning that can appear on prescription 
drug labeling7 [hereafter “drug labels”]. The purpose of a boxed warning is to alert prescribers to 
serious potential safety issues for a given drug. The FDA mandates that boxed warnings be 
displayed prominently at the top of the first page of the drug label in bolded text outlined by a 
black box (hence their name “boxed warnings” or “black box warnings”) (FDA 2007; FDA 2011, 
FDA 2012). For illustrative purposes, For illustrative purposes, Appendix 1 shows the prominent 
placement of the boxed warning on the Avandia prescription drug labeling. 
3.2.2.  Boxed warning criteria 
All drug labels include information about possible drug side effects, but few side effects 
meet the criteria for a “boxed warning.” The FDA regulates the format and content of drug labels 
and is responsible for deciding when a drug side effect is severe enough to merit a boxed warning. 
Boxed warnings are generally reserved for the following cases (FDA 2011):  
1) An adverse reaction is so serious in comparison to the drug benefits that it is vital for 
prescribers to consider the risk when making prescribing decisions 
2) A serious adverse reaction may be prevented or reduced if prescribers make specific 
changes to their prescribing of the drug and/or monitoring of patients  
                                                        
7 Also referred to as the “package insert” or “prescribing information” (FDA 2016; FDA 2012). 
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3) An adverse reaction is so serious that the FDA has restricted use and/or distribution of the 
drug 
The serious adverse reactions that meet the level to be included in a boxed warning are those where 
the drug’s causal role is likely8, and where the reaction is so severe that it can result in death, 
hospitalization, long-term disability, or congenital anomalies (FDA 2011).9  
3.2.3.  Pre-market versus post-market boxed warnings 
The FDA can require a drug’s manufacturer to add a boxed warning to the drug label at 
any point in a drug’s lifecycle.  When pre-approval studies reveal serious drug risks the FDA can 
require a boxed warning as a condition of approval, in which case the drug label will contain a 
boxed warning from the moment it launches. These boxed warnings are often referred to as “pre-
market boxed warnings.” In contrast, when risks meriting a boxed warning are not realized until 
after drug’s approval and launch, the FDA can require a boxed warning after the drug has been on 
the market for some time. These boxed warnings are known as “post-market boxed warnings.”  
3.2.4.  Prevalence of boxed warnings 
About one third of prescription drugs have boxed warnings (Cheng 2014a; Cheng 2014b) 
and this rate is increasing over time.10 Some drugs receive multiple boxed warnings over the course 
of their lifecycle, and thus it is possible for a drug to have both a pre-market boxed warning and a 
                                                        
8 Boxed warnings are reserved for drugs where there is there is “reasonable evidence” that the drug causes an adverse 
reaction, but full certainty regarding the drug’s causal role is not required (FDA 2011).  
9 Boxed warnings are generally based on observed drug outcomes. However, in certain cases, the FDA may add a 
boxed warning for an adverse event that has not been observed and is merely anticipated based on animal or 
pharmacologic studies (FDA 2011). 
10 Researchers propose several potential explanations for increases in BW prevalence. First, the FDA increased their 
focus on drug safety and communication of drug risks due to recent initiatives (Cheng 2014b; FDA 2017). Second, 
increases in FDA review speed, particularly for drugs that that qualify for accelerated approvals (orphan drugs, 
breakthrough therapies, etc.), may make drugs more susceptible to FDA safety actions (Heemstra 2010; Frank 2014). 
Third, biologic drugs, which are becoming more common, tend to have higher risks of boxed warnings (Cheng 2014b; 
Giezen 2008).  
 58 
post-market boxed warning. Among boxed warnings drugs, 58% have only pre-market BWs, 28% 
have only post-market BWs, and 14% have both pre- and post-market BWs (Cheng 2014a). In 
total, 9% of approved drugs launch without a boxed warning and then receive a post-market BW. 
3.2.5.  Prescriber information sources for boxed warning information  
Prescribers acquire and update drug knowledge through a variety of sources. In addition to 
prescription drug labeling, prescribers gain information from published clinical studies, academic 
research, medical conferences, pharmaceutical drug representatives, drug advertising, their own 
prescribing experience, and other prescribers (Avorn 1982; Smollin 2016). Prescribers also utilize 
drug compendia, including electronic drug information sources (e.g. mobile applications), which 
are increasingly popular with prescribers (Smollin 2016). However, drug compendia may not 
always have updated or accurate information regarding a drug’s boxed warning. For instance, 
studies show that drug compendium often fail to identify boxed warnings or report inaccurate 
information about the content of the warnings (Kesselheim 2013; Cheng 2011). The shortcomings 
of drug compendia may affect prescribers’ abilities to update their drug knowledge, including 
about a given drug’s boxed warning status.  
3.3.  ECONOMIC FRAMEWORK 
3.3.1.  Boxed warnings as a tool for information dissemination 
Boxed warnings can be thought of as a signal to prescribers that a drug is risky. The 
addition of a boxed warning helps to disseminate new drug safety information to prescribers so 
they can update their prior knowledge of drug risks. As the information is disseminated and 
prescribers learn about the addition of the boxed warning, their perceived risks will increase as 
compared to before the boxed warning. Post-market boxed warnings provide a good opportunity 
to observe how information shocks to prescribers’ prior risk knowledge affect their prescribing 
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decisions. The time it takes for prescribers to learn that the drug’s label and risk level have changed 
will depend on how often prescribers utilize the aforementioned information sources, or engage in 
other learning activities that update their drug knowledge.  
3.3.2.  Benefits and Costs of Acquiring Drug Information 
I rely on economic theory to describe the costs and benefits associated with updating drug 
information and how drug information enters the prescribing decision. I propose that differences 
in awareness of updated risk information are related to prescribers’ costs and benefits of acquiring 
new information, and that these costs vary by prescriber. 
Costs of Acquiring Drug Information 
Acquiring updated drug information is costly for prescribers. I assume prescribers allocate 
their time between leisure time, compensated work activities (e.g. seeing patients), and learning 
activities, such as those that allow updates to drug information. Thus, time spent learning requires 
an opportunity cost to leisure time and/or compensated work activities.  
From a budget constraint perspective, learning activities also have financial costs for the 
prescriber. First, time spent on learning activities is typically unpaid. Thus, any reductions to 
compensated work activities due to increased learning activities will impact prescribers’ budget 
constraints by reducing revenue. In addition to foregone revenue, learning activities may also have 
direct costs for prescribers. For instance, attending medical conferences requires significant 
financial expenditures (conference registration, travel costs, accommodations, etc.). Similarly, 
prescribers may pay subscription costs for medical and academic journals to stay up-to-date on 
new studies.  
The cost of acquiring drug safety information may be reduced substantially with the 
increased prevalence of electronic prescribing because electronic health records (EHRs) often have 
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built-in tools to warn prescribers about drug risks. However, the high prevalence of EHR alerts 
contributes to alert fatigue on the part of prescribers, leading to desensitization to drug alerts and 
high rates of dismissal of drug safety alerts (Ancker 2017; McCoy 2014; Van der Sijs 2006). These 
alert fatigue issues reduce the ability of EHRs to convey safety information to prescribers or to 
provide meaningful clinical decision support (McCoy 2014).  
Benefits of Acquiring Drug Information 
Prescribers also receive benefits from engaging in learning activities and updating 
information regarding the drugs they prescribe. Prescribers get intrinsic benefits from engaging in 
learning activities: prescribers’ pursuit of a career in medicine indicates they place intrinsic value 
on helping patients, and thus have a utility-based preference to improve patient health. Prescription 
drugs can cause large changes in patient health, both in positive and negative directions. By staying 
up-to-date on changes to drug information, prescribers can ensure that they are making prescribing 
decisions based on the best available information.  
In convention with economic norms, I assume that the optimal prescribing decision is to 
prescribe the treatment with the highest expected value of patient health, based on each treatment 
option’s range of possible health outcomes and their corresponding probabilities of occurring. A 
prescriber’s ability to maximize patient expected health requires them to accurately calculate the 
expected value of each treatment option. If prescribers do not have up-to-date information on drug 
risks and benefits, the inputs to this calculation may not be accurate, and thus, they may not be 
making the optimal prescribing decision for their patients. Since non-optimal prescribing may 
result in negative health consequences for their patients, prescribers have a utility-based incentive 
to invest time in updating drug information so they are using accurate information in their 
prescribing decisions. In addition to intrinsic reasons for maximizing patient health, prescribers 
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also have financial incentives to maximize patient health. For instance, prescribers in practices 
with pay-for-performance programs may have performance-based financial incentives for 
improving quality of care and patient health outcomes (Mendelson 2017).  
Prescribers may receive other benefits from engaging in learning activities. By staying up-
to-date on clinical literature, prescribers ensure that they practice evidence-based medicine, which 
will reduce prescribers’ risks of medical malpractice litigation (Williams 2008). Indeed, 
prescribers with worse training credentials have higher risks of malpractice litigation (Weycker 
2000). Prescribers also must participate in continuing medical education (CME) to keep their 
medical license active. CME requirements vary by state in terms of quantity and content, but 
generally prescribers are able to get CME credit for a variety of learning activities that could 
increase their knowledge of drug information (Miller 2008; Johnson 2005).  
3.3.3.  Expected impact of boxed warning on prescribing 
As is typical in health economics, I utilize the principal-agent framework as a basis for 
understanding drug prescribing decisions (McGuire 2000; Dranove 2000; Scherer 2000; Scott 
Morton 2012). I assume that prescribers act as patients’ agents in making prescribing decisions on 
behalf of their patients (principals). As I mention in the prior section, I assume that prescribing 
decisions involve choosing the treatment option with the highest expected value of patient health 
(McGuire 2000; Scherer 2000).   
Like other expected value calculations, expected health is calculated by summing the 
products of each possible health outcome, and its corresponding probability of occurring. Boxed 
warnings have the potential to affect prescribers’ perceptions of two inputs to expected health: the 
probability of a negative health outcome, and the resulting health level in that scenario. 
Specifically, boxed warnings indicate an increased probability of a negative health outcome (i.e. 
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increased likelihood of adverse drug events) and/or decrease in health level from a negative health 
outcome (i.e. increased severity of adverse drug events, e.g. death), compared to what was 
previously known. These changes will cause prescribers’ calculated expected health for a given 
drug to be lower in the post-boxed warning period than it was before the boxed warning was added. 
However, a decrease in the boxed warning drug’s expected health may not impact the 
prescribing decision. As is the case before a boxed warning is added, post-boxed warning 
prescribing decisions are based on drugs’ relative expected health calculations, where the drug 
with the highest expected health is prescribed. So, post-boxed warning prescribing will depend on 
whether the boxed warning drug’s updated expected health is higher or lower than the expected 
health of alternative drugs for the same treatment. However, assuming the expected health for 
other alternative drugs remains unchanged, the reduction in expected health for the boxed warning 
drug will reduce the likelihood of the boxed warning drug being the drug that maximizes expected 
health. Thus, in aggregate I expect that the decrease in expected health for these drugs will reduce 
prescribing of post-market boxed warning drugs. Accordingly, I hypothesize that prescribers who 
are aware of a given boxed warning will have a lower probability of prescribing the corresponding 
drug(s), compared to prescribers who have not yet learned about the warning. 
3.3.4.  Expected prescriber variation in costs and benefits of updating drug information 
I hypothesize that there is prescriber heterogeneity in the costs and benefits of acquiring 
updated drug information, and that these differences will cause variation in the degree to which 
prescribers acquire updated drug information. I hypothesize that prescriber characteristics that 
reduce the net costs of information gathering will predict larger differences between pre- and post-
boxed warning prescribing of boxed warning drugs. Specifically, I expect the following 
characteristics to reduce the net cost of learning:  
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1) Practice size: I predict that prescribers in group practices will face lower costs of 
learning than those in solo practices. Practice owners have incentives to subsidize prescribers’ 
learning costs because staying up-to-date on clinical information can result in better clinical 
outcomes, practice ratings, and decreased malpractice litigation. Thus, practices may provide 
academic journal subscriptions for their staff, and/or may subsidize the cost of attending 
continuing education workshops and medical conferences. Given returns to scale, larger practices 
may have a greater ability to subsidize learning activities for their prescribers. Group practices can 
reduce individual prescriber’s learning costs by dividing the burden of learning costs among the 
practice’s prescribers. For instance, while solo prescribers would be responsible for the full costs 
of academic journal subscriptions, group practices may divide the cost among the practice’s 
prescribers. In addition to impacting the financial costs of learning, I predict that practice size will 
influence prescribers’ time costs of learning. Prescribers in group practices are more likely to 
collaborate with and work in the proximity of other prescribers. These increased interactions with 
other prescribers provide more opportunities for prescribers to share knowledge (Phelps 2000). By 
sharing knowledge with their peers, prescribers reduce the time and financial costs of acquiring 
updated drug information. 
2) Urban practice settings: I expect that higher number of prescribers in urban areas will 
allow urban prescribers to interact and share knowledge with other prescribers more easily than 
their peers in rural areas. I hypothesize that this ease of information sharing will reduce costs of 
acquiring updated drug information, and thus, will predict larger changes in prescribing between 
the pre- and post-boxed warning periods.  
3) Specialty prescribers: I propose that utility returns to learning are only realized if the 
prescriber is able to make better prescribing decisions that result in greater improvements in 
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expected patient health. Thus, prescribers’ investment in learning activities for a given drug will 
depend on the composition of their patient population: Prescribers will have greater returns to 
learning about a given drug if they treat more patients with the condition for which the drug is 
indicated. For example, if a prescriber sees a large number of diabetes patients they would have a 
higher incentive to regularly update their knowledge of diabetes drugs because they are more likely 
to prescribe those drugs.  In addition to differences in benefits of learning, I expect specialists to 
face different costs of learning, as compared to generalists. Because specialists have a more 
concentrated patient case mix, and treat fewer conditions than generalists, they are likely to 
prescribe a narrower range of drug types than other prescribers. Having a narrower range of drugs 
on which to update information decreases specialists’ costs of learning and allows them to enjoy 
more certain benefits from time spent learning about updated drug information.  
4) Prescriber degree type: While there are multiple health degrees that give providers 
prescribing authority11, I only discuss doctors of osteopathic medicine (D.O.s) and doctors of 
medicine (M.D.s)12 due to the scope of the study data. M.D.s and D.O.s are both trained and 
licensed to utilize pharmacological and other conventional medical treatment options (Earley 
2010; AOA). However, these physicians differ in their training, underlying treatment principles, 
and medical philosophy (Peters 1999; Earley 2010; AOA; Johnson 2002; Kuchera 2007). 
Osteopathic principles highlight the body’s interconnectedness and natural ability to heal and self-
regulate, and encourage D.O.s to utilize a holistic whole-body approach to treatment, rather than 
                                                        
11 States laws dictate which types of health care providers are allowed to prescribe medications, but can include 
physician and non-physician health care providers. Physicians include medical doctors (M.D.s) and osteopathic 
physicians (D.O.s). Non-physician health care providers can include registered nurses (R.N.s), physician assistants 
(P.A.s), osteopathic assistants (O.A.s), pharmacists, etc. 
12 M.D.s are also referred to as allopathic physicians.   
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focusing on specific diseases or symptoms (AOA; Peters 1999; Earley 2010). Additionally, 
osteopathic medicine has a greater emphasis on alternative treatment therapies such as 
acupuncture, manipulation therapy, etc. (Peters 1999; Kuchera 2007; AOA; Johnson 2002; Early 
2010). I propose that D.O.s’ greater use and acceptance of alternative treatments translates to an 
increased number of non-pharmacological treatment options, which may crowd out their use of 
pharmaceutical treatments. Specifically, since D.O.s consider a wider range of non-
pharmacological treatments, I expect them to rely less on pharmaceutical treatment options13, and 
to be less willing to accept risks from pharmaceutical treatment. Thus, I hypothesize that D.O.s 
will prescribe less than M.D.s across all time periods (pre- and post-BW) and to be more likely to 
cease prescribing upon becoming aware of the BW. 
In summary, I expect that prescribers’ costs/benefits of acquiring information will 
influence their frequency of updates to drug information, and accordingly their awareness of a 
given boxed warning. Thus, I predict that prescribers’ costs/benefits of information gathering will 
moderate the impact of boxed warnings on post-boxed warning prescribing. Specifically, I 
hypothesize that prescribers in group practices, urban settings, specialists who focus on conditions 
treated by a boxed warning drug, and osteopathic doctors will have lower net costs of acquiring 
new drug risk information and thus will reduce boxed warning prescribing by more than solo 
prescribers, rural prescribers, specialist prescribers that focus on conditions that are not treated by 
the relevant boxed warning drug, and medical doctors (M.D.s). This hypothesis is also supported 
by existing implementation and dissemination literature that shows that physician characteristics, 
                                                        
13 Indeed, there is some evidence that osteopathic doctors have lower rates of prescribing that medical doctors. A study 
in the primary care setting found that that osteopathic doctors had a lower odds of prescribing than allopathic doctors 
(Licciardone 2015). 
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such as prescriber specialty, practice type, and location, are correlated with health technology 
adoption rates (Charles 2009; Penfold 2007).  
3.4.  DATA 
3.4.1.  Data Sources 
Visit data 
The primary data source for this study is 2002-2015 National Ambulatory Medical Care 
Survey (NAMCS) data. These data are publicly available physician visit survey data created from 
a national sample of office-based non-federal physicians. For each physician, a random sample of 
their visits in one week of each year is surveyed. Data include sample weights to allow generation 
of nationally representative estimates. These data include information on patient diagnoses, 
procedures, medications (prescribed and over-the-counter), patient demographic information, and 
various health indicators (e.g. smoking status, etc.). There are also several physician characteristics 
included in these data, such as practice setting, solo or group practice, physician specialty, and 
physician degree (Medical Doctor (M.D.) vs. Doctor of Osteopathy (D.O.)).  
Drug information 
I rely on the Food and Drug Administration (FDA)’s Drugs@FDA website, and the 
National Institute of Health (NIH)’s Daily Med website for drug labeling information for the study 
drugs. I utilize historic and current drug labels to get drug-level data on approved indications, 
boxed warning date, and boxed warning content, including adverse effects and target population. 
3.4.2. Sample 
Identification of study boxed warnings 
To identify boxed warnings for this study, I collected boxed warning data for a large 
number of drugs, and then reviewed this list for the following considerations: 1) the warning was 
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added in the post-market period rather than at drug approval,14 2) the boxed warning was added 
between 2004 and 2013, to allow sufficient observation of pre- and post-boxed warning trends in 
the 2002-2015 NAMCS data, 3) the boxed warning would affect a reasonable number of patients, 
4) the conditions treated by the boxed warning drugs are identifiable using diagnosis codes.  
This study examines the following boxed warnings: 1) Antidepressants: Suicidality risks 
for children and adolescents, 2) Atypical antipsychotics: Mortality risks for elderly with dementia, 
3) COX-2 Inhibitors: Cardiovascular risks, 4) Glitazones: Congestive heart failure risks, 5) Plavix: 
Diminished effectiveness for CYP2C19 poor metabolizers. The characteristics of these boxed 
warnings are described in more detail in Table 3.1, and the complete text of the boxed warning for 
each safety issue is included in Appendix 2. These five boxed warnings span multiple drugs, 
classes, and treatment areas, and vary across other domains as well, including issuance date 
(October 2004 to March 2010), risk category (adverse event risk vs. efficacy risks), and scope 
(single drug vs. multiple drug classes) (see Table 3.1).  
Each of the boxed warnings in this study cautions regarding use of the given product for a 
specific patient subpopulation for whom the risk of the BW adverse reaction is high. It is important 
to identify these patients because they are the patients for whom the boxed warning is relevant. I 
identify these relevant patient subpopulations in the following excerpts of the study boxed 
warnings by emphasizing with bolded text (see Appendix 2 for complete text of boxed warnings):  
1) Antidepressants: “Antidepressants increased the risk of suicidal thinking and behavior 
(suicidality) in short-term studies in children and adolescents with Major Depressive Disorder 
                                                        
14 This study is limited to drugs that only have post-market BWs so it is possible to observe prescribing before the 
drug received a boxed warning. In total, 9% of approved drugs launch without a boxed warning and then receive a 
post-market BW. (Cheng 2014a).  
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(MDD) and other psychiatric disorders. Anyone considering the use of [antidepressants] … in a 
child or adolescent must balance this risk with the clinical need.”  
2) Atypical antipsychotics: “Elderly patients with dementia-related psychosis treated 
with antipsychotic drugs are at an increased risk of death. … [Antipsychotics are] not approved 
for the treatment of patients with dementia-related psychosis”   
3) COX-2 Inhibitors: “Patients with cardiovascular disease or risk factors for 
cardiovascular disease may be at greater risk … contraindicated for the treatment of peri-
operative pain in the setting of coronary artery bypass graft (CABG) surgery.” 
4) Glitazones: “Thiazolidinediones… cause or exacerbate congestive heart failure in some 
patients … monitor patients carefully for signs and symptoms of heart failure … If heart failure 
develops, it should be managed according to current standards of care and discontinuation or dose 
reduction of [glitazones] must be considered. [Glitazones are] not recommended in patients with 
symptomatic heart failure. Initiation of [glitazones] in patients with established New York 
Heart Association (NYHA) Class III or IV heart failure is contraindicated 
5) Plavix: “Plavix … has a smaller effect on platelet function in patients who are CYP2C19 
poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing 
percutaneous coronary intervention treated with Plavix at recommended doses exhibit higher 
cardiovascular event rates than do patients with normal CYP2C19 function. … Consider 
alternative treatment or treatment strategies in patients identified as CYP2C19 poor 
metabolizers.” 
I refer to these patients as “targeted patients” because they are the patients that are targeted 
by the boxed warning. Based on the highlighted boxed warning excerpts above, I define the 
targeted patients for each of the boxed warning drug groups as follows: 1) Antidepressants: 
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Patients under age 18, 2) Atypical antipsychotics: Elderly patients (65 years or older) with 
dementia, 3) COX-2 Inhibitors: Patients with cardiovascular risk factors, 4) Glitazones: Patients 
with heart failure, 5) Plavix: poor CYP2C19 metabolizers. Detailed criteria for identifying these 
patients, including ICD-9 codes, are defined in Table 3.2.  
Identification of visits for analytic samples 
I identify separate analytic samples for each of the five boxed warnings (Figure 3.1). To be 
included in an analytic sample, a visit must meet the following inclusion criteria: 1) the visit must 
occur in the relevant time period, defined as within two years of the boxed warning, subject to the 
overall dataset time period (2002-2015)15, 2) the visit must be for a patient with a condition eligible 
for treatment by the relevant study drug(s). Eligible conditions are defined as the labeled 
indications. However, for atypical antipsychotics, the boxed warning pertains to an off-label 
indication (dementia). Thus, assessing prescribing changes among these patients requires the 
eligible conditions to include dementia, as well as the on-label indications for atypical 
antipsychotics.  
Based on the above inclusion criteria, the general definition of the analytic samples for 
each of the study drug groups is as follows: 1) Antidepressants: Patients with depression and/or 
anxiety, excluding patients aged 18-24 years because they receive a boxed warning at a different 
date, 2) Atypical antipsychotics: Patients with schizophrenia and/or bipolar disorder, or elderly 
patients (65 years or older) with dementia, 3) COX-2 Inhibitors: Patients with arthritis, ankylosing 
spondylitis, primary dysmenorrhea, and/or acute pain. 4) Glitazones: Patients with Type 2 
diabetes, 5) Plavix: Patients with acute coronary syndrome, myocardial infarction, stroke, and/or 
                                                        
15 For all analytic samples, data are limited to visits that occurred in the years in which the 2002-2015 surveys took 
place. The 2002 NAMCS data files includes a small number of visits that occurred at the end of 2001. I exclude these 
visits, which account for less than 1% of visits in the 2002 survey (see Figure 3.1). 
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peripheral arterial disease (PAD). Detailed criteria for identifying the analytic samples, including 
ICD-9 codes, are defined in Table 3.3. 
3.4.3. Measures 
Dependent variables 
The dependent variable, Rx, is a binary variable indicating whether the boxed warning drug 
was prescribed in the eligible visit. The dependent variable is “1” if the visit indicates a prescription 
for the branded or generic versions of any of the following drugs: 1) Antidepressants: all classes 
of antidepressants. 2) Atypical antipsychotics: Abilify (aripiprazole), Clozaril (clozapine), Geodon 
(ziprasidone), Invega (paliperidone), Risperdal (risperidone), Seroquel (quetiapine), Zyprexa 
(olanzapine), 3) COX-2 inhibitors: Bextra (valdecoxib), Celebrex (celecoxib), and Vioxx 
(rofecoxib), 4) Glitazones: Avandia (rosiglitazone), and Actos (pioglitazone), 5) Plavix: Plavix 
(clopidogrel).  
Key independent variables 
Boxed warning is a binary variable indicating whether the visit occurred after the boxed 
warning was added. NAMCS data specify the month and year in which each visit occurred, so 
boxed warning date is defined on the month-year level. For visits occurring in the month when the 
boxed warning is added it is not possible to ascertain whether the visit preceded the boxed warning. 
Thus, visits in the month the boxed warning was issued are excluded from the analyses to avoid 
incorrect specification of event timing (Wagner 2002).  
As I mention in section 3.4.2, each of the study boxed warnings cautions against use of the 
given product for a specific patient subpopulation for whom the risk of the BW adverse reaction 
is high. Targeted is a binary variable indicating whether the visit is for a patient in the 
subpopulation that is targeted by the boxed warning. Targeted patients are defined as follows for 
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each of the boxed warning drug groups: 1) Antidepressants: Patients under age 18, 2) Atypical 
antipsychotics: Elderly patients (65 years or older) with dementia, 3) COX-2 Inhibitors: Patients 
with cardiovascular risk factors, 4) Glitazones: Patients with heart failure, 5) Plavix: poor 
CYP2C19 metabolizers. Detailed criteria for identifying the targeted patients, including ICD-9 
codes, are defined in Table 3.2. As described in Table 3.2, the study data do not allow identification 
of the targeted patients for the Plavix BW because the study data do not include genomic 
information, which would be necessary to identify CYP2C19 poor metabolizers. Thus, the 
Targeted visit variable is not assigned for the Plavix analyses.  
Key prescriber characteristics for this study include practice size, practice rurality, 
prescriber type, and prescriber specialty category. Referent values for these variables are assigned 
based on the most common value among visits in the evaluation dataset. Practice size is 
categorized into two groups: solo practice or group practice (referent). Practice rurality  is defined 
as Metropolitan Statistical Area (MSA) (referent) vs. non-MSA. Prescriber type is defined as 
osteopathic doctor (D.O.) vs. medical doctor (M.D.) (referent). Prescriber specialty is 
operationalized as a categorical variable that differentiates between 1) primary care prescribers, 2) 
relevant specialties, 3) other specialties. Relevant specialties include specialties that treat 
conditions that are likely to be treated by the drug(s) of interest and are defined as follows for each 
of the boxed warning drug groups: 1) Antidepressants: psychiatry; 2) Atypical Antipsychotics: 
psychiatry, and neurology; 3) COX-2 Inhibitors:16 orthopedic surgery specialties, general surgery 
specialties, obstetrics and gynecology specialties, and neurology; 4) Glitazones: endocrinology, 
                                                        
16 Orthopedic and general surgery specialties are expected to be relevant for acute pain visits, obstetrics and 
gynecology is expected to be a relevant specialty for primary dysmenorrhea visits, and neurology is expected to be 
relevant for migraine. It was not possible to identify rheumatology specialists, which would be relevant for arthritis 
and ankylosing spondylitis, because rheumatologists are classified in the “other specialties” group in the NAMCS data 
and thus are not identifiable in these data. 
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but this specialty is not identifiable in the study data, so the prescriber specialty categorical variable 
for the glitazone analyses is limited to two values: primary care prescribers and other specialties. 
5) Plavix: cardiovascular diseases specialties. Primary care specialties are defined as the following 
specialties: adolescent medicine, family practice, general practice, internal medicine, geriatric 
medicine, pediatrics, gynecology, obstetrics, and maternal and fetal medicine. For COX-2 
inhibitors, three of these primary care specialists (gynecology, obstetrics, and maternal and fetal 
medicine) are relevant specialties for the primary dysmenorrhea indication. As a result, the COX-
2 inhibitor primary care measure includes only the following specialties: adolescent medicine, 
family practice, general practice, internal medicine, geriatric medicine, and pediatrics. Visits that 
do not meet the above criteria for primary care specialties or relevant specialties are defined as 
other specialties.  
Control Variables 
Control variables include U.S. Census region (Northeast, Midwest, South (referent), and 
West), a monthly time trend, and patient characteristics (for some of the models). Patient variables 
include sex, race, age, and primary payer. Patient sex is a binary variable where female is referent. 
Patient race is a defined as White (referent), Black, or other race17. Patient age is categorized into 
three age groups: youth (0-17 years), adult (18-64 years) (referent), and elderly (65 years and 
older). Patient primary payer is categorized as private insurance (referent), public insurance18, or 
other payment source19. For visits where multiple payment sources are listed, payment type is 
                                                        
17 The other race category includes Asian, Native Hawaiian, other Pacific Islander, American Indian, and Alaska 
Native. 
18 Public insurance includes non-privately insured patients with Medicare, Medicaid, and/or SCHIP (State Children’s 
Health Insurance Program). 
19 The other payment category includes self-pay, no charge/charity care, workers compensation, etc. 
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defined according to the following hierarchy: private insurance, public insurance, and other source 
of payment. Referent values for control variables are assigned based on the most common value 
among visits in the evaluation dataset. 
3.5. METHODS 
3.5.1. Descriptive statistics 
For each boxed warning drug group, descriptive statistics are reported for three sub-groups 
of visits: 1) Targeted visits: visits by targeted patients (patient subpopulations for whom the BW 
cautions against use due to high adverse reactions risk, as defined in Table 3.2), 2) Non-targeted 
visits: visits by non-targeted patients (those not included in the subpopulation mentioned in the 
BW), 3) All eligible visits: visits by all patients who have conditions eligible for treatment by the 
BW drugs, as defined in Table 3.3 and Section 3.4.2 (i.e. visits by all patients in the analytic 
sample). For each of these sub-groups, I report descriptive statistics for three time periods: before 
the boxed warning was added, after the boxed warning was added, and for the overall data period 
(2 years before and after the BW). Descriptive statistics are calculated in Stata (v14.2) using 
complex survey data adjusted means.  Differences between pre- and post-BW means are tested 
using a chi-squared test for binary and categorical variables, and a t-test for continuous variables. 
The chi-squared tests and t-tests incorporate complex survey data features. 
3.5.2. Quasi-difference-in-difference methods 
The effects of the boxed warnings are estimated using quasi difference-in-difference (DID) 
methods, where the boxed warning is the “treatment.” Quasi-treatment and control groups are 
defined based on whether the visit is for one of the patient subpopulations for which the BW 
cautions against use of the drug. “Treatment group” patients are those targeted by the BW: the 
patient subpopulations that are identified in each BW (Table 3.2). “Control group” patients are the 
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non-targeted patients: those not included in the BW high-risk subpopulation groups, and thus not 
“treated” by the boxed warning. I use DID methods for four of the study boxed warnings: 
antidepressants, atypical antipsychotics, COX-2 inhibitors, and glitazones. As I mentioned earlier, 
the patients who are targeted by the Plavix boxed warning are not identifiable in the data so Plavix 
analyses do not use these difference-in-difference methods. 
I refer to the non-targeted and targeted patient groups as quasi-control and treatment groups 
because they may not meet all of the typical assumptions for DID control and treatment groups. In 
particular, one of the key requirements for control groups is that they are not affected by the 
treatment. Spillover effects of BWs on non-targeted patients have not been studied widely 
(McClellan 2019), but there is some evidence of spillover for antidepressant and atypical 
antipsychotic FDA warnings (Libby 2009; Olfson 2008; Valuck 2007; Dorsey 2010). For instance, 
studies show that the antidepressant warnings regarding suicidality risks for youth and adolescents 
had spillover effects for young adult patients (Libby 2009), despite the fact that young adults were 
not originally subject to the BW. To avoid bias from spillover among young adults, I exclude 
young adults (age 18-23 years) from the antidepressant analyses. Dorsey et al. (2010) showed that 
while atypical antipsychotic prescribing decreased by most among the patients targeted by the 
warning (elderly with dementia), there were also small prescribing declines among other patients 
(non-elderly patients with severe mental illness). To the extent that there are spillover effects for 
atypical antipsychotics or other BW drug groups, it will bias the estimated BW effect towards the 
null. In other words, the quasi-DID methods I use in this study will result in a conservative estimate 
of the BW effects. 
Another key requirement for DID methods is that control and treatment groups have 
parallel outcome trends prior to treatment. I assess this by comparing the pre-BW prescribing 
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probability trends for the targeted and non-targeted patients. I find that the parallel trends 
requirement is met for all the study BWs (see Appendix 4 for charts of parallel pre-period trends).  
The quasi-DID methods in this study utilize the variation in boxed warning relevance 
between these two groups to estimate the degree to which other factors caused contemporaneous 
changes in prescribing. Since the relevance of the boxed warning differs between these two groups, 
the ability of the boxed warning to affect prescribing should vary accordingly. Specifically, after 
the BW is added, I expect prescribing to decrease for targeted patients because those are the 
patients that are described by the BW as high-risk for the adverse event. In contrast, since the 
boxed warning is irrelevant (or much less relevant) for patients not targeted by the warning, the 
boxed warning should not substantively affect prescribing probability for non-targeted visits. 
Because the BW is not relevant for non-targeted patients, I assume that any prescribing changes 
among non-targeted patients are due to factors outside the boxed warning. I expect that these 
contemporaneous factors will have similar effects on prescribing among targeted and non-targeted 
visits. Thus, I difference out any changes in prescribing probability among non-targeted visits from 
changes in prescribing probability among targeted visits when estimating the effect of the boxed 
warning on prescribing probability.  
3.5.3. Empirical models 
Overall effects of boxed warnings 
I first estimate the average effect of the boxed warning on prescribing among all prescribers 
(hereafter “overall effects”). This average effect is estimated using a logit model where the boxed 
warning effect is unmoderated by prescriber characteristics. I estimate separate logit models for 
each boxed warning drug group, specified as follows:  
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    where j denotes boxed warning drug group, t denotes month, and i denotes individual visit 
The outcome variable, Rx, is a binary variable indicating a prescription for a boxed warning 
drug at the given visit. BW is a binary variable for whether the visit occurred after the BW was 
issued, Target is a binary variable indicating whether the visit is for a patient in the subpopulation 
that is targeted by the BW (as described above), and BW*Target is the interaction between these 
two variables. X is a vector of prescriber characteristics (rural practice, solo practice, relevant 
specialist20, other specialist type, and osteopathic doctor). C is a vector of other control variables, 
which include U.S. Census region, a monthly time trend, and patient control variables. I estimate 
each model with and without the patient controls (race, sex, age category, and insurance type). 
The primary effects of interest in these models is the interaction effect between BW and 
Target. As mentioned above, the interaction effect is essentially a difference-in-difference estimate 
that allows estimation of the effect of the boxed warning among targeted visits. I utilize methods 
described elsewhere21 to measure the effect of treatment on the treated in nonlinear models. These 
                                                        
20 As mentioned above, the relevant specialty group for glitazones (endocrinologists) is not identifiable in the NAMCS 
data. As a result, “relevant specialty” is not included in the glitazone models. The only provider specialty variable in 
the glitazone models is the binary variable indicating primary care specialty (where "other specialties” is the referent 
category).  
21 Methods for measuring the effect of treatment on treated in nonlinear models using an interaction effect are detailed 
in the following articles:  
Karaca-Mandic, P., Norton, E.C., Dowd, B. (2012). Interaction terms in nonlinear models. Health Services Research, 
47(1): 255-274, and Appendix S1: 1-6. 
Puhani, P.A. (2008). The Treatment Effect, the Cross Difference, and the Interaction Term in Nonlinear “Difference-
in-Difference” Models. IZA Discussion Paper No. 3478, Institute of Labor Economics (IZA), retrieved from 
http://ftp.iza.org/dp3478.pdf. 
Green. W. (2010). Testing hypotheses about interaction terms in nonlinear models. Economics Letters, 107(2): 291-
296. 
Ai. C., Norton, E.C. (2003) Interaction terms in logit and probit models. Economics Letters, 80(1): 123-129. 
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methods account for non-linearities inherent to logit models to estimate the portion of the 
difference in the conditional probability of prescribing that is attributable to the boxed warning. In 
contrast to linear models, differential effects are affected by the values of all covariates, not just 
those in the interaction term. To account for this variation in differential effects across different 
values of covariates in non-linear models, I use methods of recycled predictions to calculate 
average differential effects in the predicted probabilities. I refer to these average differential effects 
as overall differential effects to indicate that this is the estimated effect of the BW is across all 
prescribers. Analyses are adjusted for complex survey design features.22 To conduct inference, I 
examined the distribution of the average differential effect across 1000 replications of 
bootstrapped stratified clusters and compared the distribution to a null hypothesis of zero.  
Boxed warning effects stratified by provider characteristics 
To assess how the boxed warning effect varies between prescriber groups, I estimate logit 
models stratified on each prescriber characteristic. In other words, I estimate Eqn. 1 above for each 
of the following prescriber subgroups: prescribers with practices in MSAs, prescribers in rural 
areas, prescribers at group practices, prescribers in solo practices, primary care prescribers, 
relevant specialty prescribers, other specialty prescribers, medical doctors (M.D.s), and orthopedic 
doctors (D.O.s).  
As with the overall effects, the primary effect of interest in these stratified models is the 
interaction effect between BW and Target, because that is the effect of the boxed warning among 
                                                        
Norton, E.C., Wang, H., Ai, C. (2004). Computing interaction effects and standard errors in logit and probit models. 
The Stata Journal, 4(2): 154-167. 
22 Survey data analysis requires multiple primary sampling units (clusters) within each strata (Lee 2006). When a 
stratum contains only one cluster, the bootstrap sampling method does not work. On average less than 4% of 
observations/visits in each BW drug group are in a singleton strata. See Appendix 3 for the algorithm applied to these 
observations. 
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those targeted by the boxed warning. By estimating these interaction effects for each of the 
stratified models, I can estimate separate average differential effects of the BW for each prescriber 
characteristic. This allows me to determine whether each subgroup of prescribers (e.g. prescribers 
in solo practices) have a decrease, increase, or no change in their probability of prescribing the 
relevant drugs following the addition of the boxed warning. Average differential effects in the 
predicted probabilities are calculated using methods of recycled predictions. To conduct inference, 
I examined the distribution of the average differential effects across 1000 replications of 
bootstrapped stratified clusters and compared the distribution to a null hypothesis of zero. To 
examine whether there are differences by physician characteristics I plotted the distributions of the 
stratified differential effects across the bootstrapped samples. 
Results from models that failed to converge are not included in the analyses. Atypical 
antipsychotic models failed to converge for 15% of the replications for the prescriber characteristic 
stratified models; the bulk of these convergence issues occurred for the models that were stratified 
to other specialties or to osteopathic doctors (D.O.s), which failed to converge in approximately 
60% of replications. For the remaining BW drug groups less than 5% of the replications for 
stratified models failed to converge. 
Specification adjustments for Plavix models 
As mentioned in Table 3.2, the patients targeted by the Plavix boxed warning (poor 
metabolizers of the drug) are not identifiable in the NAMCS data.23 Since I cannot differentiate 
between targeted and non-targeted visits, I evaluate the impact of the Plavix boxed warning on 
                                                        
23 Poor metabolizer status is determined by a patient’s CYP2C19 genotype, which is assessed via genomic testing. 
NAMCS data do not contain genetic lab testing results, so it is not possible to identify CYP2C19 poor metabolizers 
in these data. 
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prescribing among all Plavix eligible visits by specifying modified versions of Eqn. 1 to account 
for the fact that the Plavix models do not have the Target variable (see Eqn. 2 below). 
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      where j denotes boxed warning drug group, t denotes month, and i denotes individual visit 
3.6.  RESULTS 
3.6.1.  Descriptive statistics 
There are five analytic samples, one for each BW drug group, consisting of visits that are 
eligible for treatment by the given BW drug(s).  Each analytic sample is composed of two sub-
samples: targeted visits and non-targeted visits. As described earlier, targeted visits are visits by 
patients for whom the BW cautions against use of the drug, while non-targeted visits are visits by 
patients not mentioned by the BW. Descriptive statistics for each of these samples are calculated 
using the methods described in Section 3.5.1 above. 
Antidepressants:  
The antidepressants analytic sample includes 7,507 visits for patients with depression 
and/or anxiety who are under age 18, or 24 years and older (Table 3.4). Within the antidepressants 
analytic sample, 10% of the visits (764 visits) are for the patients that are targeted by the boxed 
warning (children and adolescents under age 18), and 90% of visits (6,743 visits) are for those not 
targeted by the boxed warning (patients 24 years or older). Among the full antidepressant analytic 
sample (containing both targeted and non-targeted visits) there were no statistically significant 
changes in prescribing or visit characteristics between the pre-BW and post-BW periods (see Table 
3.4). Among visits for children and adolescents, was a statistically significant decrease in the 
percentage of visits for White patients following the addition of the BW (pre-BW: 93%, post-BW: 
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83%, p=0.009). Among non-targeted patients (patients 24 years or older), there was a small 
statistically significant increase in the antidepressant prescribing rate after the boxed warning was 
added (pre-BW: 60%, post-BW: 65%, p=0.047). There were no other statistically significant 
differences in prescribing or visit characteristics between the pre- and post-BW periods for targeted 
visits or non-targeted visits.  
Atypical antipsychotics:  
 The atypical antipsychotics analytic sample includes 2,092 visits for patients with 
schizophrenia, bipolar disorder, and/or elderly with dementia (Table 3.5). Among these, 23% (479 
visits) are for the patients targeted by the BW (elderly with dementia) and 77% (1,613 visits) are 
for patients not targeted by the warning (patients with schizophrenia or bipolar disorder). Within 
the atypical antipsychotic analytic sample, there is a small statistically significant increase in the 
percentage of visits by privately insured patients between the pre-BW and post-BW periods (pre-
BW: 32%, post-BW: 43%, p=0.020). This change seems primarily driven by changes among 
targeted visits (elderly with dementia), where the percentage of visits for privately insured patients 
more than triples after the BW is added (pre-BW: 12%, post-BW: 45%, p<0.0001). Among non-
targeted patients (patients with schizophrenia or bipolar disorder) there is a small statistically 
significant increase in average patient age, increasing from 41 years old pre-BW to 44 years old 
post-BW (p=0.012). There are no other statistically significant differences in prescribing or other 
visit characteristics for the atypical antipsychotic analytic samples.  
COX-2 Inhibitors  
 The COX-2 inhibitor analytic sample includes 15,689 visits for patients with arthritis, 
ankylosing spondylitis, primary dysmenorrhea, and/or acute pain (Table 3.6). Among these, 10% 
of visits (1,534 visits) are for patients targeted by the BW (patients with cardiovascular disease or 
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risk factors). The majority of COX-2 inhibitor eligible visits (90%) are for patients that are not 
targeted by the BW (those without cardiovascular disease or risk factors). There are statistically 
significant decreases in prescribing among both targeted visits and non-targeted visits, as well as 
the overall COX-2 inhibitor analytic sample. COX-2 inhibitor prescribing decreases from 14% 
pre-BW to 5% post-BW among targeted visits (p=0.0001), from 10% to 4% among non-targeted 
visits (p<0.0001), and from 11% to 4% among all COX-2 inhibitor eligible visits (p<0.0001). 
There are small statistically significant increases in the percentage of visits by privately insured 
patients for the COX-2 inhibitor analytic sample and sub-samples (targeted and non-targeted 
visits). There are no other statistically significant differences in visit characteristics for the COX-
2 inhibitor analytic samples. 
Glitazones  
The glitazone analytic sample includes 5,086 visits for patients with Type 2 diabetes (Table 
3.7). Among Type 2 diabetes visits, only 5% (268 visits) are by patients targeted by the BW (heart 
failure patients), and 95% (4,818 visits) are for patients that are not targeted by the BW (patients 
without heart failure). There is a statistically significant decrease in prescribing among the targeted 
visits, as well as smaller statistically significant decreases for the non-targeted visits and overall 
glitazones analytic sample. Glitazone prescribing decreases from 16% pre-BW to 6% post-BW 
among targeted visits (p=0.046), from 15% to 11% among non-targeted visits (p=0.011), and from 
15% to 11% among all Type 2 diabetes visits (p=0.005). There are no other statistically significant 
differences in visit characteristics for the glitazone analytic samples.  
Plavix 
 The Plavix analytic sample includes 1,879 visits for patients that have acute coronary 
syndrome (ACS), myocardial infarction, stroke, and/or peripheral arterial disease (PAD) (Table 
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3.8). There is no statistically significant change in Plavix prescribing between the pre-BW and 
post-BW periods. The only statistically significant change in visit characteristics between the pre- 
and post-BW periods is a decrease in the percentage of visits by White patients after the BW is 
added (pre-BW: 90%, post-BW: 78%, p<0.0001).  
3.6.2. Regression results    
I utilize logit models to estimate two sets of boxed warning differential effects. First, I 
estimate the average differential effect of each boxed warning on prescribing for targeted patients 
among all prescribers (overall differential effect). Second, I estimate the average differential effect 
of the boxed warning for different types of prescribers by estimating average differential effects 
that are stratified by prescriber characteristics (stratified differential effects).   
I estimate the overall differential effects and stratified differential effects, with and without 
controls for patient characteristics. Adjustment for patient controls yielded qualitatively identical 
results in all cases. Given the similarities of these models, I report them in Table 3.9, but do not 
describe them further.  
Overall differential effects 
The estimated sign of the differential effect is negative for all drugs groups and models, 
with the exception of the COX-2 inhibitor model with patient controls, which has an estimated 
BW effect that is effectively zero. However, for all drug groups and models the overall differential 
effect of the BW is not statistically significant (see Table 3.9). 
Stratified boxed warning differential effects by prescriber subgroups  
 The antidepressant boxed warning has a statistically significant negative effect on 
prescribing for two subgroups of prescribers: prescribers in group practices and osteopathic 
doctors (D.O.s) (Table 3.9 and Figure 3.2). The differential effect of the BW among prescribers in 
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group practices is −0.15, indicating that group practice prescribers have a 15 percentage point 
decrease in their probability of prescribing an antidepressant to children and adolescents after the 
boxed warning is added (p=0.044). Osteopathic doctors have a 33 percentage point decrease in 
antidepressant prescribing probability for children and adolescents after the BW is added 
(p=0.048). While the differential effect of the BW for group prescribers and osteopathic prescribers 
are statistically significantly different from zero at the 95% confidence level, their differential 
effects are not statistically different from their respective counterpart groups (solo prescribers and 
medical doctors (M.D.s)). For all other prescriber subgroups, I fail to reject the null hypothesis 
that the antidepressant boxed warning has zero effect on prescribing (Table 3.9).  
 The atypical antipsychotic boxed warning has a statistically significant effect on 
prescribing for rural prescribers, group prescribers, and osteopathic prescribers (see Table 3.9 and 
Figure 3.3). Among prescribers in rural areas, the atypical antipsychotic BW is associated with a 
61 percentage point decrease in the probability of prescribing atypical antipsychotics to elderly 
with dementia (p=0.002). Prescribers in urban areas (MSAs) do not have a statistically significant 
change in prescribing following the atypical antipsychotic BW. The estimated impact of the BW 
among rural prescribers is statistically different at the 95% confidence level from the estimated 
impact among prescribers in Metropolitan Statistical Areas (MSAs) (p=0.002). For prescribers in 
group practices, their probability of prescribing an atypical antipsychotic to elderly with dementia 
decreases by 20 percentage points following the BW (p=0.024). The difference between the 
differential effects for prescribers in group practices versus prescribers in solo practices is not 
statistically significantly different from zero. Among osteopathic doctors (D.O.s), the atypical 
antipsychotic BW is associated with a 28 percentage point increase in the probability of prescribing 
an atypical antipsychotic to elderly with dementia (p=0.022). The difference in the differential 
 84 
effect of the boxed warning among osteopathic doctors versus medical doctors is statistically 
different from zero at the 99% confidence level (p<0.0001). For all other prescriber subgroups, I 
fail to reject the null hypothesis that the atypical antipsychotic boxed warning has zero effect on 
prescribing (Table 3.9).  
 The COX-2 inhibitor boxed warning has no statistically significant effect on prescribing 
probability for any of the prescriber groups, so I fail to reject the null hypothesize that the COX-2 
inhibitor BW has zero effect on prescribing for these subgroups (Table 3.9 and Figure 3.4).  
 The glitazone boxed warning has a statistically significant effect on prescribing probability 
for prescribers in group practices (Table 3.9 and Figure 3.5). Group practice prescribers have an 
18 percentage point decrease in their probability of prescribing a glitazone to heart failure patients 
following the glitazone boxed warning (p<0.0001). The glitazone BW does not have a statistically 
significant impact on prescribing among prescribers in solo practices (p=0.144). The impact of the 
BW among prescribers in group practices is statistically different from the impact among 
prescribers in solo practices (p<0.0001). It was not possible to estimate the effect of the BW among 
relevant specialists because the prescribers most likely to treat Type 2 diabetes (endocrinologists) 
are not distinguishable from other specialties in the study data. Models that are stratified to rural 
prescribers are not estimable because the BW*Target interaction term perfectly predicts outcomes. 
No other prescriber groups had a statistically significant change in prescribing following the 
glitazone BW.  
 The Plavix boxed warning has a statistically significant effect on prescribing probability 
for rural prescribers and primary care prescribers (Table 3.9 and Figure 3.6). Among prescribers 
in rural areas, the Plavix boxed warning is associated with a 38 percentage point decrease in the 
probability of prescribing Plavix (p=0.008). The impact of the BW among prescribers in rural 
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practices is statistically different from the impact among prescribers in MSAs (p=0.006). Primary 
care prescribers have a 22 percentage point decrease in probability of prescribing Plavix following 
the boxed warning (p=0.028). The impact of the BW among primary care prescribers is not 
statistically different from the impact among relevant specialists (cardiologists) (p=0.264), but it 
is statistically different from the impact among other specialists (p<0.0001). For all other 
prescriber subgroups, I fail to reject the null hypothesis that the Plavix boxed warning has zero 
effect on prescribing (Table 3.9).  
3.7.  DISCUSSION 
3.7.1.  Overall boxed warning effect 
After the FDA adds boxed warnings to drug labels, prescribing generally decreases among 
patients targeted by the boxed warning but statistical significance is limited (see Tables 3.4 – 3.8). 
Among the five boxed warnings in this study, the decrease in prescribing post-BW was statistically 
significant for only two of the boxed warnings (Table 3.6 and Table 3.7). Empirical model results 
also estimate that boxed warnings have a negative impact on prescribing, but these results lack 
statistical significance for all study groups. The absence of statistically significant results in this 
study may indicate that boxed warnings do not impact prescribing. Statistical significance of study 
results may also be reduced by sample size limitations and/or contamination from spillover effects. 
3.7.2.  Potential spillover effects of boxed warning 
There is some evidence of potential spillover effects in this study. Descriptive statistics for 
both COX-2 inhibitors and glitazones show prescribing decreases among non-targeted patients 
following the boxed warning. For glitazones, the prescribing decrease among non-targeted patients 
(those without heart failure) was roughly half the magnitude of the prescribing decrease among 
targeted patients (patients with heart failure). Thus, while there may be some potential spillover, 
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the fact that post-BW prescribing decreases are largest among patients who are at greatest risk 
suggests that prescribers are noting that the drug risks differ between patient types and are 
effectively incorporating this new safety information into their prescribing decisions. 
For COX-2 inhibitors, prescribing decreased by about 65% for both targeted and non-
targeted patients (Table 3.6), suggesting that patients’ cardiovascular risk factors were not a major 
factor in decisions to prescribe COX-2 inhibitors. One reason that COX-2 inhibitors may have 
larger spillover effects than the other study drugs is that two of the three drugs in the COX-2 
inhibitor class were removed from the market around the time the boxed warning was added 
(Vioxx and Bextra were removed from the market, while Celebrex remained on the market). This 
could have impacted prescribing in two ways. First, the removal of two drugs in this class may 
have increased prescribers’ safety concerns above and beyond what they would have been if all 
three drugs had simply received boxed warnings. Second, for patients who were originally taking 
Vioxx or Bextra, the decision to continue use of COX-2 inhibitors would require switching to a 
different medication (Celebrex), whereas for the other BWs no switching of drugs was required to 
continue treatment within the drug class.   
 To the extent that spillover effects are present, I expect them to reduce the estimated 
impact of the BW on prescribing because of the methods used to estimate the BW effect. 
Specifically, the BW effect is estimated as the change in prescribing among patients targeted by 
the BW, minus the change in prescribing among patients not targeted by the BW. Differencing out 
prescribing changes for non-targeted visits helps control for co-occurring changes in prescribing 
that are unrelated to the BW. This assumes that all changes in prescribing among non-targeted 
patients are caused by factors unrelated to the BW. However, if there are spillover effects of the 
BW among non-targeted patients, prescribing changes among non-targeted visits may in fact be 
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related to the BW. In this case, differencing out those changes will underestimate the effect of the 
BW on prescribing for targeted patients. Ideally, only prescribing changes that are unrelated to the 
BW would be differenced out of the BW effect. However, since study data do not allow 
differentiation of prescribing changes caused by BW spillover effects versus non-BW factors, it is 
not possible to refine the differential effect calculation.  
There is no evidence of spillover effects of the BW for antidepressants or atypical 
antipsychotics. For both of those drug groups, descriptive statistics show that prescribing actually 
increases among non-targeted patients following the boxed warning (although this increase is only 
statistically significant for antidepressants). This absence of spillover effects is a positive finding 
because the FDA’s intent in adding a BW is that prescribers will discontinue use in patients only 
when the risks of the drug outweigh the benefits. The fact that use continues among patients who 
have little to no change in expected risks suggests that the BW is succeeding at differentiating risk 
levels between patients and that prescribers are accurately conveying those risk differences into 
their daily practice.  
3.7.3.  Role of prescriber characteristics in boxed warning effect 
Overall, there is only minimal evidence that prescriber characteristics moderate the boxed 
warning effect. Among the nine prescriber subgroups studied, only three prescriber subgroups 
(group practice prescribers, rural prescribers, and osteopathic doctors) had estimated boxed 
warning effects that were statistically significant for more than one boxed warning. For osteopathic 
doctors, I find a statistically significant BW effect for two boxed warnings, but the signs of the 
BW effect are reversed between these two boxed warnings (the estimated BW effect is negative 
for antidepressants and positive for atypical antipsychotics). Given the lack of consistency in the 
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direction of the BW effect among osteopathic prescribers, it is reasonable to conclude that 
prescribers’ degree type (D.O. vs. M.D.) does not play a significant role in BW response.  
Rural prescribers have large statistically significant decreases in prescribing probability 
following the atypical antipsychotic and Plavix boxed warnings. However, this effect is not 
significant for the antidepressant or COX-2 inhibitor warnings, and not estimable in the glitazone 
models. Given the lack of statistically significant patterns between boxed warnings, it is hard to 
make a definitive statement about the role of practice rurality in BW impact. 
The prescriber characteristic that seems most promising for having a role in BW response 
is practice size. Prescribers in group practices have a statistically significant decrease in 
prescribing probability for three of the five boxed warnings. For one of these boxed warnings, the 
estimated differential effect of the BW among group practice prescribers was statistically different 
from the effect among solo prescribers at the 99% confidence level. These results support my 
hypothesis that group practices will have larger post-BW decreases in prescribing because new 
safety information will flow more easily to prescribers in group practices given their greater 
likelihood of interacting with other prescribers, and greater resources from economies of scale. 
While these results are promising for three of the five boxed warnings, the other two boxed 
warnings did not produce a statistically significant impact on prescribing for group practice 
prescribers. Thus, more research will be needed to confirm or reject the hypothesis that group 
prescribers will change prescribing by more than solo prescribers following the release of new 
safety information.  
3.7.4.  Policy Implications 
Overall, the results of this study suggest that boxed warnings are generally working as 
intended. This is evidenced by several findings. First, all study drug groups show decreased 
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prescribing following the boxed warnings (Tables 3.4 – 3.8), suggesting that BWs are succeeding 
at communicating new safety risks. Second, prescribing decreases were greater for patients 
targeted by the BW than for those not targeted by the BW for all but one of the drug groups. This 
provides evidence that prescribers calibrate prescribing changes according to each patient’s drug 
risks. Third, spillover effects were minimal: only two drug groups show evidence of potential 
spillover effects among non-targeted patients.  
Despite these positive findings, there are some potential implications for FDA to consider. 
While spillover effects are limited, the presence of any spillover to non-targeted patients may 
indicate that the BW is generating wider spread concern than the FDA intends. The FDA may want 
to increase their efforts to highlight the lack of risks and continued benefits for non-targeted 
patients. For instance, in later revisions to the antidepressant boxed warning the FDA added the 
following statement: “Short-term studies did not show an increase in the risk of suicidality with 
antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with 
antidepressants compared to placebo in adults aged 65 and older.” By adding these types of 
statements to boxed warnings, the FDA may be able to more precisely target only high-risk 
patients.  
3.7.5.  Limitations 
While this study has many strengths, there are some limitations. First, while I am interested 
in how prescriber characteristics influence awareness of the boxed warning, I am only able to 
observe a downstream impact of changes in awareness (i.e. prescribing probability). Second, it is 
difficult to tease out the impact of the boxed warning from other co-occurring events that would 
change prescriber drug knowledge. In Chapter 2 of my dissertation, I find little evidence that pre-
boxed warning FDA safety advisories impact prescribing. However, there may be other events, 
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such as major media articles or clinical studies that could impact prescribers’ knowledge of safety 
issues and their resulting prescribing decisions. To the extent that events outside the BW decrease 
prescribing before the BW is added, the estimated BW effect may underestimate the true effect of 
the new risk information on prescribing. If on the other hand those events occur at the same time 
as the boxed warning, my study may overestimate the BW impact by attributing all of the 
prescribing changes to the BW when in fact some of the changes were due to outside factors.  
Third, omitted variable bias could be caused by variables that I was not able to control for in my 
analyses. For instance, I was not able to control for changes in pharmaceutical advertising and 
promotion, which are known to impact prescribing (Rosenthal 2003; Iizuka 2005; Dave 2014; 
Datta 2017). The FDA prohibits certain promotional activities after a drug receives a BW (Lee 
Ventola 2011; FDA 2015), so decreases in promotion following the BW are likely to be related to 
the BW. Difference-in-difference methods will help control for changes in promotion. Fourth, 
boxed warnings sometimes have spillover effects on the non-targeted population (Section 3.7.2; 
Chen 2011; Dorsey 2010). To the extent that changes among non-targeted patients are caused by 
the BW, I may be differencing out some of the effect of BW, and thus underestimating the true 
effect of the BW. Lastly, the study data have a few limitations worth noting. The main issue with 
NAMCS data relates to small sample sizes for some subgroups of visits, such as targeted patient 
visits for atypical antipsychotics and glitazones. Small sample sizes may have contributed to 
convergence failures for logit models, and reduced statistical significance of results. Another issue 
with NAMCS data is that it is not possible to follow prescribers or patients over time. Thus, it not 
possible to see whether prescribing rates changed at the prescriber level. However, the NAMCS 
data offer multiple strengths. NAMCS data allow examination of prescriber characteristic 
information that would not be available in other data sources (e.g. administrative claims data). 
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Additionally, NAMCS data avoids common issues associated with use of prescription claims data, 
such as identification of diagnoses or visit dates for a given prescription, and discrepancies 
between written prescriptions versus filled prescriptions.  
3.8.  CONCLUSION 
This study leverages prescriber characteristic information in health care visit surveys to 
assess the role of prescriber characteristics in post-boxed warning prescribing for five drug groups. 
Overall, I find that boxed warnings reduce prescribing among patients targeted by the boxed 
warning. However, findings regarding the role of prescriber characteristics are inconclusive. There 
is some evidence that individual prescriber characteristics could play a role in moderating the post-
BW prescribing, but further study is needed regarding the role of prescriber characteristics, and 
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Table 3.2. Identification of Visits by Patients Targeted by the Boxed Warning 
 
BW Drug Group Targeted Patients Identification of Targeted Visits among Eligible Visits 
Antidepressants Children, adolescents and 
young adults 





Patients is 65 years or older and has a dementia diagnosis: 
(ICD-9: 290.0x, 290.1x, 290.2x, 290.3x, 290.4x, 294.1x, 
294.2x, 294.8x, 331.0x, 331.1x, 331.82)  
COX-2 Inhibitors 
 
Patients with cardiovascular 
disease or risk factors 
Patient has a diagnosis indicating cardiovascular disease 
and/or cardiovascular risk factors: myocardial infarction 
(410.xx, 412.xx), stroke (430.xx, 431.xx-436.xx, 438.xx, 
V12.54), heart failure (398.91, 402.01, 402.11, 402.91, 404.01, 
404.03, 404.11, 404.13, 404.91, 404.93, 428.xx), peripheral 
arterial disease (PAD) (249.70, 249.71, 250.70, 250.71, 
250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 
440.29, 440.30, 440.31, 440.32, 440.4, 440.8, 440.9, 443.1, 
443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02), 
unstable angina (411.1, 413.0, 413.9), other ischemic heart 
disease (411.xx, 414.xx), hypertension (401.xx-405.xx), and/or 
CABG surgery (V45.81) 
Glitazones 
 
Patients with heart failure Patients has a diagnosis of heart failure (ICD-9: 398.91, 
402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 428.xx) or is identified as having congestive 





CYP2C19 poor metabolizer status would be assessed via 
genomic testing. However, NAMCS data do not contain 
genetic lab testing results, so it is not possible to identify 
CYP2C19 poor metabolizers in these data.  
 
Notes:  
*NAMCS surveys asked respondents whether the patient has congestive heart failure (CHF) regardless of other 
diagnosis codes.  
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Figure 3.1. Consort Diagram for Study 2 Analytic Samples 
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Table 3.3. Identification of Study 2 Analytic Samples 
 
BW Drug Group Visit Inclusion Criteria for Analytic Samples 
Antidepressants Visit is for a patient with one or more of the following conditions:  
Depression: ICD-91: 296.2x, 296.3x, 300.4x, 309.00, 309.10, 311.xx; RFV2 code: 1110.0  
Anxiety: ICD-9: 293.84, 300.0x, 300.2x, 300.3, 309.24, 309.28, 309.81; RFV codes: 1100.0, 
1105.0, 1130.5 
and the patient is either under age 18, or is 24 years or older. 
and the visit occurs within the following time period: September 2002 - October 2006 
Atypical 
antipsychotics 
Visit is for a patient with one or more of the following conditions:  
Schizophrenia: ICD-9: 295.xx 
Bipolar disorder: ICD-9: 296.0x, 296.1x, 296.4x-296.8x 
Dementia3: ICD-9: 290.0x, 290.1x, 290.2x, 290.3x, 290.4x, 294.1x, 294.2x, 294.8x, 331.0x, 
331.1x, 331.82 
and the visit occurs within the following time period: March 2003 – April 2007  
COX-2  
Inhibitors 
Visit is for a patient with one or more of the following conditions:  
Arthritis:   ICD-9: 715.xx, 714.0-714.2, 714.3x; RFV code: 2900.0 
Ankylosing Spondylitis:   ICD-9: 720.0x 
Primary Dysmenorrhea:   ICD-9: 625.3x; RFV code: 1745.2 
Acute Pain:   ICD-9: 338.1x, 338.3x, 346.xx, 719.4x, 723.1x, 724.1x, 724.2x, 724.5, 729.5x, 
780.96, 784.0x; RFV codes: 1055.0, 1055.4, 1060.0, 1060.1, 1210.0, 1900.1, 1905.1, 1910.1, 
1915.1, 1920.1, 1925.1, 1930.1, 1935.1, 1940.1, 1945.1, 1950.1, 1955.1, 1960.1, 1965.1, 
1970.1, 1980.1, 2365.0, 2675.5 
and the patient has one or more of the following risk factors described in the BW:  
Cardiovascular disease or risk factors:  myocardial infarction (410.xx, 412.xx), stroke (430.xx, 
431.xx-436.xx, 438.xx, V12.54), heart failure (398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 404.93, 428.xx), peripheral arterial disease (PAD) (249.70, 249.71, 
250.70, 250.71, 250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 
440.31, 440.32, 440.4, 440.8, 440.9, 443.1, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 
445.02), unstable angina (411.1, 413.0, 413.9), other ischemic heart disease (411.xx, 414.xx), 
hypertension (401.xx-405.xx), and/or CABG surgery (V45.81) 
and the visit occurs within the following time period: March 2003 – April 2007 
Glitazones Visit is for a patient with the following condition:  
Type 2 Diabetes: ICD-9: 250.x0, 250.x2 and age of 35 years or older4 
and the visit occurs within the following time period: July 2005 – August 2009 
Plavix  
(clopidogrel)6 
Visit for a patient with at least one of the following conditions: 
Acute coronary syndrome:   ICD-9: 410.xx, 412.xx, 411.1, 413.0, 413.9 
Myocardial infarction:   ICD-9: 410.xx, 412.xx 
Stroke:   ICD-9: 430.xx, 431.xx-436.xx, 438.xx, V12.54 
Peripheral arterial disease (PAD)7:   ICD-9: 249.70, 249.71, 250.70, 250.71, 250.72, 250.73, 
440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 440.31, 440.32, 440.4x, 440.8x, 
440.9x, 443.1x, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02 
and the visit occurs within the following time period: February 2008 – March 2012 
 
Notes: 
1: ICD-9 refers to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes. 
ICD-9 codes were identified in 2003-2011 code listings from the Center for Disease Control and Prevention (CDC). Changes in 
ICD-9 codes over time were assessed and accounted for where relevant (CDC; CDC 2013).  
2: RFV code refers to Reason for Visit code; These codes are defined in the NAMCS data file documentation. RFV codes are not 
listed for conditions that lack corresponding RFV codes (e.g. due to lack of specificity of codes). 
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3 Dementia is not an FDA-approved indication for atypical antipsychotics but is included in the list of relevant conditions because 
dementia patients are the focus on the atypical antipsychotic boxed warning. 
4 Several studies note shortcomings of ICD-9 codes for identifying Type 2 diabetes among younger patients (Alexander 2008; 
Rhodes 2007). Following Alexander and others, I identify Type 2 diabetes patients using a combination of ICD-9 code and age 
criteria to address the fact that Type 1 patients are sometimes coded as Type 2 patients (Alexander 2008; Xie 2013; Karve 2008). 
Excluding younger patients accounts for the fact the onset of Type 2 diabetes generally occurs in adulthood (CDC 2019). 
5 NAMCS surveys include a question regarding whether the patient has congestive heart failure (CHF). 
6 The Plavix BW identifies patients that are CYP2C19 poor metabolizers as having higher risk of adverse events. However, the 
NAMCS data do not allow identification of these patients. Accordingly, the Plavix analytic sample includes all visits by patients 
with conditions that fall under Plavix’s FDA approved indications, rather than only those eligible for Plavix that are also poor 
metabolizers. 
7 Peripheral arterial disease (PAD) ICD-9 codes are identified in a study of PAD incidence and prevalence (Kalbaugh 2017). 
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All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 7,507 3,741 3,577 764 429 326 6,743 3,312 3,251
Antidepressant Rx 0.62 0.60 0.64 0.076 0.54 0.56 0.51 0.374 0.63 0.60 0.65 0.047
(0.012) (0.016) (0.017) (0.028) (0.036) (0.043) (0.012) (0.017) (0.018)
Prescriber characteristics
Group practice 0.54 0.54 0.53 0.729 0.58 0.52 0.65 0.104 0.53 0.54 0.52 0.540
(0.02) (0.028) (0.029) (0.042) (0.062) (0.052) (0.021) (0.028) (0.031)
Solo practice 0.46 0.46 0.47 0.42 0.48 0.35 0.47 0.46 0.48
(0.02) (0.028) (0.029) (0.042) (0.062) (0.052) (0.021) (0.028) (0.031)
PCP 0.52 0.52 0.53 0.978 0.35 0.3 0.4 0.139 0.53 0.54 0.54 0.964
(0.017) (0.024) (0.027) (0.037) (0.054) (0.049) (0.019) (0.026) (0.029)
Relevant specialty 0.41 0.41 0.41 0.63 0.69 0.57 0.4 0.39 0.39
(0.017) (0.023) (0.028) (0.038) (0.055) (0.051) (0.019) (0.025) (0.029)
Other specialty 0.067 0.069 0.068 0.021 0.013 0.032 0.071 0.074 0.071
(0.0064) (0.01) (0.008) (0.0059) (0.0072) (0.01) (0.0069) (0.011) (0.0086)
M.D. 0.91 0.91 0.91 0.859 0.96 0.97 0.95 0.242 0.91 0.91 0.91 0.941
(0.011) (0.017) (0.015) (0.013) (0.0095) (0.027) (0.012) (0.018) (0.015)
D.O. 0.088 0.087 0.091 0.037 0.026 0.051 0.093 0.092 0.094
(0.011) (0.017) (0.015) (0.013) (0.0095) (0.027) (0.012) (0.018) (0.015)
MSA practice 0.87 0.87 0.88 0.719 0.88 0.86 0.92 0.192 0.87 0.87 0.87 0.815
(0.019) (0.026) (0.026) (0.029) (0.048) (0.027) (0.019) (0.026) (0.027)
Rural practice 0.13 0.13 0.12 0.12 0.14 0.076 0.13 0.13 0.13
(0.019) (0.026) (0.026) (0.029) (0.048) (0.027) (0.019) (0.026) (0.027)
Northeast 0.23 0.22 0.24 0.431 0.16 0.16 0.17 0.750 0.23 0.23 0.25 0.308
(0.017) (0.025) (0.024) (0.027) (0.039) (0.039) (0.018) (0.026) (0.026)
Midwest 0.22 0.22 0.22 0.24 0.25 0.23 0.22 0.21 0.22
(0.014) (0.02) (0.022) (0.034) (0.05) (0.046) (0.015) (0.02) (0.023)
South 0.34 0.33 0.35 0.37 0.39 0.33 0.34 0.32 0.36
(0.018) (0.024) (0.029) (0.04) (0.059) (0.057) (0.019) (0.025) (0.03)
West 0.21 0.23 0.18 0.22 0.2 0.26 0.21 0.24 0.18
(0.015) (0.023) (0.018) (0.032) (0.045) (0.048) (0.015) (0.024) (0.019)
Patient characteristics
Female 0.67 0.67 0.66 0.664 0.53 0.52 0.54 0.605 0.68 0.68 0.67 0.508
(0.0081) (0.011) (0.012) (0.025) (0.033) (0.039) (0.0083) (0.012) (0.012)
White 0.90 0.90 0.91 0.405 0.88 0.93 0.83 0.009 0.91 0.9 0.92 0.188
(0.0068) (0.0096) (0.0094) (0.02) (0.019) (0.034) (0.007) (0.01) (0.0096)
Black 0.070 0.077 0.061 0.085 0.059 0.1 0.069 0.078 0.058
(0.0057) (0.0083) (0.0078) (0.018) (0.018) (0.03) (0.0059) (0.0088) (0.0081)
Other race 0.026 0.025 0.025 0.038 0.015 0.068 0.025 0.026 0.021
(0.0034) (0.0055) (0.004) (0.0092) (0.0054) (0.019) (0.0036) (0.006) (0.004)
Age (years) 47 47 48 0.419 12 12 12 0.790 50 50 50 0.550
(0.4) (0.56) (0.56) (0.23) (0.28) (0.39) (0.33) (0.49) (0.43)
Youth (0-17) 0.076 0.081 0.073 0.777 . .
(0.006) (0.0087) (0.0085)
Adult (18-64) 0.77 0.76 0.77 0.83 0.83 0.83
(0.0082) (0.012) (0.011) (0.0076) (0.011) (0.011)
Elderly (65+) 0.16 0.15 0.16 0.17 0.17 0.17
(0.0072) (0.01) (0.01) (0.0076) (0.011) (0.011)
Private insurance 0.60 0.57 0.62 0.166 0.55 0.55 0.56 0.424 0.6 0.58 0.63 0.148
(0.012) (0.018) (0.018) (0.037) (0.052) (0.053) (0.013) (0.019) (0.018)
Public insurance 0.24 0.25 0.22 0.29 0.27 0.32 0.23 0.25 0.22
(0.01) (0.015) (0.015) (0.035) (0.048) (0.052) (0.01) (0.015) (0.015)
Other payer 0.16 0.17 0.15 0.15 0.18 0.12 0.16 0.17 0.16
(0.01) (0.015) (0.014) (0.024) (0.035) (0.033) (0.01) (0.015) (0.014)
All eligible visits Target visits Non-target visits
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in 
parentheses. Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple 
regression for continuous variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
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All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 2,092 1,058 998 479 247 229 1,613 811 769
Atypical Rx 0.4 0.38 0.42 0.319 0.16 0.18 0.14 0.382 0.48 0.45 0.51 0.111
(0.019) (0.026) (0.029) (0.025) (0.04) (0.03) (0.021) (0.028) (0.03)
Prescriber characteristics
Group practice 0.54 0.51 0.57 0.244 0.69 0.69 0.68 0.825 0.49 0.44 0.54 0.165
(0.03) (0.042) (0.042) (0.039) (0.054) (0.056) (0.037) (0.049) (0.053)
Solo practice 0.46 0.49 0.43 0.31 0.31 0.32 0.51 0.56 0.46
(0.03) (0.042) (0.042) (0.039) (0.054) (0.056) (0.037) (0.049) (0.053)
PCP 0.31 0.29 0.33 0.639 0.66 0.66 0.65 0.780 0.19 0.16 0.21 0.390
(0.022) (0.03) (0.036) (0.036) (0.049) (0.054) (0.02) (0.024) (0.033)
Relevant specialty 0.65 0.67 0.63 0.27 0.28 0.26 0.78 0.81 0.76
(0.024) (0.032) (0.038) (0.032) (0.045) (0.048) (0.021) (0.027) (0.035)
Other specialty 0.04 0.038 0.043 0.07 0.059 0.083 0.029 0.031 0.03
(0.0075) (0.011) (0.01) (0.015) (0.022) (0.022) (0.0082) (0.012) (0.012)
M.D. 0.94 0.93 0.94 0.683 0.92 0.92 0.93 0.659 0.94 0.94 0.95 0.807
(0.012) (0.019) (0.015) (0.021) (0.032) (0.024) (0.014) (0.022) (0.017)
D.O. 0.065 0.067 0.058 0.08 0.085 0.067 0.059 0.061 0.055
(0.012) (0.019) (0.015) (0.021) (0.032) (0.024) (0.014) (0.022) (0.017)
MSA practice 0.86 0.87 0.85 0.643 0.84 0.84 0.83 0.875 0.87 0.88 0.85 0.619
(0.023) (0.032) (0.033) (0.035) (0.047) (0.049) (0.025) (0.033) (0.039)
Rural practice 0.14 0.13 0.15 0.16 0.16 0.17 0.13 0.12 0.15
(0.023) (0.032) (0.033) (0.035) (0.047) (0.049) (0.025) (0.033) (0.039)
Northeast 0.22 0.23 0.21 0.558 0.24 0.3 0.17 0.167 0.22 0.2 0.22 0.763
(0.022) (0.033) (0.028) (0.041) (0.063) (0.044) (0.026) (0.038) (0.036)
Midwest 0.2 0.19 0.21 0.22 0.18 0.24 0.19 0.19 0.2
(0.021) (0.027) (0.032) (0.035) (0.04) (0.055) (0.023) (0.033) (0.036)
South 0.36 0.33 0.39 0.3 0.26 0.36 0.37 0.36 0.39
(0.028) (0.037) (0.041) (0.04) (0.048) (0.061) (0.034) (0.045) (0.053)
West 0.22 0.25 0.2 0.24 0.26 0.22 0.21 0.24 0.19
(0.022) (0.035) (0.028) (0.035) (0.053) (0.048) (0.028) (0.045) (0.035)
Patient characteristics
Female 0.61 0.6 0.64 0.239 0.68 0.66 0.69 0.608 0.59 0.58 0.62 0.271
(0.015) (0.022) (0.022) (0.029) (0.042) (0.043) (0.018) (0.024) (0.026)
White 0.87 0.86 0.89 0.313 0.89 0.87 0.9 0.349 0.87 0.85 0.89 0.384
(0.013) (0.02) (0.016) (0.025) (0.039) (0.032) (0.014) (0.023) (0.018)
Black 0.092 0.11 0.075 0.061 0.084 0.037 0.1 0.11 0.088
(0.012) (0.019) (0.013) (0.017) (0.03) (0.017) (0.014) (0.023) (0.016)
Other race 0.035 0.036 0.035 0.054 0.043 0.066 0.028 0.034 0.024
(0.0057) (0.0078) (0.0085) (0.018) (0.024) (0.027) (0.0048) (0.0071) (0.0065)
Age (years) 52 51 53 0.239 80 80 80 0.938 42 41 44 0.012
(0.92) (1.4) (1.3) (0.4) (0.53) (0.6) (0.69) (1) (0.9)
Youth (0-17) 0.063 0.075 0.049 0.435 . 0.085 0.1 0.066 0.077
(0.009) (0.014) (0.011) (0.012) (0.019) (0.015)
Adult (18-64) 0.63 0.62 0.63 0.84 0.84 0.84
(0.022) (0.03) (0.034) (0.014) (0.02) (0.021)
Elderly (65+) 0.31 0.3 0.32 0.072 0.054 0.089
(0.021) (0.029) (0.032) (0.0089) (0.01) (0.015)
Private insurance 0.38 0.32 0.43 0.020 0.28 0.12 0.45 0.000 0.41 0.4 0.43 0.412
(0.021) (0.029) (0.03) (0.035) (0.038) (0.058) (0.024) (0.035) (0.035)
Public insurance 0.5 0.54 0.46 0.7 0.87 0.52 0.43 0.42 0.44
(0.022) (0.031) (0.031) (0.035) (0.038) (0.059) (0.025) (0.036) (0.034)
Other payer 0.13 0.13 0.11 0.022 0.006 0.03 0.16 0.18 0.14
(0.011) (0.015) (0.015) (0.0088) (0.0036) (0.016) (0.014) (0.02) (0.019)
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in 
parentheses. Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple 
regression for continuous variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
All eligible visits Target visits Non-target visits
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All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 15,689 7,552 7,814 1,534 701 812 14,155 6,851 7,002
COX-2 Inhibitor Rx 0.072 0.11 0.0370 0.0000 0.094 0.14 0.050 0.0001 0.069 0.10 0.035 0.0000
(0.0036) (0.0062) (0.0035) (0.011) (0.018) (0.013) (0.0038) (0.0065) (0.0035)
Prescriber characteristics
Group practice 0.64 0.63 0.66 0.279 0.57 0.6 0.54 0.367 0.65 0.63 0.68 0.162
(0.017) (0.025) (0.024) (0.031) (0.043) (0.043) (0.017) (0.026) (0.024)
Solo practice 0.36 0.37 0.34 0.43 0.4 0.46 0.35 0.37 0.32
(0.017) (0.025) (0.024) (0.031) (0.043) (0.043) (0.017) (0.026) (0.024)
PCP 0.57 0.59 0.55 0.291 0.81 0.8 0.82 0.370 0.55 0.57 0.52 0.225
(0.015) (0.022) (0.022) (0.021) (0.027) (0.034) (0.016) (0.023) (0.022)
Relevant specialty 0.24 0.24 0.24 0.022 0.031 0.014 0.27 0.27 0.27
(0.012) (0.017) (0.019) (0.0033) (0.0061) (0.003) (0.013) (0.019) (0.02)
Other specialty 0.18 0.17 0.21 0.17 0.17 0.17 0.19 0.17 0.21
(0.013) (0.019) (0.02) (0.02) (0.025) (0.034) (0.014) (0.02) (0.022)
M.D. 0.87 0.87 0.87 0.800 0.89 0.88 0.9 0.593 0.87 0.87 0.87 0.859
(0.01) (0.015) (0.015) (0.015) (0.026) (0.017) (0.011) (0.016) (0.017)
D.O. 0.13 0.13 0.13 0.11 0.12 0.1 0.13 0.13 0.13
(0.01) (0.015) (0.015) (0.015) (0.026) (0.017) (0.011) (0.016) (0.017)
MSA practice 0.85 0.86 0.84 0.579 0.85 0.85 0.84 0.823 0.85 0.86 0.84 0.561
(0.019) (0.024) (0.028) (0.025) (0.034) (0.035) (0.019) (0.025) (0.028)
Rural practice 0.15 0.14 0.16 0.15 0.15 0.16 0.15 0.14 0.16
(0.019) (0.024) (0.028) (0.025) (0.034) (0.035) (0.019) (0.025) (0.028)
Northeast 0.2 0.21 0.18 0.303 0.21 0.2 0.21 0.653 0.19 0.21 0.17 0.278
(0.013) (0.019) (0.019) (0.023) (0.031) (0.036) (0.014) (0.021) (0.019)
Midwest 0.23 0.21 0.25 0.23 0.21 0.26 0.23 0.21 0.25
(0.013) (0.017) (0.022) (0.024) (0.031) (0.035) (0.014) (0.017) (0.022)
South 0.37 0.36 0.36 0.39 0.4 0.37 0.36 0.36 0.36
(0.016) (0.023) (0.022) (0.028) (0.042) (0.037) (0.017) (0.023) (0.023)
West 0.21 0.22 0.21 0.18 0.19 0.16 0.22 0.22 0.21
(0.013) (0.019) (0.018) (0.019) (0.03) (0.025) (0.013) (0.02) (0.019)
Patient characteristics
Female 0.61 0.62 0.61 0.496 0.62 0.62 0.62 0.836 0.61 0.62 0.61 0.509
(0.006) (0.0084) (0.0087) (0.016) (0.022) (0.024) (0.0063) (0.009) (0.0091)
White 0.87 0.87 0.86 0.558 0.79 0.79 0.79 0.660 0.87 0.88 0.87 0.441
(0.0067) (0.0088) (0.011) (0.019) (0.027) (0.028) (0.0064) (0.0085) (0.01)
Black 0.096 0.091 0.1 0.16 0.17 0.15 0.088 0.082 0.096
(0.0054) (0.0071) (0.0086) (0.017) (0.025) (0.023) (0.0051) (0.0065) (0.0081)
Other race 0.038 0.037 0.041 0.045 0.037 0.054 0.038 0.037 0.039
(0.0043) (0.0057) (0.0069) (0.01) (0.013) (0.015) (0.0042) (0.0058) (0.0063)
Age (years) 51 50 51 0.363 63 63 63 0.968 49 49 49 0.378
(0.35) (0.48) (0.5) (0.59) (0.85) (0.74) (0.35) (0.48) (0.52)
Youth (0-17) 0.076 0.077 0.075 0.923 0.0029 0.0015 0.0043 0.547 0.085 0.086 0.084 0.864
(0.0041) (0.0061) (0.006) (0.0018) (0.00099) (0.0035) (0.0045) (0.0069) (0.0065)
Adult (18-64) 0.66 0.66 0.66 0.51 0.5 0.52 0.68 0.68 0.67
(0.0077) (0.012) (0.0098) (0.02) (0.029) (0.028) (0.0076) (0.012) (0.0096)
Elderly (65+) 0.26 0.26 0.27 0.49 0.5 0.47 0.24 0.24 0.24
(0.0074) (0.011) (0.0096) (0.02) (0.029) (0.028) (0.0071) (0.011) (0.0093)
Private insurance 0.59 0.57 0.61 0.001 0.49 0.45 0.52 0.041 0.61 0.58 0.62 0.002
(0.0093) (0.013) (0.014) (0.021) (0.03) (0.029) (0.0097) (0.014) (0.015)
Public insurance 0.28 0.31 0.25 0.44 0.49 0.39 0.26 0.29 0.23
(0.0082) (0.013) (0.01) (0.02) (0.03) (0.029) (0.0084) (0.013) (0.01)
Other payer 0.13 0.12 0.14 0.075 0.063 0.089 0.14 0.12 0.15
(0.0066) (0.008) (0.011) (0.009) (0.012) (0.014) (0.0071) (0.0087) (0.011)
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in 
parentheses. Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple 
regression for continuous variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
All eligible visits Target visits Non-target visits
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All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 5,086 2,439 2,529 268 133 128 4,818 2,306 2,401
Glitazone Rx 0.13 0.15 0.11 0.005 0.11 0.16 0.057 0.046 0.13 0.15 0.11 0.011
(0.0075) (0.012) (0.0096) (0.026) (0.045) (0.026) (0.0078) (0.012) (0.01)
Prescriber characteristics
Group practice 0.64 0.63 0.65 0.541 0.62 0.64 0.61 0.753 0.64 0.63 0.66 0.499
(0.022) (0.032) (0.029) (0.046) (0.067) (0.063) (0.022) (0.032) (0.03)
Solo practice 0.36 0.37 0.35 0.38 0.36 0.39 0.36 0.37 0.34
(0.022) (0.032) (0.029) (0.046) (0.067) (0.063) (0.022) (0.032) (0.03)
PCP 0.72 0.73 0.7 0.000 0.72 0.74 0.72 0.000 0.72 0.73 0.7 0.000
(0.019) (0.026) (0.028) (0.05) (0.074) (0.069) (0.019) (0.025) (0.028)
Other specialty 0.28 0.27 0.3 0.28 0.26 0.28 0.28 0.27 0.3
(0.019) (0.026) (0.028) (0.05) (0.074) (0.069) (0.019) (0.025) (0.028)
M.D. 0.91 0.91 0.92 0.721 0.89 0.88 0.9 0.736 0.92 0.91 0.92 0.754
(0.0079) (0.012) (0.011) (0.022) (0.032) (0.03) (0.0079) (0.012) (0.011)
D.O. 0.086 0.09 0.084 0.11 0.12 0.1 0.085 0.088 0.083
(0.0079) (0.012) (0.011) (0.022) (0.032) (0.03) (0.0079) (0.012) (0.011)
MSA practice 0.87 0.85 0.88 0.331 0.79 0.76 0.81 0.469 0.87 0.85 0.89 0.347
(0.02) (0.028) (0.025) (0.042) (0.064) (0.051) (0.019) (0.027) (0.024)
Rural practice 0.13 0.15 0.12 0.21 0.24 0.19 0.13 0.15 0.11
(0.02) (0.028) (0.025) (0.042) (0.064) (0.051) (0.019) (0.027) (0.024)
Northeast 0.19 0.17 0.21 0.603 0.2 0.15 0.26 0.356 0.19 0.18 0.21 0.677
(0.016) (0.023) (0.026) (0.041) (0.048) (0.07) (0.016) (0.023) (0.025)
Midwest 0.21 0.21 0.22 0.34 0.32 0.37 0.21 0.2 0.21
(0.017) (0.023) (0.025) (0.052) (0.079) (0.071) (0.016) (0.021) (0.024)
South 0.41 0.41 0.4 0.3 0.31 0.25 0.41 0.41 0.41
(0.021) (0.029) (0.031) (0.043) (0.06) (0.061) (0.021) (0.029) (0.031)
West 0.19 0.21 0.17 0.17 0.21 0.12 0.19 0.21 0.17
(0.015) (0.025) (0.02) (0.036) (0.062) (0.036) (0.015) (0.025) (0.02)
Patient characteristics
Female 0.51 0.51 0.52 0.567 0.46 0.49 0.43 0.510 0.52 0.51 0.52 0.480
(0.01) (0.015) (0.015) (0.043) (0.059) (0.061) (0.011) (0.015) (0.015)
White 0.79 0.8 0.79 0.649 0.81 0.84 0.79 0.402 0.79 0.79 0.79 0.735
(0.012) (0.017) (0.018) (0.032) (0.044) (0.047) (0.013) (0.017) (0.018)
Black 0.14 0.14 0.15 0.13 0.092 0.16 0.15 0.14 0.15
(0.01) (0.014) (0.015) (0.028) (0.032) (0.045) (0.011) (0.015) (0.016)
Other race 0.065 0.067 0.059 0.056 0.065 0.048 0.065 0.067 0.059
(0.0082) (0.0099) (0.012) (0.019) (0.031) (0.021) (0.0085) (0.01) (0.013)
Age (years) 64 64 64 0.631 70 70 70 0.720 64 63 64 0.489
(0.27) (0.38) (0.39) (1.03) (1.53) (1.46) (0.28) (0.39) (0.4)
Youth (0-17)
Adult (18-64) 0.51 0.52 0.51 0.766 0.34 0.29 0.39 0.176 0.52 0.53 0.52 0.503
(0.01) (0.014) (0.015) (0.036) (0.048) (0.053) (0.011) (0.015) (0.016)
Elderly (65+) 0.49 0.48 0.49 0.66 0.71 0.61 0.48 0.47 0.48
(0.01) (0.014) (0.015) (0.036) (0.048) (0.053) (0.011) (0.015) (0.016)
Private insurance 0.57 0.56 0.6 0.201 0.5 0.46 0.55 0.591 0.58 0.56 0.6 0.269
(0.013) (0.019) (0.018) (0.039) (0.059) (0.052) (0.013) (0.019) (0.018)
Public insurance 0.35 0.36 0.34 0.45 0.46 0.41 0.35 0.36 0.33
(0.012) (0.017) (0.017) (0.045) (0.071) (0.057) (0.012) (0.017) (0.017)
Other payer 0.074 0.08 0.066 0.057 0.073 0.043 0.075 0.08 0.068
(0.0063) (0.009) (0.0083) (0.022) (0.03) (0.034) (0.0066) (0.0094) (0.0085)
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in parentheses. 
Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple regression for continuous 
variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
All eligible visits Target visits Non-target visits
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Table 3.8. Descriptive Statistics for Plavix Analytic Sample 
 
  
All years Pre-BW Post-BW p
N 1,879 958 877
Plavix Rx 0.2 0.21 0.19 0.701
(0.016) (0.018) (0.028)
Prescriber characteristics
Group practice 0.67 0.64 0.7 0.331
(0.03) (0.045) (0.038)
Solo practice 0.33 0.36 0.3
(0.03) (0.045) (0.038)
PCP 0.38 0.35 0.41 0.159
(0.028) (0.035) (0.044)
Relevant specialty 0.29 0.34 0.23
(0.027) (0.041) (0.032)
Other specialty 0.33 0.31 0.36
(0.029) (0.039) (0.045)
M.D. 0.94 0.93 0.95 0.247
(0.0095) (0.016) (0.0098)
D.O. 0.059 0.069 0.049
(0.0095) (0.016) (0.0098)
MSA practice 0.86 0.83 0.89 0.191
(0.029) (0.047) (0.028)
Rural practice 0.14 0.17 0.11
(0.029) (0.047) (0.028)
Northeast 0.17 0.16 0.18 0.173
(0.019) (0.024) (0.03)
Midwest 0.19 0.23 0.15
(0.019) (0.031) (0.021)
South 0.47 0.46 0.48
(0.03) (0.042) (0.045)
West 0.17 0.15 0.2
(0.018) (0.021) (0.031)
Patient characteristics
Female 0.51 0.53 0.5 0.422
(0.018) (0.024) (0.029)
White 0.84 0.90 0.78 0.000
(0.015) (0.013) (0.026)
Black 0.11 0.075 0.14
(0.012) (0.012) (0.022)
Other race 0.047 0.023 0.077
(0.011) (0.0051) (0.022)
Age (years) 68 68 68 0.933
(0.5) (0.68) (0.74)
Youth (0-17) 0.0019 0.0034 0.00019 0.274
(0.00096) (0.0018) (0.00019)
Adult (18-64) 0.36 0.35 0.37
(0.017) (0.023) (0.025)
Elderly (65+) 0.63 0.64 0.63
(0.017) (0.023) (0.025)
Private insurance 0.54 0.57 0.5 0.152
(0.021) (0.029) (0.03)
Public insurance 0.4 0.38 0.44
(0.02) (0.027) (0.03)
Other payer 0.056 0.05 0.063
(0.0083) (0.01) (0.014)
All eligible visits
Means and standard errors and p-values are adjusted for complex survey data 
weights and design features. Linearized standard errors reported in parentheses. 
Differences between pre- and post-BW means are tested using a chi-squared test for 
binary and categorical variables, and a simple regression for continuous variables (p-
values are reported). Bolded p-values are statistically significant at the 95% 
confidence level.
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Table 3.9. Differential Effects of Boxed Warnings 
 
Note: Bolded p-values are statistically significant at the 95% confidence level. Atypical antipsychotic stratified 
models for other specialties fail to converge, so no results are reported for other specialties.  
 
Diff Eff p Diff Eff p Diff Eff p Diff Eff p
Overall differential effect -0.081 0.128 -0.090 0.074 -0.104 0.142 -0.087 0.258
Stratified differential effects
MSA -0.083 0.142 -0.097 0.076 0.006 0.888 0.038 0.626
Rural -0.092 0.486 -0.072 0.573 -0.609 0.002 -0.596 0.002
Group -0.145 0.044 -0.162 0.024 -0.197 0.024 -0.174 0.064
Solo 0.030 0.702 0.029 0.744 0.025 0.804 0.036 0.732
MD -0.079 0.184 -0.090 0.098 -0.139 0.082 -0.123 0.146
DO -0.330 0.048 -0.348 0.021 0.275 0.022 0.320 0.049
PCP -0.148 0.184 -0.170 0.092 -0.140 0.074 -0.160 0.217
Relevant Specialties -0.065 0.262 -0.055 0.322 0.044 0.674 0.082 0.464
Other specialties -0.082 0.653 -0.051 0.765
Comparisons of stratified effects
MSA vs. Rural 0.00917 0.943 -0.0256 0.879 0.6148 0.002 0.63391 0.004
Group vs. Solo -0.175 0.114 -0.1912 0.090 -0.2221 0.128 -0.2098 0.220
MD vs. DO 0.2506 0.138 0.2583 0.087 -0.414 0.000 -0.4428 0.007
PCP vs. Relevant Specialties -0.0837 0.490 -0.1155 0.348 -0.1846 0.194 -0.242 0.185
PCP vs. Other Specialties -0.0659 0.811 -0.1188 0.647
Relevant vs. Other Specialties 0.01777 0.938 -0.0033 0.986
Antidepressants Atypicals
Other spec. models fail to converge
Other spec. models fail to converge











Note: Bolded p-values are statistically significant at the 95% confidence level. COX-2 inhibitor models that are 
stratified for relevant specialties have perfect prediction problems, so no results are reported for that group of 
prescribers. The relevant specialties for glitazones are not identifiable in the data and thus results are not reported for 
those prescribers.  
Diff Eff p Diff Eff p Diff Eff p Diff Eff p
Overall differential effect -0.0010 0.932 0.001 0.984 -0.070 0.145 -0.065 0.175
Stratified differential effects
MSA -0.0006 0.984 0.00218 0.932 -0.0871 0.137 -0.0792 0.165
Rural 0.0115 0.834 0.01516 0.734
Group 0.0256 0.422 0.02184 0.404 -0.1783 0.000 -0.169 0.000
Solo -0.0385 0.144 -0.035 0.152 0.13868 0.110 0.14819 0.091
MD -0.0028 0.880 -0.0008 0.930 -0.072 0.177 -0.0663 0.223
DO 0.0305 0.346 0.03003 0.386 -0.073 0.706 -0.0752 0.688
PCP 0.0075 0.736 0.007 0.714 -0.0616 0.253 -0.0563 0.281
Relevant Specialties
Other specialties -0.0221 0.441 -0.0183 0.491 -0.008 0.611 -0.008 0.597
Comparisons of stratified effects
MSA vs. Rural -0.0121 0.840 -0.013 0.802
Group vs. Solo 0.0641 0.136 0.05652 0.128 -0.317 0.000 -0.3172 0.000
MD vs. DO -0.0333 0.420 -0.0308 0.448 0.00103 0.753 0.00895 0.774
PCP vs. Relevant Specialties
PCP vs. Other Specialties 0.0296 0.408 0.02576 0.414 -0.0536 0.341 -0.048 0.383
Relevant vs. Other Specialties
Perfectly predicted outcomes
Relevant spec. not reported in data
Perfectly predicted outcomes
Relevant spec. not reported in data
















Note: Bolded p-values are statistically significant at the 95% confidence level. 
  
Diff Eff p Diff Eff p
Overall differential effect -0.036 0.676 -0.040 0.628
Stratified differential effects
MSA 0.035 0.630 0.032 0.656
Rural -0.381 0.008 -0.345 0.003
Group 0.009 0.914 0.015 0.852
Solo -0.205 0.060 -0.198 0.078
MD -0.007 0.952 -0.010 0.932
DO -0.371 0.084 -0.382 0.177
PCP -0.218 0.028 -0.225 0.022
Relevant Specialties -0.081 0.510 -0.075 0.564
Other specialties 0.154 0.190 0.149 0.208
Comparisons of stratified effects
MSA vs. Rural 0.416 0.006 0.377 0.024
Group vs. Solo 0.214 0.108 0.213 0.126
MD vs. DO 0.364 0.094 0.372 0.194
PCP vs. Relevant Specialties -0.137 0.264 -0.150 0.220
PCP vs. Other Specialties -0.372 0.010 -0.373 0.008
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Differential Effects by Specialty Type
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Differential Effects by Specialty Type
 107 









-.2 -.1 0 .1
Differential effect of BW on prescribing
MSA Rural
Difference between MSA and Rural practices
COX-2 Inhibitors eligible visits, NAMCS data files





-.2 -.1 0 .1 .2 .3
Differential effect of BW on prescribing
Group Solo
Difference between Practice Sizes
COX-2 Inhibitors eligible visits, NAMCS data files





-.2 -.1 0 .1 .2
Differential effect of BW on prescribing
M.D. D.O.
Difference between M.D. and D.O.
COX-2 Inhibitors eligible visits, NAMCS data files






-.2 -.1 0 .1 .2 .3
Differential effect of BW on prescribing
Primary Care Specialties Other Specialties
Difference between Specialty Types
COX-2 Inhibitors eligible visits, NAMCS data files
Differential Effects by Specialty Type
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Differential Effects by Specialty Type
 109 









-1 -.5 0 .5 1
Differential effect of BW on prescribing
MSA Rural
Difference between MSA and Rural practices
Plavix eligible visits, NAMCS data files







-.4 -.2 0 .2 .4 .6
Differential effect of BW on prescribing
Group Solo
Difference between Practice Sizes
Plavix eligible visits, NAMCS data files







-1 -.5 0 .5 1
Differential effect of BW on prescribing
M.D. D.O.
Difference between M.D. and D.O.
Plavix eligible visits, NAMCS data files







Differential effect of BW on prescribing
Primary Care Specialties Relevant Specialties
Other Specialties
Plavix eligible visits, NAMCS data files




Ai. C., Norton, E.C. (2003) Interaction terms in logit and probit models. Economics Letters, 80(1): 
123-129. 
Alexander, G.C., Sehgal, N.L., Moloney, R.M. Stafford, R.S. (2008). National Trends in 
Treatment of Type 2 Diabetes Mellitus, 1994 - 2007. Arch Intern Med, 168(19): 2088-
2094. 
American Osteopathic Association (AOA). “What is Osteopathic Medicine? What is a DO?” 
https://osteopathic.org/what-is-osteopathic-medicine/what-is-a-do/, accessed April 2019. 
Ancker, J. S., Edwards, A., Nosal, S., Hauser, D., Mauer, E., Kaushal, R., & with the HITEC 
Investigators (2017). Effects of workload, work complexity, and repeated alerts on alert 
fatigue in a clinical decision support system. BMC medical informatics and decision 
making, 17(1), 36. https://doi.org/10.1186/s12911-017-0430-8 
Avorn, J., Chen, M., & Hartley, R. (1982). Scientific versus commercial sources of influence on 
the prescribing behavior of physicians. The American journal of medicine, 73(1), 4–8. 
https://doi.org/10.1016/0002-9343(82)90911-1 
Centers for Disease Control and Prevention (CDC). (2019). “Type 2 Diabetes,” Revised as of May 
20, 2019, accessed June 2019. Retrieved from 
https://www.cdc.gov/diabetes/basics/type2.html  
Centers for Disease Control and Prevention (CDC), International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) code files, 
ftp://ftp.cdc.gov/pub/health_statistics/nchs/publications/icd9-cm/, accessed December 
2018.  
Centers for Disease Control and Prevention (CDC). (2013). “Conversion Table of New ICD-9-
CM Codes, October 2013” https://www.cdc.gov/nchs/data/icd/icd-9-
cm_fy14_cnvtbl_final.pdf, accessed December 2018.  
Charles, R. F., Powe, N. R., Jaar, B. G., Troll, M. U., Parekh, R. S., & Boulware, L. E. (2009). 
Clinical testing patterns and cost implications of variation in the evaluation of CKD among 
US physicians. American journal of kidney diseases : the official journal of the National 
Kidney Foundation, 54(2), 227–237. https://doi.org/10.1053/j.ajkd.2008.12.044 
 Chen, S.-Y. and Toh, S. (2011). National trends in prescribing antidepressants before and after an 
FDA advisory on suicidality risk in youths. Psychiatric Services, 62(7): 727-733. 
Cheng, C. M., Fu, C., Guglielmo, B. J., & Auerbach, A. D. (2011). Boxed warning inconsistencies 
between drug information resources and the prescribing information. American journal of 
health-system pharmacy : AJHP : official journal of the American Society of Health-System 
Pharmacists, 68(17), 1626–1631. https://doi.org/10.2146/ajhp110025 
 111 
Cheng, C., C. DeLizza, J. Kapusnik-Uner. (2014b). Prevalence and Therapeutic Classifications of 
FDA-Approved Prescription Drugs with Boxed Warnings. Therapeutic Innovation & 
Regulatory Science, 48(2): 165-172. 
Cheng,.C., J. Shin, B.J. Guglielmo. (2014a). Trends in Boxed Warnings and Withdrawals for 
Novel Therapeutic Drugs, 1996 Through 2012. JAMA Internal Medicine, 174(4): 1704-
1705., (2014) 
Cohen, A., A. Rabbani, N. Shah, G.C. Alexander. (2010). Changes in Glitazone Use Among 
Office-Based Physicians in the U.S., 2003-2009. Diabetes Care, 33(4): 823-825.  
Datta, A., & Dave, D. (2017). Effects of Physician-directed Pharmaceutical Promotion on 
Prescription Behaviors: Longitudinal Evidence. Health economics, 26(4), 450–468. 
https://doi.org/10.1002/hec.3323 
Dave D. (2014). Pharmaceutical marketing and promotion. In A. Culyer (ed.), Encyclopedia of 
Health Economics (pp. 9-19). Amsterdam: Elsevier, Inc. 
Dorsey, E. R., Rabbani, A., Gallagher, S. A., Conti, R. M., & Alexander, G. C. (2010). Impact of 
FDA black box advisory on antipsychotic medication use. Archives of internal 
medicine, 170(1), 96–103. https://doi.org/10.1001/archinternmed.2009.456 
Dranove, D. and Satterthwaite, M.A. (2000). The Industrial Organization of Health Care Markets. 
In A.J. Culyer and J.P. Newhouse (Ed.). Handbook of Health Economics (Vol 1B, pp. 
1093-1139). https://doi.org/10.1016/S1574-0064(00)80033-5 
Dusetzina, S. B., Higashi, A. S., Dorsey, E. R., Conti, R., Huskamp, H. A., Zhu, S., Garfield, C. 
F., & Alexander, G. C. (2012). Impact of FDA drug risk communications on health care 
utilization and health behaviors: a systematic review. Medical care, 50(6), 466–478. 
https://doi.org/10.1097/MLR.0b013e318245a160 
Earley, B.E., & H. Luce. (2010). An Introduction to Clinical Research in Osteopathic Medicine. 
Primary Care: Clinics in Office Practice, 37(1): 49-64. 
Food and Drug Administration (FDA). (2007). 21 CFR 201.57(c)(1): Title 21--Food and Drugs, 
Chapter I: Department of Health and Human Services, Subchapter C: Drugs: General, Part 
201: Labeling. 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.57, 
accessed October 2017. 
Food and Drug Administration (FDA). (2011) Guidance for Industry: Warnings and Precautions, 
Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug 
and Biological Products — Content and Format. May 2011. U.S. Department of Health 
and Human Services Food and Drug Administration, Center for Drug Evaluation and 
Research (CDER), Center for Biologics Evaluation and Research (CBER). Accessed Nov 
2015 at www.fda.gov/downloads/Drugs/.../Guidances/ucm075096.pdf 
 112 
Food and Drug Administration (FDA). (2012) “A Guide to Drug Safety Terms at the FDA,” 
https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf 
Food and Drug Administration (FDA). (2015). “Basics of Drug Ads,” Revised June 19, 2015, 
https://www.fda.gov/drugs/prescription-drug-advertising/basics-drug-ads. 
Food and Drug Administration (FDA). (2016). “An Introduction to the Improved FDA 
Prescription Drug Labeling,” https://www.fda.gov/training-and-continuing-
education/cderlearn-training-and-education/introduction-improved-fda-prescription-drug-
labeling. 
Food and Drug Administration (FDA). (2017). “FDA Basics Webinar: A Brief Overview of Risk 
Evaluation and Mitigation Strategies (REMS),” Revised as of October 11, 2017, Accessed 
Oct 2017 at https://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm. 
Food and Drug Administration (FDA). Drugs@FDA: FDA Approved Products, 
https://www.accessdata.fda.gov/scripts/cder/drugsatfda/. 
Frank, C., D. Himmelstein, S. Woolhandler, D. Bor, S. Wolfe, O. Heymann, L. Zallman, K. Lasser. 
(2014). Era of faster FDA drug approval has also seen increased black-box warnings and 
market withdrawals. Health Affairs, 33(8): 1453-9. 
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M., Schellekens, H., Leufkens, H. G., & Egberts, 
A. C. (2008). Safety-related regulatory actions for biologicals approved in the United States 
and the European Union. JAMA, 300(16), 1887–1896. 
https://doi.org/10.1001/jama.300.16.1887 
Green. W. (2010). Testing hypotheses about interaction terms in nonlinear models. Economics 
Letters, 107(2): 291-296. 
Habib, A., and T. Gan. (2008). The use of droperidol before and after the Food and Drug 
Administration black box warning: a survey of the members of the Society of Ambulatory 
Anesthesia. Journal of Clinical Anesthesia, 20(1): 35-39. 
Heemstra, H. E., Giezen, T. J., Mantel-Teeuwisse, A. K., de Vrueh, R. L., & Leufkens, H. G. 
(2010). Safety-related regulatory actions for orphan drugs in the US and EU: a cohort 
study. Drug safety, 33(2), 127–137. https://doi.org/10.2165/11319870-000000000-00000 
Iizuka T, Jin GZ. (2005). The effect of prescription drug advertising on doctor visits. Journal of 
Economics and Management Strategy, 14(3): 701–727. 
Johnson, D., Austin, D., Thompson, J. (2005). Role of State Medical Boards in Continuing Medical 
Education. Journal of Continuing Education in the Health Professions, 25(3): 183-189. 
Johnson, S.M., and M.E. Kurtz. (2002). Perceptions of philosophic and practice differences 
between US osteopathic physicians and their allopathic counterparts. Social Science & 
Medicine, 55(12): 2141-2148. 
 113 
Kalbaugh, C.A., et al. (2017). Peripheral Artery Disease Prevalence and Incidence Estimated from 
Both Outpatient and Inpatient Settings Among Medicare Fee-for-Service Beneficiaries in 
the Atherosclerosis Risk in Communities (ARIC) Study. Journal of the American Heart 
Association, 6(5): 1-9, and supplemental materials. 
Karaca-Mandic, P., Norton, E.C., Dowd, B. (2012). Interaction terms in nonlinear models. Health 
Services Research, 47(1): 255-274, and Appendix S1: 1-6. 
Karpel, J. P., Peters, J. I., Szema, A. M., Smith, B., & Anderson, P. J. (2009). Differences in 
physicians' self-reported knowledge of, attitudes toward, and responses to the black box 
warning on long-acting beta-agonists. Annals of allergy, asthma & immunology : official 
publication of the American College of Allergy, Asthma, & Immunology, 103(4), 304–310. 
https://doi.org/10.1016/S1081-1206(10)60529-7 
Karve, S., Cleves, M.A., Helm, M., Hudson, T.J., West, D.S., & Martin, B.C. (2008). An Empirical 
Basis for Standardizing Adherence Measures Derived from Administrative Claims Data 
among Diabetic Patients. Medical Care, 46(11): 1125-1133. 
Kesselheim, A. S., Franklin, J. M., Avorn, J., & Duke, J. D. (2013). Speaking the same language? 
International variations in the safety information accompanying top-selling prescription 
drugs. BMJ quality & safety, 22(9), 727–734. https://doi.org/10.1136/bmjqs-2012-001704 
Kornfield, R., Watson, S., Higashi, A. S., Conti, R. M., Dusetzina, S. B., Garfield, C. F., Dorsey, 
E. R., Huskamp, H. A., & Alexander, G. C. (2013). Effects of FDA advisories on the 
pharmacologic treatment of ADHD, 2004-2008. Psychiatric services (Washington, 
D.C.), 64(4), 339–346. https://doi.org/10.1176/appi.ps.201200147 
Kuchera, M.L. (2007). Applying Osteopathic Principles to Formulate Treatment for Patients With 
Chronic Pain. The Journal of the American Osteopathic Association, 107: ES28-ES38. 
Lee Ventola, C. (2011). Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic? 
Pharmacy and Therapeutics (P&T), 36(10): 669-674, 681-684. 
Lee, E.S., & Forthofer, R.N. (2006). Analyzing complex survey data (2nd ed.). Thousand Oaks, 
CA: Sage Publications.  
Libby, A. M., Orton, H. D., & Valuck, R. J. (2009). Persisting decline in depression treatment after 
FDA warnings. Archives of general psychiatry, 66(6), 633–639. 
https://doi.org/10.1001/archgenpsychiatry.2009.46 
Licciardone, J.C. (2015). A National Study of Primary Care Provided by Osteopathic Physicians. 
The Journal of the American Osteopathic Association, 115(12): 704-713. 
McClellan, M., Daniel, G., Sheehan, S., Romine, M., Richardson, E., Burnell, J., Freed, M., 
Briesacher, B., Dusetzina, S., Good, C., Hornbuckle, K., Ross, J. (2019). A Framework for 
Evaluating the Impact of Prescription Drug Postmarketing Safety Labeling Changes 




McCoy, A. B., Thomas, E. J., Krousel-Wood, M., & Sittig, D. F. (2014). Clinical decision support 
alert appropriateness: a review and proposal for improvement. The Ochsner journal, 14(2), 
195–202. 
McGuire, T. G. (2000). Physician agency. In A.J. Culyer and J.P. Newhouse (Ed.). Handbook of 
Health Economics (Vol. 1A, pp. 461-536). Elsevier. https://doi.org/10.1016/S1574-
0064(00)80168-7 
Mendelson, A., Kondo, K., Damberg, C., Low, A., Motúapuaka, M., Freeman, M., O'Neil, M., 
Relevo, R., & Kansagara, D. (2017). The Effects of Pay-for-Performance Programs on 
Health, Health Care Use, and Processes of Care: A Systematic Review. Annals of internal 
medicine, 166(5), 341–353. https://doi.org/10.7326/M16-1881 
Miller, S. Thompson, J., Mazmanian, P., Aparacio, A., Davis, D., Spivey, B., Kahn, N. (2008). 
Continuing Medical Education, Professional Development, and Requirements for Medical 
Licensure: A White Paper of the Conjoint Committee on Continuing Medical Education. 
Journal of Continuing Education in the Health Professions, 28(2): 95-98. 
Mittal, M., D. Harrison, M. Miller, N. Brahm. (2014). National antidepressant prescribing in 
children and adolescents with mental health disorders after a FDA boxed warning. 
Research in Social and Administrative Pharmacy, 10: 781-790. 
National Institutes of Health, U.S. National Library of Medicine, “Daily Med,” 
https://dailymed.nlm.nih.gov/dailymed/, accessed June 2016.  
Norton, E.C., Wang, H., Ai, C. (2004). Computing interaction effects and standard errors in logit 
and probit models. The Stata Journal, 4(2): 154-167. 
Olfson, M., Marcus, S. C., & Druss, B. G. (2008). Effects of Food and Drug Administration 
warnings on antidepressant use in a national sample. Archives of general psychiatry, 65(1), 
94–101. https://doi.org/10.1001/archgenpsychiatry.2007.5 
Penfold, R.B., & Kelleher, K.J. (2007). Use of surveillance data in developing geographic 
dissemination strategies: A study of the diffusion of olanzapine to Michigan children 
insured by Medicaid. Clinical Therapeutics, 29(2): 359-370. 
Peters, A.S, Clark-Chiarelli, N., Block, S.D. (1999). Comparison of Osteopathic and Allopathic 
Medical Schools’ Support for Primary Care. Journal of General Internal Medicine, 14(12): 
730-739. 
Phelps, C. E. (2000). Information diffusion and best practice adoption. In A.J. Culyer and J.P. 
Newhouse (Ed.). Handbook of Health Economics (Vol. 1A, pp. 223-264). Elsevier. 
https://doi.org/10.1016/S1574-0064(00)80168-7 
 115 
Puhani, P.A. (2008). The Treatment Effect, the Cross Difference, and the Interaction Term in 
Nonlinear “Difference-in-Difference” Models. IZA Discussion Paper No. 3478, Institute 
of Labor Economics (IZA), retrieved from http://ftp.iza.org/dp3478.pdf. 
Rhodes E.T., Gonzalez, T.V., Laffel, L.M., Ludwig, D.S. (2007). Accuracy of coding for type 2 
diabetes in children, adolescents, and young adults. Diabetes Care, 30(1): 141–143.  
Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Epstein, A. M., & Frank, R. G. (2003). Demand 
Effects of Recent Changes in Prescription Drug Promotion, Forum for Health Economics 
& Policy, 6(1). https://doi.org/10.2202/1558-9544.1044 
Scherer, F.M. (2000). The Pharmaceutical Industry. In A.J. Culyer and J.P. Newhouse (Ed.). 
Handbook of Health Economics (Vol 1B, pp. 1297-1336). Elsevier. 
https://doi.org/10.1016/S1574-0064(00)80038-4 
Scott Morton, F. and Kyle, M. (2012). Markets for Pharmaceutical Products. In M.V. Pauly, T.G. 
McGuire, and P.P. Barros (Ed.). Handbook of Health Economics (Volume 2, pp. 763-823). 
Elsevier. https://doi.org/10.1016/B978-0-444-53592-4.00012-8 
Smollin, C. G., Fu, J., & Levin, R. (2016). Recognition and Knowledge of Medications with Black 
Box Warnings Among Pediatricians and Emergency Physicians. Journal of Medical 
Toxicology, 12(2), 180–184. 
Stewart, K. A., Natzke, B. M., Williams, T., Granger, E., Casscells, S. W., & Croghan, T. W. 
(2009). Temporal trends in anti-diabetes drug use in TRICARE following safety warnings 
in 2007 about rosiglitazone. Pharmacoepidemiology and drug safety, 18(11), 1048–1052. 
https://doi.org/10.1002/pds.1819 
Valuck, R. J., Libby, A. M., Orton, H. D., Morrato, E. H., Allen, R., & Baldessarini, R. J. (2007). 
Spillover effects on treatment of adult depression in primary care after FDA advisory on 
risk of pediatric suicidality with SSRIs. The American journal of psychiatry, 164(8), 1198–
1205. https://doi.org/10.1176/appi.ajp.2007.07010007 
van der Sijs, H., Aarts, J., Vulto, A., & Berg, M. (2006). Overriding of drug safety alerts in 
computerized physician order entry. Journal of the American Medical Informatics 
Association : JAMIA, 13(2), 138–147. https://doi.org/10.1197/jamia.M1809 
Ventimiglia, J., Kalali, A. H., Vahia, I. V., & Jeste, D. V. (2010). An analysis of the intended use 
of atypical antipsychotics in dementia. Psychiatry (Edgmont (Pa. : Township)), 7(11), 14–
17. 
Wagner, A. K., Chan, K. A., Dashevsky, I., Raebel, M. A., Andrade, S. E., Lafata, J. E., Davis, R. 
L., Gurwitz, J. H., Soumerai, S. B., & Platt, R. (2006). FDA drug prescribing warnings: is 
the black box half empty or half full?. Pharmacoepidemiology and drug safety, 15(6), 369–
386. https://doi.org/10.1002/pds.1193 
Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002). Segmented regression 
analysis of interrupted time series studies in medication use research. Journal of clinical 
 116 
pharmacy and therapeutics, 27(4), 299–309. https://doi.org/10.1046/j.1365-
2710.2002.00430.x 
Weycker, D. A., & Jensen, G. A. (2000). Medical malpractice among physicians: who will be sued 
and who will pay?. Health care management science, 3(4), 269–277. 
https://doi.org/10.1023/a:1019014028914 
Williams D. G. (2008). Practice patterns to decrease the risk of a malpractice suit. Clinical 
obstetrics and gynecology, 51(4), 680–687. 
https://doi.org/10.1097/GRF.0b013e3181899bc7 
Xie, L., Wei W., Pan C., & Baser, O. (2013). Real-world rates, predictors, and associated costs of 
hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: 
results of a pooled analysis of six retrospective observational studies. Journal of Medical 




CHAPTER 4: STUDY 3:  
ASSESSING PATIENT DISPARITIES IN POST-BOXED WARNING PRESCRIBING 
CHANGES 
 
4.1.  INTRODUCTION 
“Boxed warnings” (BW) are the highest level of prescription drug warning issued by the 
Food and Drug Administration (FDA). The FDA requires boxed warnings on a prescription drug 
label when there is reasonable evidence that the drug causes irreversible disability, death, or other 
very serious adverse drug reactions (FDA 2011). The addition of a boxed warning indicates that 
newly discovered safety information revealed that the drug is more risky than previously thought. 
This new information may not necessarily indicate that the drug is inherently unsafe and should 
not be prescribed; the risks may be specific to certain subpopulations, or may be outweighed by 
potential benefits. However, holding all else constant, an increase in expected drug risks should 
decrease the likelihood of prescribing as prescribers and patients become more circumspect about 
the expected net benefit of the drug. Thus, in aggregate, I expect drug use to decrease when 
prescribers and patients become aware of the boxed warning. Indeed, I find that the probability of 
a prescription decreases after a drug receives a boxed warning (see Chapters 2 and 3). In this study, 
I examine whether the responses varies by patient characteristics; that is, I am testing whether 
patient characteristics influence the rates at which prescribing probability decreases following the 
addition of a boxed warning.  
It is well known that patient characteristics are an important predictor of health care 
utilization and health disparities. Race, ethnicity, sex, age, and insurance status are known to 
influence health care seeking, quality of care, and health outcomes (Babitsch 2012; Ben 2017; 
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Insaf 2010; AHRQ 2019; IOM 2003; Nelson 2002). Specifically, studies show that ethnic and 
racial minorities, uninsured patients, and females are likely to have lower quality of care than other 
patients (Ben 2017; AHRQ 2019; IOM 2003; Nelson 2002; Teunissen 2016). These pathways by 
which patient characteristics are likely to influence health utilization and quality will be further 
discussed in the Conceptual Framework section below. Prior literature on the impact of boxed 
warnings has not examined whether there are patient disparities in post-BW drug prescribing or 
utilization. In addition to the general pattern of patient characteristics influencing quality of care, 
to the extent that the risks are larger for certain patients, I expect larger decreases in prescribing 
among the higher-risk population. 
In this study, I evaluate patient characteristics that are known to be important predictors of 
health care quality: race, ethnicity, sex, insurance status, and age. I hypothesize that patients who 
are more likely to receive a lower quality of care will be less likely to receive care that is concordant 
with new safety information, and thus will be less likely to have a decrease in prescribing 
probability after the boxed warning is added. On the flip side, patients groups who tend to have a 
higher quality of care will be more likely to receive care that incorporates new safety findings, and 
thus are more likely to have a decrease in their prescribing probability after the boxed warning is 
added. In this study, I focus on five boxed warnings to assess whether race, ethnicity, sex, age, and 
insurance status are associated with differences in prescribing probability after the boxed warning 
is added. I hypothesize that non-White, Hispanic, female, and non-privately insured patients will 
have little to no change in prescribing probability after the boxed warning is added, but that White, 
non-Hispanic, male, and privately insured patients will have a statistically significant decrease in 
prescribing probability after the boxed warning is added. 
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This study fills gaps in prior knowledge by assessing whether patient characteristics are 
associated with variation in post-boxed warning prescribing probability. This is important because 
if patient characteristics are correlated with differences in post-boxed warning prescribing 
probability, it could indicate disparities in the degree to which prescribers transmit boxed warning 
safety information to their patients. If certain patients are less apt to decrease use of the boxed 
warning drug following the BW, those patients may have a higher risk for adverse drug events. If 
I find that certain types of patients are less likely to receive BW concordant care, this represents 
an important opportunity to intervene to increase equity in quality of care. 
4.2.  CONCEPTUAL FRAMEWORK 
My model draws from Andersen’s Behavioral Model of Health Services Use as a 
conceptual framework for this study (Andersen 1973; Andersen 1995; Andersen 2008). The 
Andersen model is widely-used in health care utilization research (Ricketts 2005; Babistch 2012). 
Andersen’s model designates three key determinants of individual health care use: predisposing 
characteristics, enabling resources, and need factors (Andersen 1973; Andersen 1995).  
Early versions of the Andersen model focused on the role of predisposing, enabling, and 
need factors on health care access and utilization (Andersen 1973; Andersen 1995). However, 
more recent iterations show that the influence of these three factors extends to quality of health 
care measures (Andersen 1995; Anderson 2008). In particular, these factors influence the “process 
of medical care,” which encompasses characteristics of the provider-patient interaction, such as 
whether the patient receives counseling from the prescriber, what tests or treatments are prescribed, 
and quality of the provider-patient interaction (Andersen 2008). By exploring how predisposing, 
enabling, and need factors influence health care access, utilization, and quality, I illustrate how 
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patient characteristics could influence prescribing rates following the addition of a boxed warning 
(see Figure 4.1). 
Andersen defines predisposing characteristics as factors that impact a patient’s propensity 
to use health services. These include patient demographic characteristics, social structure, personal 
health beliefs, and cultural norms for seeking care. Predisposing characteristics in this study 
include race, ethnicity, sex, and age. Multiple studies of health care quality and disparities show 
that racial and ethnic minorities typically receive a lower quality of care (AHRQ 2019; Ben 2017; 
IOM 2003; Nelson 2002). A recent AHRQ study reported that non-White patients and Hispanic 
patients had worse care than White patients on over a third of the study’s quality measures (AHRQ 
2019). A meta-analysis of 59 papers found that racism has a statistically significant impact on 
patients’ perceived quality of care, satisfaction, and trust in their health care providers (Ben 2017). 
Hispanic patients are also more likely to face linguistic barriers which could decrease their quality 
of care (IOM 2003). Studies generally find that racial and ethnic disparities persist after controlling 
for disease severity and sociodemographic factors (IOM 2003). For example, non-White patients 
have higher death rates for cancer, heart disease, and diabetes, even after controlling for disease 
severity (Nelson 2002; IOM 2003). There are also some disparities by patient sex: females report 
lower quality of care (Teunissen 2016), and have poorer health outcomes than males (Shi 2010; 
AHRQ 2019; Araujo 2018). Based on these findings, I expect race, ethnicity, and to a lesser extent, 
sex to be important predisposing characteristics for health care use and quality.  
Enabling resources are factors that make health care easier for patients to access, or that 
impede their access to care. Enabling resources can be divided into two sub-groups: individual 
resources and community resources. Individual enabling factors include income and health 
insurance characteristics. Community enabling factors include the quantity and quality of health 
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care providers and facilities in the patient’s area. In this study, I include health insurance type as 
an enabling factor. Compared to privately insured patients, patients with public insurance are more 
likely to report worse quality of care and poor provider-patient communication (AHRQ 2019). 
Public insurance is also associated with worse outcomes in certain settings (Swensen 2017).  One 
possible reason that public insurance is associated with lower quality is that Medicaid and 
Medicare are more likely to have narrower provider networks than privately insured patients, and 
thus publicly insured patients may have fewer high-quality providers to choose from. Also, since 
most private insurance is employer-sponsored health insurance, patients with private insurance are 
more likely to have jobs or family members with jobs. This means that private insurance will also 
associated with economic enabling factors, which often increase patients’ ability to receive higher-
quality care (AHRQ 2019).   
Need factors are characteristics that influence a patient’s actual or perceived heath status, 
and thus their actual or perceived need for health care. In this study, I incorporate need factors by 
utilizing patient diagnosis and health conditions to identify patients in need of treatment by the 
study drugs. Additionally, I incorporate a patient’s need for receiving the updated safety 
information by distinguishing between patients that are high-risk for the adverse event versus those 
that are not high-risk.  
I propose that predisposing, enabling, and need factors will impact post-boxed warning 
prescribing probability by influencing patients’ health care utilization quantity and quality. First, 
patients with predisposing, enabling, and need factors are more likely to seek care, and thus are 
more likely to see their doctor, which is a necessary requirement for getting treated for a condition. 
Patients who seek care more often will also have more opportunities to learn about the updated 
safety information that is presented in the boxed warning, and thus, may be less likely to request a 
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BW drug prescription or more likely to request a non-BW drug prescription. This would result in 
lower probability of a boxed warning prescriptions among patients that have a higher quantity of 
health care utilization. However, in this study I am limited in my ability to measure the impact of 
quantity of care on prescribing because the study relies on visit-level data. In other words, a 
patient’s inclusion in the data is conditional on seeking care.  
This study focuses on quality of care as the key pathway by which predisposing, enabling, 
and need factors are likely to influence prescribing of boxed warning drugs. Patients receiving 
poorer quality of care may be more likely to be treated by prescribers who are unaware of the 
updated safety information in the boxed warning, or prescribers who are not implementing new 
safety findings into their prescribing decisions. As a result, those prescribers may be more likely 
to continue prescribing the boxed warning drugs even after the warning is added. This would result 
in patients with lower quality of care having higher post-BW prescribing rates than patients with 
higher quality care. As described above, I expect that non-White, Hispanic, publicly insured, 
and/or female patients will have lower quality of care, and thus will reduce prescribing by less than 
those with higher quality of care (White, non-Hispanic, male, privately insured patients). 
4.3.  DATA 
4.3.1.  Data Sources 
Visit data 
This study relies on visit-level physician survey data from the National Ambulatory 
Medical Care Surveys (NAMCS) and National Hospital Ambulatory Medical Care Surveys 
(NHAMCS). These data are collected using a multi-stage sampling design from a national sample 
of physicians in three health care settings: office-based outpatient visits, hospital outpatient visits, 
and emergency department visits. I utilize the publicly available data files for 2002 through 2011, 
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the most recent data year that includes all three settings. NAMCS data include office-based 
outpatient visits from a national sample of office-based non-federal physicians. For each physician, 
a random sample of their visits in one week of each year is surveyed. NHAMCS data include 
hospital outpatient and emergency department visits from a national sample of non-federal, non-
institutional general and short-stay hospitals with at least six patient beds. For each hospital, a 
random sample of visits is surveyed from a randomly assigned four-week reporting period. 
NAMCS and NHAMCS data include patient diagnoses, reasons for visit, medications, 
demographics, visit setting, U.S. Census region, and physician/hospital characteristics. Data 
include complex survey data sampling weights to allow generation of nationally representative 
estimates. 
Drug information 
I rely on the Food and Drug Administration (FDA)’s website, and the National Institute of 
Health (NIH)’s Daily Med website for data on FDA safety communications and FDA drug labeling 
for the study drugs. I utilize historic and current drug labels to identify FDA approved indications, 
boxed warning date, and boxed warning content.  
4.3.2.  Sample 
Selection of study boxed warnings 
To identify boxed warnings for this study, I collected boxed warning data for a large 
number of drugs, and then reviewed this list for the following considerations: 1) the boxed warning 
was added in the post-market period rather than at drug approval24, 2) the boxed warning was 
added between 2004 and 2010, to allow sufficient observation of prescribing trends during the pre- 
                                                        
24 This study is limited to drugs that only have post-market BWs so it is possible to observe prescribing before the 
drug received a boxed warning. In total, 9% of approved drugs launch without a boxed warning and then receive a 
post-market BW. (Cheng 2014). 
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and post-boxed warning periods in the 2002-2011 NAMCS/NHAMCS data, 3) the boxed warning 
would affect a reasonable amount of patients, 4) the conditions treated by the drugs are identifiable 
using diagnosis codes.  
This study examines the FDA boxed warnings for the following drug safety issues: 1) 
Antidepressants: Suicidality risks for younger patients, 2) Atypical antipsychotics: Mortality risks 
for elderly with dementia, 3) COX-2 Inhibitors: Cardiovascular risks, 4) Glitazones: Congestive 
heart failure risks, 5) Plavix: Diminished effectiveness for CYP2C19 poor metabolizers. The 
characteristics of these boxed warnings are described in more detail in Table 4.1, and the complete 
text of the boxed warnings for each safety issue is included in Appendix 2. These five boxed 
warnings span multiple drugs, classes, and treatment areas, and vary across other domains as well, 
including issuance date (October 2004 to March 2010), risk category (adverse event risk vs. 
efficacy risks), and scope (single drug vs. multiple drug classes) (see Table 4.1). 
Each of the boxed warnings in this study cautions regarding use of the given product for a 
specific patient subpopulation for whom the risk of the BW adverse reaction is high. It is important 
to identify these patients because they are the patients for whom the boxed warning is relevant. I 
identify these relevant patient subpopulations in the following excerpts of the study boxed 
warnings by emphasizing with bolded text (see Appendix 2 for complete text of boxed warnings):  
1) Antidepressants: “Antidepressants increased the risk of suicidal thinking and behavior 
(suicidality) in short-term studies in children and adolescents with Major Depressive Disorder 
(MDD) and other psychiatric disorders. Anyone considering the use of [antidepressants] … in a 
child or adolescent must balance this risk with the clinical need.”  
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2) Atypical antipsychotics: “Elderly patients with dementia-related psychosis treated 
with antipsychotic drugs are at an increased risk of death. … [Antipsychotics are] not approved 
for the treatment of patients with dementia-related psychosis”   
3) COX-2 Inhibitors: “Patients with cardiovascular disease or risk factors for 
cardiovascular disease may be at greater risk … contraindicated for the treatment of peri-
operative pain in the setting of coronary artery bypass graft (CABG) surgery.” 
4) Glitazones: “Thiazolidinediones… cause or exacerbate congestive heart failure in some 
patients … monitor patients carefully for signs and symptoms of heart failure … If heart failure 
develops, it should be managed according to current standards of care and discontinuation or dose 
reduction of [glitazones] must be considered. [Glitazones are] not recommended in patients with 
symptomatic heart failure. Initiation of [glitazones] in patients with established New York 
Heart Association (NYHA) Class III or IV heart failure is contraindicated 
5) Plavix: “Plavix … has a smaller effect on platelet function in patients who are CYP2C19 
poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing 
percutaneous coronary intervention treated with Plavix at recommended doses exhibit higher 
cardiovascular event rates than do patients with normal CYP2C19 function. … Consider 
alternative treatment or treatment strategies in patients identified as CYP2C19 poor 
metabolizers.” 
I refer to these patients as “targeted patients” because they are the patients that are targeted 
by the boxed warning. Based on the highlighted boxed warning excerpts above, I define the 
targeted patients for each of the boxed warning drug groups as follows: 1) Antidepressants: 
Patients under age 18, 2) Atypical antipsychotics: Elderly patients (65 years or older) with 
dementia, 3) COX-2 Inhibitors: Patients with cardiovascular risk factors, 4) Glitazones: Patients 
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with heart failure, 5) Plavix: poor CYP2C19 metabolizers. Detailed criteria for identifying these 
patients, including ICD-9 codes, are defined in Table 4.2.  
Identification of visits for analytic samples 
I identify separate analytic samples for each of the five boxed warnings (see Figure 4.2). 
To be included in an analytic sample, a visit must meet the following inclusion criteria: 1)  the 
visit must occur in the relevant time period, defined as within two years of the boxed warning, 
subject to the overall dataset time period (2002-2011)25, 2) the visit must be for a patient with a 
condition eligible for treatment by the relevant study drug(s). Eligible conditions are defined as 
the labeled indications. However, for atypical antipsychotics, the boxed warning pertains to an off-
label indication (dementia). Thus, assessing prescribing changes among these patients requires the 
eligible conditions to include dementia, as well as the on-label indications for atypical 
antipsychotics.  
Based on the above inclusion criteria, the general definition of the analytic samples for 
each of the study drug groups is as follows: 1) Antidepressants: Patients with depression and/or 
anxiety, excluding patients aged 18-23 years because they receive a boxed warning at a different 
date, 2) Atypical antipsychotics: Patients with schizophrenia and/or bipolar disorder, or elderly 
patients (65 years or older) with dementia, 3) COX-2 Inhibitors: Patients with arthritis, ankylosing 
spondylitis, primary dysmenorrhea, and/or acute pain. 4) Glitazones: Patients with Type 2 
diabetes, 5) Plavix: Patients with acute coronary syndrome, myocardial infarction, stroke, and/or 
peripheral arterial disease (PAD). Detailed criteria for identifying the analytic samples, including 
ICD-9 codes, are defined in Table 4.3. 
                                                        
25 For all analytic samples, data are limited to visits that occurred in the years in which the 2002-2011 surveys took 
place. The 2002 NAMCS and NHAMCS data files includes a small number of visits that occurred at the end of 2001. 
I exclude these visits, which account for less than 1% of visits in the 2002 survey (see Figure 4.2). 
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4.3.3.  Measures 
Dependent variables 
The dependent variable, Rx, is a binary variable indicating whether the boxed warning drug 
was prescribed in the eligible visit. The dependent variable is “1” if the visit indicates a prescription 
for the branded or generic versions of any of the following drugs: 1) Antidepressants: all classes 
of antidepressants. 2) Atypical antipsychotics: Abilify (aripiprazole), Clozaril (clozapine), Geodon 
(ziprasidone), Invega (paliperidone), Risperdal (risperidone), Seroquel (quetiapine), Zyprexa 
(olanzapine), 3) COX-2 inhibitors: Bextra (valdecoxib), Celebrex (celecoxib), and Vioxx 
(rofecoxib), 4) Glitazones: Avandia (rosiglitazone), and Actos (pioglitazone), 5) Plavix: Plavix 
(clopidogrel). 
Key Independent variables 
Boxed warning is a binary variable indicating whether the visit occurred after the boxed 
warning was added. NAMCS and NHAMCS data specify the month and year in which each visit 
occurred, so boxed warning date is defined on the month-year level. For visits occurring in the 
month when the boxed warning is added it is not possible to ascertain whether the visit preceded 
the boxed warning. Thus, visits in the month the boxed warning was issued are excluded from the 
analyses to avoid incorrect specification of event timing (Wagner 2002).  
As I mention in Section 4.3.2, each of the study boxed warnings cautions against use of a 
given product for a specific patient subpopulation for whom the risk of the BW adverse reaction 
is high. Targeted is a binary variable indicating whether the visit is for a patient in the 
subpopulation that is targeted by the boxed warning. Targeted patients are defined as follows for 
each of the boxed warning drug groups: 1) Antidepressants: Patients under age 18, 2) Atypical 
antipsychotics: Elderly patients (65 years or older) with dementia, 3) COX-2 Inhibitors: Patients 
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with cardiovascular risk factors, 4) Glitazones: Patients with heart failure, 5) Plavix: poor 
CYP2C19 metabolizers. Detailed criteria for identifying the targeted patients, including ICD-9 
codes, are defined in Table 4.2. As described in Table 4.2, the study data do not allow identification 
of the targeted patients for the Plavix BW because the study data do not include genomic 
information, which would be necessary to identify CYP2C19 poor metabolizers. Thus, the 
Targeted visit variable is not assigned for the Plavix analyses.  
Other key patient characteristics for this study include patient race, ethnicity, sex, age, and 
primary payer. Due to sample sizes, patient race is a defined as White (referent), Black, or other 
race26. Patient ethnicity is a binary variable defined as Hispanic or non-Hispanic (referent). Patient 
sex is a binary variable where female is referent. Patient age is categorized into three age groups: 
youth (0-17 years), adult (18-64 years) (referent), and elderly (65 years and older). Patient primary 
payer is categorized as private insurance (referent), public insurance27, or other payment source28. 
For visits with multiple payment sources, payment type is defined according to the following 
hierarchy: private insurance, public insurance, and other source of payment. Referent values for 
categorical variables are assigned based on the most common value among visits in the evaluation 
dataset. 
Control variables 
Control variables include U.S. Census region (Northeast, Midwest, South (referent), and 
West), a monthly time trend, and prescriber characteristics (for some of the models). Prescriber 
                                                        
26 The other race category includes Asian, Native Hawaiian, other Pacific Islander, American Indian, and Alaska 
Native. 
27 Public insurance includes non-privately insured patients with Medicare, Medicaid, and/or SCHIP. 
28 The other payment category includes self-pay, no charge/charity care, workers compensation, etc. 
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control variables include prescriber practice size (solo vs. group (referent), physician specialty 
(primary care (referent) or specialist), prescriber type (M.D. (referent) vs. D.O.), and prescriber 
practice rurality (Metropolitan Statistical Area (MSA) (referent) or non-MSA). Referent values 
for categorical variables are assigned based on the most common value among visits in the 
evaluation dataset. 
4.4.  METHODS 
4.4.1.  Descriptive statistics 
For each boxed warning drug group, descriptive statistics are reported for three sub-groups 
of visits: 1) Targeted visits: visits by targeted patients (patient subpopulations for whom the BW 
cautions against use due to high adverse reactions risk, as defined in Table 4.2), 2) Non-targeted 
visits: visits by non-targeted patients (those not included in the subpopulation mentioned in the 
BW), 3) All eligible visits: visits by all patients who have conditions eligible for treatment by the 
BW drugs, as defined in Table 4.3 and Section 4.3.2 (i.e. visits by all patients in the analytic 
sample). For each of these sub-groups, I report descriptive statistics for three time periods: before 
the boxed warning was added, after the boxed warning was added, and for the overall data period 
(2 years before and after the BW). Descriptive statistics are calculated in Stata (v14.2) using 
complex survey data adjusted means.  Differences between pre- and post-BW means are tested 
using a chi-squared test for binary and categorical variables, and a t-test for continuous variables. 
The chi-squared tests and t-tests incorporate complex survey data features.  
4.4.2.  Quasi difference-in-difference methods 
The effects of the boxed warnings are estimated using quasi difference-in-difference (DID) 
methods, where the boxed warning is the “treatment.” Quasi-treatment and control groups are 
defined based on whether the visit is for one of the patient subpopulations for which the BW 
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cautions against use of the drug. “Treatment group” patients are those targeted by the BW: the 
patient subpopulations that are identified in each BW (Table 4.2). “Control group” patients are the 
non-targeted patients: those not included in the BW high-risk subpopulation groups, and thus not 
“treated” by the boxed warning. I use DID methods for four of the study boxed warnings: 
antidepressants, atypical antipsychotics, COX-2 inhibitors, and glitazones. As I mentioned earlier, 
the patients who are targeted by the Plavix boxed warning are not identifiable in the data so Plavix 
analyses do not use these difference-in-difference methods. 
I refer to the non-targeted and targeted patient groups as quasi-control and treatment groups 
because they may not meet all of the typical assumptions for DID control and treatment groups. In 
particular, one of the key requirements for control groups is that they are not affected by the 
treatment. Spillover effects of BWs on non-targeted patients have not been studied widely 
(McClellan 2019), but there is some evidence of spillover for antidepressant and atypical 
antipsychotic FDA warnings (Libby 2009; Olfson 2008; Valuck 2007; Dorsey 2010). For instance, 
studies show that the antidepressant warnings regarding suicidality risks for youth and adolescents 
had spillover effects for young adult patients (Libby 2009), despite the fact that young adults were 
not originally subject to the BW. To avoid bias from spillover among young adults, I exclude 
young adults (aged 18-23 years) from the antidepressant analyses. Dorsey et al. (2010) showed 
that while atypical antipsychotic prescribing decreased by most among the patients targeted by the 
warning (elderly with dementia), there were also small prescribing declines among other patients 
(non-elderly patients with severe mental illness). To the extent that there are spillover effects for 
atypical antipsychotics or other BW drug groups, it will bias the estimated BW effect towards the 
null. In other words, the quasi-DID methods I use in this study will result in a conservative estimate 
of the BW effects. 
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Another key requirement for DID methods is that control and treatment groups have 
parallel outcome trends prior to treatment. I assess this by comparing the pre-BW prescribing 
probability trends for the targeted and non-targeted patients. I find that the parallel trends 
requirement is met for all the study BWs (see Appendix 5 for charts of parallel pre-period trends).  
The quasi-DID methods in this study utilize the variation in boxed warning relevance 
between these two groups to estimate the degree to which other factors caused contemporaneous 
changes in prescribing. Since the relevance of the boxed warning differs between these two groups, 
the ability of the boxed warning to affect prescribing should vary accordingly. Specifically, after 
the BW is added, I expect prescribing to decrease for targeted patients because those are the 
patients that are described by the BW as high-risk for the adverse event. In contrast, since the 
boxed warning is irrelevant (or much less relevant) for patients not targeted by the warning, the 
boxed warning should not substantively affect prescribing probability for non-targeted visits. 
Because the BW is not relevant for non-targeted patients, I assume that any prescribing changes 
among non-targeted patients are due to factors outside the boxed warning. I expect that these 
contemporaneous factors will have similar effects on prescribing among targeted and non-targeted 
visits. Thus, I difference out any changes in prescribing probability among non-targeted visits from 
changes in prescribing probability among targeted visits when estimating the effect of the boxed 
warning on prescribing probability.  
4.4.3.  Empirical models 
Overall effects of boxed warnings 
I first estimate the average effect of the boxed warning on prescribing among all patient 
visits (hereafter “overall effects”). This average effect is estimated using a logit model where the 
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boxed warning effect is unmoderated by patient characteristics. I estimate separate logit models 
for each boxed warning drug group, specified as follows:  
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      where j denotes boxed warning drug group, t denotes month, and i denotes individual visit 
The outcome variable, Rx, is a binary variable indicating a prescription for a boxed warning 
drug at the given visit. BW is a binary variable for whether the visit occurred after the BW was 
issued, Target is a binary variable indicating whether the visit is for a patient in the subpopulation 
that is targeted by the BW (as described above), and BW*Target is the interaction between these 
two variables. X is a vector of patient characteristics (patient race, ethnicity, sex, age, and primary 
payer). C is a vector of other control variables, which include U.S. Census region, a monthly time 
trend, and prescriber control variables. I estimate each model with and without the prescriber 
controls (prescriber specialty, prescriber degree type, practice size, and practice rurality).  
The primary effects of interest in these models is the interaction effect between BW and 
Target. As mentioned above, the interaction effect is essentially a difference-in-difference estimate 
that allows estimation of the effect of the boxed warning among targeted patients’ visits. I utilize 
methods described elsewhere29 to measure the effect of treatment on the treated in nonlinear 
                                                        
29 Methods for measuring the effect of treatment on treated in nonlinear models using an interaction effect are detailed 
in the following articles:  
Karaca-Mandic, P., Norton, E.C., Dowd, B. (2012). Interaction terms in nonlinear models. Health Services Research, 
47(1): 255-274, and Appendix S1: 1-6. 
Puhani, P.A. (2008). The Treatment Effect, the Cross Difference, and the Interaction Term in Nonlinear “Difference-
in-Difference” Models. IZA Discussion Paper No. 3478, Institute of Labor Economics (IZA), retrieved from 
http://ftp.iza.org/dp3478.pdf. 
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models. These methods account for non-linearities inherent to logit models to estimate the portion 
of the difference in the conditional probability of prescribing that is attributable to the boxed 
warning. In contrast to linear models, differential effects are affected by the values of all covariates, 
not just those in the interaction term. To account for this variation in differential effects across 
different values of covariates in non-linear models, I use methods of recycled predictions to 
calculate average differential effects in the predicted probabilities. I refer to the average differential 
effects that are estimated by this equation as overall differential effects to denote that the estimated 
effect of the BW is unmoderated by patient characteristics. Analyses are adjusted for complex 
survey design features.30 To conduct inference, I examined the distribution of the average 
differential effect across 1000 replications of bootstrapped stratified clusters and compared the 
distribution to a null hypothesis of zero.  
Boxed warning effects stratified by patient characteristics 
To assess how the boxed warning effect varies by patient characteristic, I estimate logit 
models stratified on each patient characteristic. In other words, I separately estimate Eqn. 1 above 
for each of the following subgroups of patients: female, male, White, Black, other race, Hispanic, 
non-Hispanic, youth, adults, elderly, privately insured patients, publicly insured patients, and 
patients with other payment sources. I also do a sensitivity analysis where I separate publicly 
                                                        
Green. W. (2010). Testing hypotheses about interaction terms in nonlinear models. Economics Letters, 107(2): 291-
296. 
Ai. C., Norton, E.C. (2003) Interaction terms in logit and probit models. Economics Letters, 80(1): 123-129. 
Norton, E.C., Wang, H., Ai, C. (2004). Computing interaction effects and standard errors in logit and probit models. 
The Stata Journal, 4(2): 154-167. 
30 Survey data analysis requires multiple primary sampling units (clusters) within each strata (Lee 2006). When a 
stratum contains only one cluster, the bootstrap sampling method does not work. On average less than 2% of 
observations/visits in each BW drug group are in a singleton strata. See Appendix 3 for the algorithm applied to these 
observations. 
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insured patients into Medicare and Medicaid patients and assess the effect of the boxed warning 
separately for these two subsets of publicly insured patients. 
As with the overall effects, the primary effect of interest in these stratified models is the 
interaction effect between BW and Target, because that is the effect of the boxed warning among 
those targeted by the boxed warning. By estimating these interaction effects for each of the 
stratified models, I can estimate the average differential effect of the BW for each patient type. 
This allows to me assess whether a given patient subgroup (e.g. females) have a decrease, increase, 
or no change in their probability of receiving a prescription after the BW. Average differential 
effects in the predicted probabilities are calculated using methods of recycled predictions. To 
conduct inference, I examined the distribution of the stratified differential effects across 1000 
replications of bootstrapped stratified clusters and compared the distribution to a null hypothesis 
of zero. To conduct inference, I examined the distribution of the average differential effects across 
1000 replications of bootstrapped stratified clusters and compared the distribution to a null 
hypothesis of zero. To examine whether there are differences by patient characteristics I plotted 
the distributions of the stratified differential effects across the bootstrapped samples. 
Results from models that failed to converge are not included in the analyses. This is 
occurred in less than 5% of replications for atypical antipsychotics and less than 1% of replications 
for the other study drug groups. 
Specification adjustments for Plavix models 
As mentioned in Table 4.2 above, the patients targeted by the Plavix boxed warning (poor 
metabolizers of the drug) are not identifiable in the NAMCS/NHAMCS data.31 Since I cannot 
                                                        
31 Poor metabolizer status is determined by a patient’s CYP2C19 genotype, which is assessed via genomic testing. 
NAMCS data do not contain genetic lab testing results, so it is not possible to identify CYP2C19 poor metabolizers 
in these data. 
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differentiate between targeted and non-targeted visits, I evaluate the impact of the Plavix boxed 
warning on prescribing among all Plavix eligible visits by specifying modified versions of Eqn. 1 
to account for the fact that the Plavix models do not have the Target variable (see Eqn. 2 below). 




with	𝑋&'(𝛽& = 𝛽;& + 𝛽2&𝐵𝑊&'( + 𝛽?&𝑋&'( + 𝛽F&𝐶&'(  
      where j denotes boxed warning drug group, t denotes month, and i denotes individual visit 
4.5.  RESULTS 
4.5.1.  Descriptive statistics 
There are five analytic samples, one for each BW drug group, consisting of visits that are 
eligible for treatment by the given BW drug(s).  Each analytic sample is composed of two sub-
samples: targeted visits and non-targeted visits. As described earlier, targeted visits are visits by 
patients for whom the BW cautions against use of the drug, while non-targeted visits are visits by 
patients not mentioned by the BW.  
Antidepressants 
The antidepressants analytic sample includes 20,467 visits for patients with depression 
and/or anxiety who are under age 18, or 24 years and older (Table 4.4). Within the antidepressants 
analytic sample, 13% of the visits (2,677 visits) are for the patients that are targeted by the boxed 
warning (children and adolescents under age 18), and 87% of visits (17,799 visits) are for those 
not targeted by the boxed warning (patients 24 years or older). Among antidepressant eligible 
visits, there were no statistically significant changes in prescribing or visit characteristics between 
the pre-BW and post-BW periods (see Table 4.4). Among visits for children and adolescents, was 
a statistically significant decrease in the percentage of visits for White patients following the 
addition of the BW (pre-BW: 90%, post-BW: 82%, p=0.002). There were no other statistically 
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significant differences in prescribing or visit characteristics between the pre- and post-BW periods 
for targeted visits or non-targeted visits.  
Atypical antipsychotics 
 The atypical antipsychotics analytic sample includes 7,344 visits (Table 4.5). Among these, 
16% (1,164 visits) are by patients targeted by the BW (elderly with dementia) and 84% (6,180 
visits) are for patients not targeted by the warning (patients with schizophrenia and/or bipolar 
disorder). Within the atypical antipsychotic analytic sample, there is a small statistically significant 
increase in the percentage of visits that are privately insured between the pre-BW and post-BW 
periods (pre-BW: 30%, post-BW: 39%, p=0.014). This change seems primarily driven by changes 
among targeted visits (elderly with dementia), where the percentage of visits for privately insured 
patients more than triples after the BW is added (pre-BW: 13%, post-BW: 44%, p<0.0001). There 
are no other statistically significant differences in prescribing or other visit characteristics for the 
atypical antipsychotic analytic samples.  
COX-2 Inhibitors  
 The COX-2 inhibitor analytic sample includes 68,736 visits for patients with arthritis, 
ankylosing spondylitis, primary dysmenorrhea, and/or acute pain (Table 4.6). Among these, only 
6% of visits (4,704 visits) are by patients targeted by the BW (patients with cardiovascular disease 
or risk factors). The majority of COX-2 inhibitor eligible visits (94%) are by patients that are not 
targeted by the BW (those without cardiovascular disease or risk factors). There are statistically 
significant decreases in prescribing among both targeted visits and non-targeted visits, as well as 
the overall COX-2 inhibitor analytic sample. COX-2 inhibitors prescribing decreases from 13% 
pre-BW to 5% post-BW among targeted visits (p<0.0001), from 9% to 3% among non-targeted 
visits (p<0.0001), and from 9% to 3% among all COX-2 inhibitor eligible visits (p<0.0001). The 
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COX-2 inhibitor analytic sample and sub-samples (targeted and non-targeted visits) also have 
small statistically significant increases in the percentage of visits by privately insured patients. 
There are no other statistically significant differences in visit characteristics for the COX-2 
inhibitor analytic samples.  
Glitazones  
The glitazone analytic sample includes 13,010 visits for patients with Type 2 diabetes 
(Table 4.7). Among Type 2 diabetes visits, 6% (751 visits) are by patients targeted by the BW 
(heart failure patients), and 94% (12,259 visits) are by patients that are not targeted by the BW 
(patients without heart failure). There is a statistically significant decrease in glitazone prescribing 
among the targeted visits, as well as smaller statistically significant decreases among non-targeted 
visits and for the overall glitazones analytic sample. Glitazone prescribing decreases from 14% 
pre-BW to 5% post-BW among targeted visits (p=0.037), from 15% to 11% among non-targeted 
visits (p=0.006), and from 15% to 11% among all Type 2 diabetes visits (p=0.002). There are no 
other statistically significant differences in visit characteristics for the glitazone analytic samples.  
Plavix 
 The Plavix analytic sample includes 5,439 visits for patients that have acute coronary 
syndrome (ACS), myocardial infarction, stroke, and/or peripheral arterial disease (PAD) (Table 
4.8). There is no statistically significant change in Plavix prescribing between the pre-BW and 
post-BW periods. The only statistically significant change in visit characteristics between the pre- 
and post-BW periods is a decrease in the percent of visits by White patients after the BW is added 
(pre-BW: 88%, post-BW: 77%, p<0.0001).  
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4.5.2.  Regression results 
I utilize logit models to estimate two sets of boxed warning differential effects. First, I 
estimate the average differential effect of each boxed warning on prescribing among all the patients 
targeted by that boxed warning (overall differential effect). Second, I estimate stratified average 
differential effects for relevant subgroups of the patients targeted by the boxed warning (stratified 
differential effects).   
I estimate these overall differential effects and stratified differential effects, with and 
without controls for prescriber characteristics. Adjustment for patient controls yielded 
qualitatively identical results in all cases. Given the similarities of these models, I report them in 
Table 4.9, but do not describe them further. 
Overall boxed warning effect 
For four of the five study boxed warnings I estimate that the BW has a negative effect on 
prescribing of the BW drugs among targeted patients. However, this effect is statistically 
significant for only one of the boxed warnings: antidepressants (Table 4.9). For antidepressants, 
the average differential effect of the boxed warning is −0.11, indicating that the antidepressant 
boxed warning is associated with an 11 percentage point decrease in prescribing probability among 
targeted patients, compared to the pre-boxed warning period. This effect is statistically significant 
at the 99% confidence level (p=0.010). For the remaining four study boxed warnings, I fail to reject 
the null hypothesis that the boxed warning has no effect on prescribing probability.  
Stratified boxed warning differential effects for patient subgroups 
The antidepressant boxed warning has a statistically significant negative effect on 
prescribing for female patients, Hispanic patients, non-Hispanic patients, and publicly insured 
patients (Table 4.9 and Figure 4.3). Among female patients, the average differential effect of 
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−0.13 indicates that the prescribing probability among female patients decreases by 13 percentage 
points after the boxed warning is added (p=0.032). For Black patients, the antidepressant boxed 
warning is associated with a 16 percentage point decrease in prescribing probability (p=0.046). 
Among Hispanic patients, the boxed warning is associated with a 15 percentage point decrease in 
prescribing probability (p=0.004), while non-Hispanic patients have a 11 percentage point 
decrease in prescribing probability (p=0.018). The difference between the differential effects for 
Hispanics and non-Hispanic patients is not statistically significantly different from zero. Among 
publicly insured patients, the boxed warning is associated with a 15 percentage point decrease in 
prescribing probability (p=0.034). The boxed warning differential effects are not statistically 
significantly different between payer groups so I fail to reject the null hypothesis that patient payer 
type is associated with differences in boxed warning effect. For all other patient subgroups, I fail 
to reject the null hypothesis that the boxed warning has no effect on prescribing probability. 
The atypical antipsychotic boxed warning has a statistically significant effect on 
prescribing for Hispanic patients, “other race” patients (non-White and non-Black patients), and 
privately insured patients (Table 4.9 and Figure 4.4). Among Hispanic patients, the boxed warning 
is associated with a 28 percentage point decrease in prescribing probability. Among non-White 
and non-Black patients the boxed warning is associated with an 8 percentage point decrease in 
prescribing probability (p=0.016). The atypical antipsychotic boxed warning is associated with a 
17 percentage point increase in prescribing probability among privately insured patients (p=0.028). 
For publicly insured patients and patients with other forms of payment, I fail to reject the null 
hypothesis that the boxed warning has no effect on prescribing. The difference between the boxed 
warning differential effects for privately insured and publicly insured patients is statistically 
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significantly different from zero (p=0.018). For all other patient subgroups, I fail to reject the null 
hypothesis that the boxed warning has no effect on prescribing probability. 
The glitazone boxed warning has a statistically significant effect on prescribing among 
publicly insured patients (Table 4.9 and Figure 4.6). Among publicly insured patients, the average 
differential effect of the boxed warning is −0.13, indicating that the boxed warning is associated 
with a 13 percentage point decrease in prescribing probability among publicly insured patients. 
For all other patient subgroups, I fail to reject the null hypothesis that the boxed warning has no 
effect on prescribing probability. 
For COX-2 inhibitor (Table 4.9 and Figure 4.5) and Plavix (Table 4.9 and Figure 4.7) 
boxed warnings, none of the patient subgroups have a statistically significant boxed warning 
differential effect so I fail to reject the null hypothesis that the boxed warning has no effect on 
prescribing probability for any of the patient subgroups.  
I perform sensitivity analyses for all five of the boxed warnings where I separate publicly 
insured patients into Medicare and Medicaid patients to assess whether the effect of the BW varies 
between these two subsets of publicly insured patients. I find that that the results from these 
sensitivity analyses are almost identical to the results reported above and in Table 4.9, so I do not 
report these results.  
4.6.  DISCUSSION 
4.6.1.  Overall boxed warning effect 
In general, boxed warnings appear to decrease prescribing for patients targeted by the 
boxed warning. Although statistical significance is limited, all of the BW drug groups show a 
decrease in prescribing among targeted visits after the BW is added (see descriptive statistics in 
Tables 4.4 - 4.8). Empirical model results estimate that the differential effect of the boxed warning 
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is negative for four of the five study boxed warnings, but this is only statistically significant for 
one of the study boxed warnings (the antidepressant boxed warning for children and adolescents). 
Overall, while the boxed warning is generally associated with a dampening effect on prescribing, 
the ability to reject the null hypothesis that there is no effect is limited. It is not clear whether my 
inability to find statistically significant results means that the boxed warning is not an important 
factor in prescribing probability, a limitation due to sample size, or contamination due to spillover.   
4.6.2.  Role of patient characteristics in boxed warning effect 
Overall, I find little evidence that patient characteristics predict variation in post-BW 
prescribing. Estimated boxed warning differential effects for patient subgroups were rarely 
statistically significant; indeed 15% of the individual patient characteristic differential effects were 
significant, a rate not much higher than what would be expected for Type I error. Additionally, the 
directional impact of patient characteristics varied between drug groups. For instance, for 
antidepressants and atypical antipsychotics, Hispanics patients decreased prescribing by more than 
non-Hispanic patients, but for COX-2 inhibitors, glitazones, and Plavix this was not true. 
Additionally, the difference between Hispanics and non-Hispanics was not statistically significant 
for any of the five boxed warnings.  
I had hypothesized that patient characteristics that are often associated with disparities in 
care would be associated with a smaller effect of the boxed warning. However, this does not appear 
to be the case.  Overall, it is reassuring that there is little evidence of patient disparities in post-
boxed warning prescribing. 
This study suggests that variation in boxed warning effect is unrelated to patient 
characteristics.  More research is needed to examine what factors influence prescribing changes 
after a boxed warning is added. One particularly ripe area for further research is how the presence 
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of alternative treatment options (pharmacologic and non-pharmacologic) affect changes in 
prescribing following the boxed warning.  
4.6.3.  Limitations 
While this study has many strengths, there are some limitations. First, omitted variable bias 
could be caused by variables not included in my analyses. For instance, I was not able to control 
for changes in pharmaceutical advertising and promotion, which are known to impact prescribing 
(Rosenthal 2003; Iizuka 2005; Dave 2014; Datta 2017). The FDA prohibits certain promotional 
activities after a drug receives a BW (Lee Ventola 2011; FDA 2015), so decreases in promotion 
following the BW are likely to be related to the BW. Difference-in-difference methods will help 
control for changes in promotion. Second, there could be events outside the scope of this study 
that impact prescribing. For example, atypical antipsychotics were subject to safety concerns other 
than those in the BW; in the study period there were two FDA alerts and a Professional Society 
Consensus statement warning about metabolic risks of atypical antipsychotics. It is possible that 
inclusion of these co-occurring safety events would impact the study findings.  
Third, there may be measurement error in identifying the timing of key FDA events. I 
operationalized the BW date as the date that the BW was announced by the FDA. However, in 
some cases there are a few months delay between the announcement of the BW and manufacturers 
adding the BW wording to their drug labels. Additionally, many prescribers may rely on drug 
compendia to stay up-to-date on drug information, and these sources are also susceptible to lags 
in adding the BW (Smollin 2016; Cheng 2011). These lags in implementation of the boxed warning 
could cause the boxed warning effect estimates to be biased towards the null. 
Lastly, the study data have a few limitations worth noting. NAMCS and NHAMCS data 
have small sample sizes for some subgroups of visits, particularly for glitazones and atypical 
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antipsychotics. Data are de-identified and do not allow following patients or prescribers over time.  
Thus, it not possible to see whether prescribing rates changed at the patient level. However, the 
NAMCS and NHAMCS data offer important strengths over prescription claims data. For instance, 
visit-level data allows easy identification of the diagnoses associated with the visit where a drug 
was prescribed. Additionally, visit data allows precise measurement of written prescriptions 
instead of relying on filled prescriptions.  
4.7.  CONCLUSION 
Generally, boxed warnings appear to have a dampening effect on prescribing. The negative 
effect of the boxed warning does not seem to vary significantly based on patient characteristics. 
This suggests that there are not patient disparities in post-boxed warning prescribing changes. 
Overall, this is a positive finding as it suggests that there are not major inequities in the rate at 
which prescribers are translating the boxed warning safety information into changes in prescribing 
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Table 4.2. Identification of Visits by Patients Targeted by the Boxed Warning 
 
BW Drug Group Targeted Patients Identification of Targeted Visits among Eligible Visits 
Antidepressants Children, adolescents and 
young adults 





Patients is 65 years or older and has a dementia diagnosis: 
(ICD-9: 290.0x, 290.1x, 290.2x, 290.3x, 290.4x, 294.1x, 
294.2x, 294.8x, 331.0x, 331.1x, 331.82)  
COX-2 Inhibitors 
 
Patients with cardiovascular 
disease or risk factors 
Patient has a diagnosis indicating cardiovascular disease 
and/or cardiovascular risk factors: myocardial infarction 
(410.xx, 412.xx), stroke (430.xx, 431.xx-436.xx, 438.xx, 
V12.54), heart failure (398.91, 402.01, 402.11, 402.91, 404.01, 
404.03, 404.11, 404.13, 404.91, 404.93, 428.xx), peripheral 
arterial disease (PAD) (249.70, 249.71, 250.70, 250.71, 
250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 
440.29, 440.30, 440.31, 440.32, 440.4, 440.8, 440.9, 443.1, 
443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02), 
unstable angina (411.1, 413.0, 413.9), other ischemic heart 
disease (411.xx, 414.xx), hypertension (401.xx-405.xx), and/or 
CABG surgery (V45.81) 
Glitazones 
 
Patients with heart failure Patients has a diagnosis of heart failure (ICD-9: 398.91, 
402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 428.xx) or is identified as having congestive 





CYP2C19 poor metabolizer status would be assessed via 
genomic testing. However, NAMCS and NHAMCS data do 
not contain genetic lab testing results, so it is not possible to 
identify CYP2C19 poor metabolizers in these data.  
 
Notes:  
*NAMCS and NHAMCS surveys asked respondents whether the patient has congestive heart failure (CHF) regardless 
of other diagnosis codes. 
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Table 4.3. Identification of Study 3 Analytic Samples 
 
BW Drug Group Visit Inclusion Criteria for Analytic Samples 
Antidepressants Visit is for a patient with one or more of the following conditions:  
Depression: ICD-91: 296.2x, 296.3x, 300.4x, 309.00, 309.10, 311.xx; RFV2 code: 1110.0  
Anxiety: ICD-9: 293.84, 300.0x, 300.2x, 300.3, 309.24, 309.28, 309.81; RFV codes: 1100.0, 
1105.0, 1130.5 
and the patient is either under age 18, or is 24 years or older. 
and the visit occurs within the following time period: September 2002 - October 2006 
Atypical 
antipsychotics 
Visit is for a patient with one or more of the following conditions:  
Schizophrenia: ICD-9: 295.xx 
Bipolar disorder: ICD-9: 296.0x, 296.1x, 296.4x-296.8x 
Dementia3: ICD-9: 290.0x, 290.1x, 290.2x, 290.3x, 290.4x, 294.1x, 294.2x, 294.8x, 331.0x, 
331.1x, 331.82 
and the visit occurs within the following time period: March 2003 – April 2007  
COX-2  
Inhibitors 
Visit is for a patient with one or more of the following conditions:  
Arthritis:   ICD-9: 715.xx, 714.0-714.2, 714.3x; RFV code: 2900.0 
Ankylosing Spondylitis:   ICD-9: 720.0x 
Primary Dysmenorrhea:   ICD-9: 625.3x; RFV code: 1745.2 
Acute Pain:   ICD-9: 338.1x, 338.3x, 346.xx, 719.4x, 723.1x, 724.1x, 724.2x, 724.5, 729.5x, 
780.96, 784.0x; RFV codes: 1055.0, 1055.4, 1060.0, 1060.1, 1210.0, 1900.1, 1905.1, 1910.1, 
1915.1, 1920.1, 1925.1, 1930.1, 1935.1, 1940.1, 1945.1, 1950.1, 1955.1, 1960.1, 1965.1, 
1970.1, 1980.1, 2365.0, 2675.5 
and the patient has one or more of the following risk factors described in the BW:  
Cardiovascular disease or risk factors:  myocardial infarction (410.xx, 412.xx), stroke (430.xx, 
431.xx-436.xx, 438.xx, V12.54), heart failure (398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 404.93, 428.xx), peripheral arterial disease (PAD) (249.70, 249.71, 
250.70, 250.71, 250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 
440.31, 440.32, 440.4, 440.8, 440.9, 443.1, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 
445.02), unstable angina (411.1, 413.0, 413.9), other ischemic heart disease (411.xx, 414.xx), 
hypertension (401.xx-405.xx), and/or CABG surgery (V45.81) 
and the visit occurs within the following time period: March 2003 – April 2007 
Glitazones Visit is for a patient with the following condition:  
Type 2 Diabetes: ICD-9: 250.x0, 250.x2 and age of 35 years or older4 
and the visit occurs within the following time period: July 2005 – August 2009 
Plavix  
(clopidogrel)6 
Visit for a patient with at least one of the following conditions: 
Acute coronary syndrome:   ICD-9: 410.xx, 412.xx, 411.1, 413.0, 413.9 
Myocardial infarction:   ICD-9: 410.xx, 412.xx 
Stroke:   ICD-9: 430.xx, 431.xx-436.xx, 438.xx, V12.54 
Peripheral arterial disease (PAD)7:   ICD-9: 249.70, 249.71, 250.70, 250.71, 250.72, 250.73, 
440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 440.31, 440.32, 440.4x, 440.8x, 
440.9x, 443.1x, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02 
and the visit occurs within the following time period: February 2008 – December 2011 
 
Notes: 
1: ICD-9 refers to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes. 
ICD-9 codes were identified in 2003-2011 code listings from the Center for Disease Control and Prevention (CDC). Changes in 
ICD-9 codes over time were assessed and accounted for where relevant (CDC; CDC 2013).  
2: RFV code refers to Reason for Visit code; These codes are defined in the NAMCS/NHAMCS data file documentation. RFV 
codes are not listed for conditions that lack corresponding RFV codes (e.g. due to lack of specificity of codes). 
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3 Dementia is not an FDA-approved indication for atypical antipsychotics but is included in the list of relevant conditions 
because dementia patients are the focus on the atypical antipsychotic boxed warning. 
4 Several studies note shortcomings of ICD-9 codes for identifying Type 2 diabetes among younger patients (Alexander 2008; 
Rhodes 2007). Following Alexander and others, I identify Type 2 diabetes patients using a combination of ICD-9 code and age 
criteria to address the fact that Type 1 patients are sometimes coded as Type 2 patients (Alexander 2008; Xie 2013; Karve 
2008). Excluding younger patients accounts for the fact the onset of Type 2 diabetes generally occurs in adulthood (CDC 2019). 
5 NAMCS/NHAMCS surveys include a question regarding whether the patient has congestive heart failure (CHF). 
6 The Plavix BW identifies patients that are CYP2C19 poor metabolizers as having higher risk of adverse events. However, the 
NAMCS/NHAMCS data do not allow identification of these patients. Accordingly, the Plavix analytic sample includes all visits 
by patients with conditions that fall under Plavix’s FDA approved indications, rather than only those eligible for Plavix that are 
also poor metabolizers. 
7 Peripheral arterial disease (PAD) ICD-9 codes are identified in a study of PAD incidence and prevalence (Kalbaugh 2017).  
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All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 20,476 10,374 9,769 2,677 1,417 1,240 17,799 8,957 8,529
Antidepressant Rx 0.59 0.57 0.6 0.108 0.48 0.51 0.45 0.187 0.6 0.58 0.62 0.057
(0.011) (0.014) (0.015) (0.023) (0.03) (0.035) (0.011) (0.015) (0.016)
Female 0.66 0.67 0.66 0.680 0.54 0.52 0.55 0.542 0.68 0.68 0.67 0.520
(0.0071) (0.01) (0.01) (0.02) (0.027) (0.031) (0.0073) (0.011) (0.011)
White 0.89 0.89 0.9 0.579 0.86 0.90 0.82 0.002 0.89 0.89 0.91 0.261
(0.0061) (0.0087) (0.0085) (0.016) (0.016) (0.027) (0.0063) (0.0092) (0.0086)
Black 0.083 0.088 0.077 0.11 0.08 0.13 0.081 0.089 0.073
(0.0052) (0.0075) (0.0072) (0.015) (0.015) (0.024) (0.0054) (0.008) (0.0073)
Other race 0.026 0.025 0.024 0.036 0.016 0.059 0.025 0.026 0.021
(0.003) (0.0048) (0.0034) (0.0074) (0.0045) (0.015) (0.0032) (0.0053) (0.0034)
Hispanic 0.018 0.019 0.016 0.402 0.029 0.032 0.028 0.619 0.016 0.018 0.015 0.444
(0.0017) (0.0029) (0.0019) (0.0038) (0.0057) (0.0052) (0.0017) (0.003) (0.0019)
Age (years) 46 46 47 0.400 12 12 12 0.926 50 49 50 0.466
(0.35) (0.49) (0.49) (0.19) (0.25) (0.31) (0.28) (0.42) (0.38)
Youth (0-17) 0.083 0.086 0.08 0.852 . .
(0.0053) (0.0077) (0.0076)
Adult (18-64) 0.77 0.77 0.77 0.84 0.84 0.84
(0.0071) (0.01) (0.0099) (0.0066) (0.0096) (0.0092)
Elderly (65+) 0.15 0.15 0.15 0.16 0.16 0.16
(0.0062) (0.009) (0.0087) (0.0066) (0.0096) (0.0092)
Private insurance 0.56 0.54 0.58 0.222 0.53 0.54 0.53 0.303 0.57 0.55 0.59 0.192
(0.011) (0.016) (0.016) (0.029) (0.042) (0.041) (0.012) (0.017) (0.016)
Public insurance 0.27 0.28 0.26 0.32 0.29 0.36 0.26 0.28 0.25
(0.009) (0.013) (0.013) (0.027) (0.039) (0.04) (0.0093) (0.013) (0.013)
Other payer 0.17 0.18 0.16 0.14 0.17 0.12 0.17 0.18 0.16
(0.0087) (0.013) (0.012) (0.019) (0.028) (0.025) (0.0091) (0.014) (0.012)
MSA 0.86 0.86 0.87 0.910 0.88 0.87 0.91 0.364 0.86 0.86 0.86 0.991
(0.017) (0.023) (0.023) (0.024) (0.039) (0.025) (0.017) (0.023) (0.025)
Northeast 0.25 0.24 0.26 0.383 0.2 0.19 0.21 0.729 0.25 0.25 0.27 0.275
(0.015) (0.022) (0.022) (0.023) (0.033) (0.034) (0.016) (0.023) (0.024)
Midwest 0.22 0.22 0.23 0.25 0.25 0.26 0.22 0.21 0.22
(0.013) (0.018) (0.019) (0.027) (0.041) (0.038) (0.013) (0.018) (0.02)
South 0.33 0.32 0.34 0.35 0.37 0.31 0.33 0.32 0.34
(0.016) (0.021) (0.025) (0.033) (0.049) (0.044) (0.017) (0.022) (0.026)
West 0.2 0.22 0.17 0.2 0.18 0.23 0.2 0.22 0.17
(0.013) (0.02) (0.015) (0.025) (0.036) (0.037) (0.013) (0.021) (0.016)
All eligible visits Target visits Non-target visits
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in 
parentheses. Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple 
regression for continuous variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
 151 




All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 7,344 3,538 3,609 1,164 587 558 6,180 2,951 3,051
Atypical Rx 0.39 0.37 0.4 0.403 0.16 0.17 0.14 0.442 0.46 0.44 0.48 0.193
(0.016) (0.023) (0.023) (0.021) (0.034) (0.024) (0.017) (0.024) (0.025)
Female 0.6 0.59 0.62 0.237 0.67 0.66 0.69 0.562 0.57 0.56 0.59 0.276
(0.013) (0.018) (0.018) (0.025) (0.037) (0.036) (0.015) (0.019) (0.021)
White 0.84 0.83 0.85 0.656 0.87 0.86 0.88 0.378 0.83 0.83 0.84 0.749
(0.011) (0.018) (0.015) (0.022) (0.034) (0.027) (0.013) (0.02) (0.016)
Black 0.12 0.13 0.11 0.082 0.1 0.06 0.14 0.14 0.13
(0.01) (0.017) (0.012) (0.016) (0.027) (0.016) (0.012) (0.02) (0.015)
Other race 0.035 0.035 0.036 0.049 0.04 0.059 0.03 0.034 0.028
(0.0048) (0.0066) (0.0072) (0.015) (0.02) (0.023) (0.0041) (0.0059) (0.0059)
Hispanic 0.017 0.019 0.016 0.455 0.011 0.012 0.01 0.667 0.019 0.021 0.017 0.502
(0.0022) (0.0039) (0.0022) (0.0023) (0.0031) (0.0034) (0.0027) (0.005) (0.0027)
Age (years) 51 51 52 81 81 80 42 41 43
(0.79) (1.2) (1) (0.35) (0.48) (0.51) (0.56) (0.85) (0.72)
Youth (0-17) 0.063 0.073 0.052 0.439 . 0.083 0.098 0.068 0.105
(0.0074) (0.012) (0.0088) (0.0099) (0.016) (0.012)
Adult (18-64) 0.64 0.63 0.64 0.85 0.85 0.85
(0.019) (0.027) (0.027) (0.012) (0.017) (0.016)
Elderly (65+) 0.3 0.29 0.3 0.067 0.054 0.078
(0.018) (0.027) (0.025) (0.0074) (0.0094) (0.012)
Private insurance 0.34 0.3 0.39 0.014 0.29 0.13 0.44 0.000 0.36 0.36 0.37 0.435
(0.017) (0.023) (0.025) (0.03) (0.034) (0.049) (0.02) (0.028) (0.028)
Public insurance 0.53 0.57 0.5 0.69 0.86 0.53 0.47 0.47 0.49
(0.018) (0.026) (0.025) (0.03) (0.034) (0.049) (0.02) (0.029) (0.027)
Other payer 0.13 0.14 0.12 0.022 0.0094 0.029 0.16 0.18 0.14
(0.0091) (0.013) (0.012) (0.0075) (0.0036) (0.013) (0.011) (0.016) (0.015)
MSA 0.87 0.87 0.86 0.667 0.84 0.84 0.84 0.892 0.88 0.88 0.86 0.640
(0.019) (0.027) (0.028) (0.03) (0.041) (0.04) (0.021) (0.028) (0.032)
Northeast 0.26 0.27 0.25 0.333 0.24 0.3 0.17 0.081 0.27 0.26 0.28 0.513
(0.02) (0.031) (0.026) (0.034) (0.055) (0.036) (0.023) (0.033) (0.033)
Midwest 0.2 0.19 0.21 0.22 0.18 0.25 0.19 0.19 0.2
(0.017) (0.023) (0.026) (0.029) (0.035) (0.046) (0.019) (0.027) (0.028)
South 0.34 0.31 0.36 0.31 0.27 0.37 0.34 0.33 0.36
(0.023) (0.031) (0.034) (0.034) (0.042) (0.051) (0.028) (0.037) (0.042)
West 0.2 0.23 0.17 0.23 0.25 0.21 0.19 0.23 0.16
(0.018) (0.03) (0.022) (0.03) (0.046) (0.039) (0.022) (0.037) (0.027)
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in 
parentheses. Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple 
regression for continuous variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
All eligible visits Target visits Non-target visits
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All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 68,736 34,879 32,532 4,704 2,401 2,202 64,033 32,478 30,331
COX-2 Rx 0.061 0.092 0.0300 0.0000 0.088 0.13 0.046 0.0000 0.058 0.088 0.028 0.0000
(0.0028) (0.0049) (0.0027) (0.0098) (0.016) (0.011) (0.003) (0.0052) (0.0027)
Female 0.61 0.61 0.6 0.481 0.63 0.63 0.62 0.801 0.61 0.61 0.6 0.503
(0.0047) (0.0067) (0.0068) (0.014) (0.02) (0.02) (0.0049) (0.0071) (0.007)
White 0.84 0.84 0.83 0.497 0.77 0.76 0.77 0.476 0.84 0.85 0.84 0.337
(0.0057) (0.0075) (0.0089) (0.017) (0.024) (0.024) (0.0054) (0.0072) (0.0084)
Black 0.13 0.12 0.13 0.19 0.2 0.18 0.12 0.11 0.13
(0.0047) (0.0062) (0.0073) (0.015) (0.022) (0.02) (0.0044) (0.0058) (0.0069)
Other race 0.037 0.036 0.039 0.045 0.036 0.054 0.036 0.035 0.037
(0.0033) (0.0045) (0.0053) (0.0086) (0.011) (0.013) (0.0032) (0.0046) (0.0048)
Hispanic 0.026 0.025 0.028 0.201 0.019 0.02 0.018 0.576 0.027 0.025 0.029 0.136
(0.0013) (0.0018) (0.002) (0.0021) (0.0034) (0.0027) (0.0014) (0.0018) (0.0021)
Age (years) 48 48 49 0.491 63 63 63 0.875 47 47 47 0.511
(0.29) (0.4) (0.41) (0.52) (0.76) (0.64) (0.29) (0.4) (0.43)
Youth (0-17) 0.087 0.088 0.086 0.959 0.0032 0.0022 0.0042 0.661 0.096 0.097 0.095 0.909
(0.0033) (0.005) (0.0048) (0.0015) (0.00092) (0.003) (0.0036) (0.0056) (0.0052)
Adult (18-64) 0.68 0.68 0.67 0.53 0.52 0.54 0.69 0.69 0.69
(0.006) (0.0091) (0.0076) (0.018) (0.026) (0.024) (0.0059) (0.0091) (0.0073)
Elderly (65+) 0.24 0.24 0.24 0.47 0.47 0.46 0.21 0.21 0.22
(0.0058) (0.0086) (0.0075) (0.018) (0.026) (0.024) (0.0055) (0.0084) (0.0073)
Private insurance 0.55 0.53 0.57 0.000 0.46 0.42 0.49 0.020 0.56 0.54 0.57 0.001
(0.0076) (0.011) (0.011) (0.018) (0.026) (0.025) (0.0078) (0.011) (0.011)
Public insurance 0.29 0.32 0.27 0.44 0.5 0.4 0.28 0.3 0.25
(0.0065) (0.01) (0.008) (0.018) (0.026) (0.025) (0.0066) (0.011) (0.0081)
Other payer 0.16 0.15 0.17 0.095 0.086 0.11 0.17 0.16 0.18
(0.0054) (0.0066) (0.0085) (0.0084) (0.011) (0.013) (0.0057) (0.007) (0.009)
MSA 0.85 0.85 0.84 0.645 0.85 0.85 0.85 0.908 0.85 0.85 0.84 0.622
(0.015) (0.02) (0.022) (0.022) (0.03) (0.03) (0.015) (0.02) (0.022)
Northeast 0.2 0.21 0.18 0.172 0.21 0.2 0.22 0.628 0.2 0.21 0.18 0.155
(0.01) (0.015) (0.015) (0.02) (0.025) (0.031) (0.011) (0.017) (0.015)
Midwest 0.23 0.21 0.26 0.23 0.21 0.25 0.23 0.21 0.26
(0.011) (0.014) (0.017) (0.021) (0.027) (0.03) (0.011) (0.014) (0.017)
South 0.37 0.37 0.37 0.39 0.41 0.38 0.37 0.36 0.37
(0.013) (0.018) (0.018) (0.024) (0.036) (0.032) (0.013) (0.019) (0.018)
West 0.2 0.21 0.19 0.17 0.18 0.15 0.2 0.21 0.2
(0.01) (0.015) (0.014) (0.016) (0.025) (0.021) (0.01) (0.016) (0.015)
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in 
parentheses. Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple 
regression for continuous variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
All eligible visits Target visits Non-target visits
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All years Pre-BW Post-BW p All years Pre-BW Post-BW p All years Pre-BW Post-BW p
N 13,010 6,489 6,240 751 358 381 12,259 6,131 5,859
Glitazone Rx 0.13 0.15 0.11 0.002 0.098 0.14 0.054 0.037 0.13 0.15 0.11 0.006
(0.0066) (0.011) (0.0085) (0.023) (0.04) (0.022) (0.0069) (0.011) (0.009)
Female 0.52 0.52 0.52 0.685 0.47 0.48 0.45 0.695 0.52 0.52 0.53 0.628
(0.0093) (0.013) (0.013) (0.037) (0.053) (0.051) (0.0096) (0.013) (0.014)
White 0.77 0.77 0.77 0.778 0.8 0.83 0.78 0.346 0.77 0.77 0.77 0.831
(0.011) (0.016) (0.016) (0.028) (0.04) (0.039) (0.011) (0.016) (0.017)
Black 0.16 0.16 0.17 0.15 0.11 0.17 0.17 0.17 0.17
(0.0095) (0.014) (0.014) (0.025) (0.03) (0.038) (0.0097) (0.014) (0.014)
Other race 0.063 0.066 0.057 0.054 0.065 0.044 0.063 0.066 0.057
(0.0072) (0.0086) (0.011) (0.016) (0.028) (0.018) (0.0075) (0.0089) (0.012)
Hispanic 0.019 0.019 0.018 0.924 0.014 0.011 0.018 0.304 0.019 0.019 0.018 0.817
(0.0018) (0.0024) (0.0026) (0.0037) (0.0045) (0.006) (0.0018) (0.0025) (0.0027)
Age (years) 63 63 64 0.527 69 70 69 0.687 63 63 63 0.408
(0.24) (0.35) (0.35) (0.89) (1.4) (1.2) (0.25) (0.35) (0.37)
Youth (0-17) 0.726 0.139 0.469
Adult (18-64) 0.53 0.53 0.53 0.36 0.31 0.41 0.54 0.55 0.53
(0.0094) (0.013) (0.014) (0.033) (0.043) (0.05) (0.0098) (0.013) (0.015)
Elderly (65+) 0.47 0.47 0.47 0.64 0.69 0.59 0.46 0.45 0.47
(0.0094) (0.013) (0.014) (0.033) (0.043) (0.05) (0.0098) (0.013) (0.015)
Private insurance 0.55 0.53 0.57 0.096 0.47 0.45 0.51 0.666 0.55 0.53 0.58 0.117
(0.012) (0.017) (0.016) (0.036) (0.053) (0.049) (0.012) (0.017) (0.017)
Public insurance 0.37 0.38 0.35 0.47 0.47 0.44 0.36 0.38 0.34
(0.011) (0.016) (0.015) (0.041) (0.063) (0.053) (0.011) (0.015) (0.015)
Other payer 0.085 0.09 0.079 0.065 0.081 0.052 0.087 0.091 0.08
(0.0059) (0.0084) (0.0078) (0.02) (0.027) (0.029) (0.0061) (0.0087) (0.008)
MSA 0.86 0.85 0.87 0.419 0.79 0.77 0.81 0.613 0.86 0.85 0.88 0.425
(0.018) (0.025) (0.023) (0.037) (0.056) (0.046) (0.017) (0.024) (0.022)
Northeast 0.2 0.19 0.21 0.727 0.2 0.16 0.26 0.379 0.2 0.19 0.21 0.798
(0.015) (0.02) (0.023) (0.034) (0.043) (0.054) (0.015) (0.021) (0.023)
Midwest 0.22 0.22 0.23 0.33 0.32 0.35 0.21 0.21 0.22
(0.015) (0.021) (0.022) (0.046) (0.07) (0.06) (0.014) (0.019) (0.022)
South 0.4 0.4 0.4 0.31 0.31 0.28 0.41 0.4 0.4
(0.019) (0.026) (0.028) (0.038) (0.054) (0.054) (0.019) (0.026) (0.028)
West 0.18 0.2 0.17 0.16 0.2 0.12 0.18 0.2 0.17
Means and standard errors and p-values are adjusted for complex survey data weights and design features. Linearized standard errors reported in 
parentheses. Differences between pre- and post-BW means are tested using a chi-squared test for binary and categorical variables, and a simple 
regression for continuous variables (p-values are reported). Bolded p-values are statistically significant at the 95% confidence level.
All eligible visits Target visits Non-target visits
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All years Pre-BW Post-BW p
N 5,439 2,947 2,371
Plavix Rx plav 0.18 0.19 0.18 0.790
(0.013) (0.015) (0.025)
Female female 0.5 0.52 0.49 0.248
(0.015) (0.019) (0.024)
White race 0.83 0.88 0.77 0.000
(0.013) (0.011) (0.023)
Black 0.13 0.097 0.16
(0.011) (0.011) (0.019)
Other race 0.046 0.027 0.072
(0.0089) (0.0046) (0.02)
Hispanic hisp 0.019 0.017 0.022 0.166
(0.0019) (0.0025) (0.0031)
Age (years) age 67 68 67 0.515
(0.42) (0.57) (0.64)
Youth (0-17) agecat 0.003 0.0042 0.0015 0.331
(0.00089) (0.0016) (0.00048)
Adult (18-64) 0.39 0.38 0.4
(0.014) (0.019) (0.022)
Elderly (65+) 0.61 0.62 0.6
(0.014) (0.019) (0.022)
Private insurance pay 0.53 0.55 0.5 0.305
(0.018) (0.024) (0.027)
Public insurance 0.4 0.39 0.43
(0.017) (0.022) (0.026)
Other payer 0.064 0.061 0.068
(0.007) (0.0088) (0.012)
MSA msa 0.85 0.83 0.88 0.220
(0.025) (0.038) (0.025)
Northeast region 0.18 0.18 0.19 0.256
(0.016) (0.02) (0.026)
Midwest 0.2 0.24 0.17
(0.017) (0.025) (0.02)
South 0.44 0.44 0.44
(0.026) (0.035) (0.041)
West 0.17 0.15 0.19
(0.015) (0.018) (0.028)
All eligible visits
Means and standard errors and p-values are adjusted for complex survey data weights and 
design features. Linearized standard errors reported in parentheses. Differences between pre- 
and post-BW means are tested using a chi-squared test for binary and categorical variables, 
and a simple regression for continuous variables (p-values are reported). Bolded p-values are 
statistically significant at the 95% confidence level.
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Note: Bolded p-values are statistically significant at the 95% confidence level. 
 
  
Diff Eff p Diff Eff p Diff Eff p Diff Eff p
Overall differential effect -0.11 0.010 -0.11 0.008 -0.06 0.312 -0.07 0.308
Stratified differential effects
Female -0.13 0.032 -0.13 0.028 -0.12 0.164 -0.13 0.162
Male -0.05 0.362 -0.06 0.328 -0.01 0.892 -0.01 0.896
White -0.09 0.072 -0.09 0.058 -0.07 0.354 -0.06 0.386
Black -0.16 0.046 -0.16 0.062 -0.10 0.548 -0.09 0.574
Other Race -0.22 0.198 -0.18 0.316 -0.08 0.016 -0.24 0.011
Hispanic -0.15 0.004 -0.16 0.004 -0.28 0.006 -0.35 0.004
Non-hispanic -0.11 0.018 -0.11 0.014 -0.06 0.336 -0.06 0.334
Youth
Adult
Elderly -0.08 0.274 -0.10 0.234
Private Insurance -0.11 0.134 -0.11 0.136 0.17 0.028 0.19 0.020
Public Insurance -0.15 0.034 -0.15 0.020 -0.09 0.262 -0.10 0.244
Other payer -0.04 0.640 -0.04 0.706 0.27 0.407 0.26 0.432
Comparisons of stratified effects
Female vs. Male -0.07 0.364 -0.07 0.382 -0.11 0.368 -0.11 0.348
White vs. Black 0.07 0.516 0.07 0.526 0.03 0.908 0.02 0.914
White vs. Other 0.09 0.478 0.04 0.686 0.02 0.440 0.18 0.155
Hispanic vs. Non-hispanic -0.06 0.498 -0.06 0.484 -0.21 0.169 -0.29 0.096
Adult vs. Youth
Adult vs. Elderly 0.08 0.274 0.10 0.234
Private vs. Public 0.05 0.654 0.05 0.622 0.26 0.018 0.29 0.016













Note: Bolded p-values are statistically significant at the 95% confidence level. 
 
  
Diff Eff p Diff Eff p Diff Eff p Diff Eff p
Overall differential effect 0.002 0.924 0.002 0.940 -0.06 0.180 -0.06 0.180
Stratified differential effects
Female 0.01 0.754 0.00 0.794 -0.08 0.146 -0.09 0.140
Male 0.00 0.826 0.00 0.808 -0.03 0.586 -0.03 0.578
White 0.01 0.824 0.00 0.858 -0.07 0.208 -0.07 0.204
Black -0.01 0.718 -0.01 0.724 0.05 0.586 0.05 0.564
Other Race -0.01 0.792 -0.01 0.752
Hispanic 0.03 0.193 0.02 0.213 0.02 0.419 0.03 0.277
Non-hispanic 0.00 0.979 0.00 0.990 -0.06 0.178 -0.06 0.174
Youth
Adult 0.02 0.522 0.02 0.492 -0.03 0.596 -0.03 0.646
Elderly -0.01 0.546 -0.01 0.530 -0.09 0.126 -0.10 0.118
Private Insurance 0.00 0.888 0.00 0.884 0.02 0.800 0.02 0.798
Public Insurance 0.01 0.840 0.01 0.794 -0.13 0.042 -0.13 0.042
Other payer 0.02 0.519 0.01 0.587
Comparisons of stratified effects
Female vs. Male 0.01 0.696 0.01 0.690 -0.05 0.567 -0.06 0.529
White vs. Black 0.01 0.664 0.01 0.676 -0.11 0.108 -0.12 0.102
White vs. Other 0.02 0.779 0.02 0.742
Hispanic vs. Non-hispanic 0.03 0.276 0.02 0.414 0.08 0.171 0.09 0.124
Adult vs. Youth
Adult vs. Elderly 0.03 0.328 0.03 0.288 0.06 0.604 0.07 0.560
Private vs. Public 0.00 0.938 0.00 0.926 0.15 0.094 0.15 0.090














Note: Bolded p-values are statistically significant at the 95% confidence level. 
  
Diff Eff p Diff Eff p
Overall differential effect -0.05 0.460 -0.04 0.524
Stratified differential effects
Female -0.07 0.308 -0.07 0.366
Male -0.02 0.846 -0.02 0.902
White -0.05 0.426 -0.04 0.494
Black -0.04 0.844 0.00 0.760
Other Race -0.25 0.480 -0.18 0.727
Hispanic 0.02 0.818 0.02 0.882
Non-hispanic -0.05 0.458 -0.04 0.512
Youth
Adult -0.05 0.592 -0.03 0.736
Elderly -0.04 0.578 -0.03 0.664
Private Insurance -0.11 0.130 -0.10 0.168
Public Insurance 0.08 0.390 0.08 0.420
Other payer -0.13 0.150 -0.14 0.134
Comparisons of stratified effects
Female vs. Male -0.06 0.538 -0.05 0.530
White vs. Black -0.01 0.828 -0.04 0.500
White vs. Other 0.20 0.6186 0.13 0.8408
Hispanic vs. Non-hispanic 0.06 0.5576 0.06 0.6392
Adult vs. Youth
Adult vs. Elderly -0.01 0.966 0.00 0.994
Private vs. Public -0.19 0.068 -0.18 0.104
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CHAPTER 5: CONCLUSION 
 
 The overall objective of this study was to learn more about how FDA boxed warnings 
affect prescribing. In Study 1, I examined the relative prescribing impacts of initial FDA low-level 
risk communications versus boxed warnings (Chapter 2). Study 2 examined whether prescriber 
characteristics predict heterogeneity in post-boxed warning prescribing (Chapter 3). Study 3 
assessed whether there are patient disparities in post-boxed warning prescribing changes (Chapter 
4). In this final chapter, I summarize the main findings of these studies, their implications, and 
potential areas for future research.  
This dissertation has several key findings. First, prescribers generally do not change 
prescribing after a low-level risk communication (Study 1).  Initial low-level FDA risk 
communications do not have a statistically significant impact on prescribing for any models or 
drug groups, and that the direction of estimated effect of these low-level communications varies 
across drugs and models.  There are several possible reasons for this: 1) there may be a lack of 
prescriber attention to frequent low-level risk communications; 2) initial low-level 
communications typically apply to a single drug, and prescribers may not change behavior until 
safety risks are more widespread within a drug class or treatment area, and; 3) prescribers may 
reserve judgement on a drug when low-level FDA risk communications indicate that research is 
ongoing. 
Second, boxed warnings generally have a dampening effect on prescribing. Although 
statistical significance is mixed, the estimated boxed warning effect is negative for most models 
and boxed warning drug groups across all three studies. This suggests that the highest-level FDA 
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warning successfully conveys risk information to prescribers. Together the first and second 
findings show that prescribers respond more to boxed warnings than to low-level risk 
communications, and calibrate their prescribing changes to the level of risks and strength of 
evidence of the risk information.  
Third, there is minimal evidence that prescriber characteristics impact boxed warning 
response (Study 2). In comparing boxed warning effects between prescriber subgroups, I find that 
most prescriber characteristics lack consistent directional effects on boxed warning impact across 
the studied drug groups. Additionally, the number of significant findings is similar to what would 
be expected for Type 1 error. Based on these findings, it seems unlikely that prescriber 
characteristics play a significant role in moderating the impact of boxed warnings. 
The two prescriber characteristics that were most likely play a role in boxed warning 
response: rural practice location and group practice, both of which are correlated with proximity 
to other prescribers. Prescribers in group practices and in urban areas are more likely to interact 
with other prescribers than solo practitioners and prescribers in rural areas. This finding suggests 
peer influence in prescriber awareness of risk information and/or prescribing practices. 
 Fourth, there is little evidence that patient characteristics predict variation in post-BW 
prescribing (Study 3). The directional impact of patient characteristics varies between boxed 
warning drug groups and the number of significant findings is not much higher than what would 
be expected for Type I error.  This finding suggests that prescribers translate boxed warnings into 
changes in prescribing decisions regardless of patient race, ethnicity, sex, age, or insurance status. 
Finally, there are two important methods findings.  First, pooling boxed warnings is not 
appropriate.  To achieve greater power, options for models that included all boxed warning drug 
groups were explored.  Ultimately this approach was unsupported by the data, and it was necessary 
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to model boxed warnings separately (Study 2).  Second, there is some evidence of spillover effects 
for COX-2 inhibitors and glitazones (Chapter 3 and 4). Specifically, descriptive statistics show 
prescribing decreases among patients not targeted by the boxed warning. This study found no 
evidence of spillover effects among non-targeted patients for the antidepressants or atypical 
antipsychotics boxed warnings. Spillover effects were a particular concern for the antidepressant 
boxed warning among young adults (aged 18-24 years) because they are close in age to the patients 
targeted by the BW (children and adolescents, aged 0-18 years) and because young adults became 
subject to the suicidality boxed warning at a later date. To minimize spillover contamination, 
young adults were excluded from models. Future studies should pursue similar avenues to reduce 
spillover contamination.  
 There are several areas of future research that have the potential to extend knowledge in 
this field. One of the ripest areas for future research is the role of alternative treatment options, and 
how they influence the impact of a boxed warning. Among the boxed warnings in this study, some 
of the warnings applied to all drugs in a treatment area or drug class (antidepressants, atypical 
antipsychotics, COX-2 inhibitors), while other boxed warnings applied only to one or two drugs 
(Plavix and glitazones). It is reasonable that boxed warning drugs for which there are non-boxed 
warning treatment alternatives will have a greater decrease in prescribing post-BW than drugs 
where the entire drug class or treatment area received the BW. However, this has not been studied 
sufficiently. In addition to alternative drug treatment options, it would be good to consider non-
pharmacologic treatments. For example, it would be interesting to see if mental health counseling 
rates increased or decreased following the antidepressant boxed warning.  
 Another area of future study is examining non-boxed warning concordant prescribing. 
Studies show that the population targeted by the boxed warning typically experiences the largest 
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decrease in post-boxed warning drug use (Dorsey 2010; Pamer 2010). However, these studies also 
show that significant use remains among the targeted population following the boxed warning, and 
that there is often spillover to non-targeted populations (Dorsey 2010; Libby 2009; Pamer 2010; 
OIG 2011). These post-warning usage patterns indicate that boxed warning recommendations are 
not always followed by prescribers. The appropriateness of this non-boxed warning compliant use 
is not known.  
Future studies may benefit from using different data sources. NAMCS and NHAMCS had 
some strengths for these studies, but alternative approaches may be able to address some of the 
limitations of these two datasets for this question. Longitudinal data that allows researchers to 
follow patients and prescribers over time. The ability to follow patients over time would make it 
possible to evaluate past treatment history, treatment switching, treatment duration, and disease 
severity. These factors are likely to influence the expected drug benefits and risks for a given 
patient, so it would be interesting to examine whether these factors affect post-BW prescribing. 
Following patients over time will allow more complete understanding of treatment decisions and 
whether they are appropriate. Clinical data (e.g. from an electronic health record) would allow 
more specificity for some models. For example, clinical data could enable identification of patients 
with certain genetic profiles, such as the patients targeted by the Plavix boxed warning (CYP2C19 
poor metabolizers). Finally, large claim data files would dramatically increase sample size, which 
would help with power, but would involve tradeoffs, such as using prescription fills rather than 
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APPENDIX 1: EXAMPLE OF BOXED WARNING ON DRUG LABEL 
 
Figure A1.1: Prominent Placement of Glitazone Boxed Warning on Avandia Drug Label 
 
 
Source: FDA, Drugs@FDA, Avandia (rosiglitazone maleate) drug label, excerpt of p. 1.  
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Suicidality in Children and Adolescents  
 
Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in 
short-term studies in children and adolescents with Major Depressive Disorder (MDD) 
and other psychiatric disorders. Anyone considering the use of [Drug name] or any 
other antidepressant in a child or adolescent must balance this risk with the clinical 
need. Patients who are started on therapy should be observed closely for clinical 
worsening, suicidality, or unusual changes in behavior. Families and caregivers should 
be advised of the need for close observation and communication with the prescriber. 
[Drug name] is not approved for use in pediatric patients. (See Warnings and 
Precautions: Pediatric Use) Pooled analyses of short-term (4 to 16 weeks) placebo 
controlled trials of 9 antidepressant drugs (SSRIs and others) in children and 
adolescents with major depressive disorder (MDD), obsessive compulsive disorder 
(OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) 
have revealed a greater risk of adverse events representing suicidal thinking or 
behavior (suicidality) during the first few months of treatment in those receiving 
antidepressants. The average risk of such events in patients receiving antidepressants 
was 4%, twice the placebo risk of 2%. No suicides occurred in these trials. 
 
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH 
DEMENTIA-RELATED PSYCHOSIS 
 
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at 
an increased risk of death. Analyses of seventeen placebo-controlled trials (modal 
duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a 
risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in 
placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate 
of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in 
the placebo group. Although the causes of death were varied, most of the deaths appeared 
to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., 
pneumonia) in nature. Observational studies suggest that, similar to atypical 
antipsychotic drugs, treatment with conventional antipsychotic drugs may increase 
mortality. The extent to which the findings of increased mortality in observational 
studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) 
of the patients is not clear. [Drug name] is not approved for the treatment of patients 
with dementia-related psychosis [see Warnings and Precautions (5.1, 5.12) and Patient 
















































APPENDIX 3: SINGLETON CLUSTER AND STRATA METHODOLOGY 
 
Cardiovascular Risk 
• [Drug name] may cause an increased risk of serious cardiovascular thrombotic 
events, myocardial infarction, and stroke, which can be fatal. All NSAIDs may have 
a similar risk. This risk may increase with duration of use. Patients with 
cardiovascular disease or risk factors for cardiovascular disease may be at greater 
risk (see WARNINGS and CLINICAL TRIALS). 
• [Drug name] is contraindicated for the treatment of peri-operative pain in the setting 
of coronary artery bypass graft (CABG) surgery (see WARNINGS). 
Gastrointestinal Risk 
• NSAIDs, including [drug name], cause an increased risk of serious gastrointestinal 
adverse events including bleeding, ulceration, and perforation of the stomach or 
intestines, which can be fatal. These events can occur at any time during use and 
without warning symptoms. Elderly patients are at greater risk for serious 
gastrointestinal events (see WARNINGS). 
 
 
WARNING: CONGESTIVE HEART FAILURE 
• Thiazolidinediones, including [drug name], cause or exacerbate congestive heart 
failure in some patients [see Warnings and Precautions (5.1)].  
• After initiation of [drug name], and after dose increases, monitor patients carefully 
for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, 
and/or edema). If heart failure develops, it should be managed according to current 
standards of care and discontinuation or dose reduction of [drug name] must be 
considered.  
• [Drug name] is not recommended in patients with symptomatic heart failure.  
• Initiation of [drug name] in patients with established New York Heart Association 
(NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4) 
and Warnings and Precautions (5.1)]. 
 
WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS  
 
The effectiveness of Plavix is dependent on its activation to an active metabolite by the 
cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions 
(5.1)]. Plavix at recommended doses forms less of that metabolite and has a smaller 
effect on platelet function in patients who are CYP2C19 poor metabolizers. Poor 
metabolizers with acute coronary syndrome or undergoing percutaneous coronary 
intervention treated with Plavix at recommended doses exhibit higher cardiovascular 
event rates than do patients with normal CYP2C19 function. Tests are available to 
identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining 
therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment 
or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage 
and Administration (2.3)]. 
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Artificial singleton strata occur when analysis is conducted on data subgroups, as is the 
case when analyses are limited to the eligible visits of each drug group.32 Singleton strata issues 
occur in instances where only one of the clusters within a given strata have eligible visits for the 
drug group. On average less than 5% of visits for each drug group occur in singleton strata. In 
those cases, I implement the following methodology to address drug-group level singletons prior 
to conducting drug subgroup analyses. Clusters containing more than one eligible visit are split 
into two clusters, where each new cluster is randomly assigned half of the eligible visits from the 
previous cluster.  Clusters with only one eligible visit are grouped with other single visit clusters 
from the same data year33 to create a new stratum with multiple clusters. To illustrate how this 
methodology was implemented, I include a consort diagram below to show how singletons were 
handled for the atypical antipsychotics analytic sample in Study 1. 
  
                                                        
32 As is required for proper subgroup analysis in complex survey data, all observations were retained for subgroup 
analyses but observations outside subgroups were given a weight of zero. Retaining all observations preserves 
complex survey data design features to ensure correct variance estimates. This was implemented using Stata (v14.2) 
commands that are appropriate for survey subgroup analysis. (Lee 2006, at pp. 42-43, 55-57). 
33 Data year refers to the year of the NAMCS/NHAMCS data file. For a small number of visits that occur near the end 
of the year, the data year is different than the visit year. 
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Figure A3.1: Singleton Cluster and Strata Methodology Illustrated by Study 1 Atypical 
Antipsychotics Analytic Sample 
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 APPENDIX 4: CHARTS OF PARALLEL TRENDS IN PRE-BW PERIOD (STUDY 2) 
 
Figure A4.1. Antidepressant Pre-Period Trends  
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Figure A4.3. COX-2 Inhibitors Pre-Period Trends  
 
 
Figure A4.4. Glitazone Pre-Period Trends 
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APPENDIX 5: CHARTS OF PARALLEL TRENDS IN PRE-BW PERIOD (STUDY 3) 
 
Figure A5.1. Antidepressant Pre-Period Trends 
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Figure A5.3. COX-2 Inhibitors Pre-Period Trends 
 
 
Figure A5.4. Glitazone Pre-Period Trends 
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